"AU","AF","TI","SO","SO_CO","LA","DT","DE","ID","MESH","AB","C1","CR","TC","SN","J9","JI","PY","PY_IS","VL","DI","PG","GRANT_ID","GRANT_ORG","UT","PMID","DB","AU_UN"
"Marchand T;Pinho S","Marchand, Tony;Pinho, Sandra","Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.","Frontiers in immunology","Switzerland","eng","Journal Article","acute myeloid leukemia;genetic heterogeneity;leukemic stem cell (LSC);stem cell niche;therapeutic targets","Biomarkers, Tumor;Bone Marrow;Disease Management;Disease Susceptibility;Genetic Heterogeneity;Genetic Predisposition to Disease;Humans;Leukemia, Myeloid, Acute;Molecular Targeted Therapy;Neoplastic Stem Cells;Phenotype;Stem Cell Niche;Tumor Microenvironment","Biomarkers, Tumor;Bone Marrow;Disease Management;Disease Susceptibility;Genetic Heterogeneity;Genetic Predisposition to Disease;Humans;Leukemia, Myeloid, Acute;Molecular Targeted Therapy;Neoplastic Stem Cells;Phenotype;Stem Cell Niche;Tumor Microenvironment","Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. While complete remission can be obtained with intensive chemotherapy in young and fit patients, relapse is frequent and prognosis remains poor. Leukemic cells are thought to arise from a pool of leukemic stem cells (LSCs) which sit at the top of the hierarchy. Since their discovery, more than 30 years ago, LSCs have been a topic of intense research and their identification paved the way for cancer stem cell research. LSCs are defined by their ability to self-renew, to engraft into recipient mice and to give rise to leukemia. Compared to healthy hematopoietic stem cells (HSCs), LSCs display specific mutations, epigenetic modifications, and a specific metabolic profile. LSCs are usually considered resistant to chemotherapy and are therefore the drivers of relapse. Similar to their HSC counterpart, LSCs reside in a highly specialized microenvironment referred to as the ""niche"". Bidirectional interactions between leukemic cells and the microenvironment favor leukemic progression at the expense of healthy hematopoiesis. Within the niche, LSCs are thought to be protected from genotoxic insults. Improvement in our understanding of LSC gene expression profile and phenotype has led to the development of prognosis signatures and the identification of potential therapeutic targets. In this review, we will discuss LSC biology in the context of their specific microenvironment and how a better understanding of LSC niche biology could pave the way for new therapies that target AML.","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Department of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, United States.","NA",0,"1664-3224","Front Immunol","Front Immunol",2021,"2021","12","10.3389/fimmu.2021.775128","775128","","","34721441","34721441","PUBMED","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Department of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, United States."
"Turban A;Gaubert S;Luque-Paz D;René C;Collet N;Pawlowski M;Bendavid C;Lefèvre CR","Turban, Adrien;Gaubert, Sophie;Luque-Paz, David;René, Céline;Collet, Nicolas;Pawlowski, Maxime;Bendavid, Claude;Lefèvre, Charles R","Validation of a short turnaround time automated method for the 24/7 determination of plasma d-lactate on Roche Cobas c502.","Practical laboratory medicine","Netherlands","eng","Journal Article","","","","NA","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.","NA",0,"2352-5517","Pract Lab Med","Pract Lab Med",2022,"2023","36","10.1016/j.plabm.2023.e00317","e00317","","","37425622","37425622","PUBMED","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France."
"Epaillard N;Lusque A;Jacot W;Mailliez A;Bachelot T;Arnedos M;Le Du F;Brain E;Ferrero JM;Massard V;Desmoulins I;Mouret-Reynier MA;Levy C;Gonçalves A;Leheurteur M;Petit T;Filleron T;Bosquet L;Pistilli B;Frenel JS","Epaillard, N;Lusque, A;Jacot, W;Mailliez, A;Bachelot, T;Arnedos, M;Le Du, F;Brain, E;Ferrero, J M;Massard, V;Desmoulins, I;Mouret-Reynier, M A;Levy, C;Gonçalves, A;Leheurteur, M;Petit, T;Filleron, T;Bosquet, L;Pistilli, B;Frenel, J S","Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.","ESMO open","England","eng","Journal Article","HER2-low;HER2-positive;brain metastases;breast cancer;metastasis","Humans;Breast Neoplasms;Female;Middle Aged;France;Brain Neoplasms;Incidence;Receptor, ErbB-2;Meningeal Neoplasms;Aged;Cohort Studies;Adult","Humans;Breast Neoplasms;Female;Middle Aged;France;Brain Neoplasms;Incidence;Receptor, ErbB-2;Meningeal Neoplasms;Aged;Cohort Studies;Adult","Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (mBC) may develop brain metastases over the course of the disease. Nevertheless, little is known about the prevalence and the outcome of brain and leptomeningeal metastases (BLMM) in HER2-low BC. We compared the cumulative incidence of BLMM and associated outcomes among patients with HER2-low, HER2-negative (HER2-) and HER2+ mBC. This cohort study was conducted from the Epidemiological Strategy and Medical Economics (ESME) mBC database and included patients treated for mBC between 2012 and 2020 across 18 French comprehensive cancer centers and with known HER2 and hormone receptor (HR) status. The cumulative incidence of BLMM after metastatic diagnosis was estimated using a competing risk methodology with death defined as a competing event. 19 585 patients were included with 6118 (31.2%), 9943 (50.8%) and 3524 (18.0%) being HER2-low, HER2- and HER2+ mBC, respectively. After a median follow-up of 48.6 months [95% confidence interval (CI) 47.7-49.3 months], BLMM were reported in 4727 patients: 1192 (25.2%) were diagnosed with BLMM at first metastatic diagnosis and 3535 (74.8%) after metastatic diagnosis. Multivariable analysis adjusted for age, histological grade, metastases-free interval and HR status showed that the risk of BLMM at metastatic diagnosis was similar in patients with HER2- compared to HER2-low mBC [odds ratio (OR) (95% CI) 1.00 (0.86-1.17)] and higher in those with HER2+ compared to HER2-low [OR (95% CI) 2.23 (1.87-2.66)]. Similar results were found after metastatic diagnosis; the risk of BLMM was similar in HER2- compared to HER2-low [subdistribution hazard ratio (sHR) (95% CI) 1.07 (0.98-1.16)] and higher in the HER2+ group [sHR (95% CI) 1.56 (1.41-1.73)]. The prevalence and evolution of BLMM in HER2-low mBC are similar to those in patients with HER2- tumors. In contrast to patients with HER2+ mBC, the prognosis of BLMM remains dismal in this population.","Department of Medical Oncology, Gustave Roussy;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Department of Medical Oncology, Institut régional du Cancer, Montpellier.;Department of Medical Oncology, Centre Oscar Lambret, Lille.;Department of Medical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Institut Bergonié, Bordeaux.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, Institut Curie, Saint-Cloud.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand.;Department of Medical Oncology, Centre François Baclesse, Caen.;Department of Medical Oncology, Institut Paoli Calmette, Marseille.;Department of Medical Oncology, Centre Henri Becquerel, Rouen.;Department of Medical Oncology, Centre Paul Strauss ICANS, Strasbourg.;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Health Data and Partnership Department, Unicancer, Paris.;Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U1279, Gustave Roussy, Villejuif.;Department of Medical Oncology, Institut de Cancerologie de L'Ouest, Saint-Herblain, France.","NA",0,"2059-7029","ESMO Open","ESMO Open",2024,"2024","9","10.1016/j.esmoop.2024.103447","103447","","","38703431","38703431","PUBMED","Department of Medical Oncology, Gustave Roussy;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Department of Medical Oncology, Institut régional du Cancer, Montpellier.;Department of Medical Oncology, Centre Oscar Lambret, Lille.;Department of Medical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Institut Bergonié, Bordeaux.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, Institut Curie, Saint-Cloud.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand.;Department of Medical Oncology, Centre François Baclesse, Caen.;Department of Medical Oncology, Institut Paoli Calmette, Marseille.;Department of Medical Oncology, Centre Henri Becquerel, Rouen.;Department of Medical Oncology, Centre Paul Strauss ICANS, Strasbourg.;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Health Data and Partnership Department, Unicancer, Paris.;Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U1279, Gustave Roussy, Villejuif.;Department of Medical Oncology, Institut de Cancerologie de L'Ouest, Saint-Herblain, France."
"Heddar A;Ogur C;Da Costa S;Braham I;Billaud-Rist L;Findikli N;Beneteau C;Reynaud R;Mahmoud K;Legrand S;Marchand M;Cedrin-Durnerin I;Cantalloube A;Peigne M;Bretault M;Dagher-Hayeck B;Perol S;Droumaguet C;Cavkaytar S;Nicolas-Bonne C;Elloumi H;Khrouf M;Rougier-LeMasle C;Fradin M;Le Boette E;Luigi P;Guerrot AM;Ginglinger E;Zampa A;Fauconnier A;Auger N;Paris F;Brischoux-Boucher E;Cabrol C;Brun A;Guyon L;Berard M;Riviere A;Gruchy N;Odent S;Gilbert-Dussardier B;Isidor B;Piard J;Lambert L;Hamamah S;Guedj AM;Brac de la Perriere A;Fernandez H;Raffin-Sanson ML;Polak M;Letur H;Epelboin S;Plu-Bureau G;Wołczyński S;Hieronimus S;Aittomaki K;Catteau-Jonard S;Misrahi M","Heddar, Abdelkader;Ogur, Cagri;Da Costa, Sabrina;Braham, Inès;Billaud-Rist, Line;Findikli, Necati;Beneteau, Claire;Reynaud, Rachel;Mahmoud, Khaled;Legrand, Stéphanie;Marchand, Maud;Cedrin-Durnerin, Isabelle;Cantalloube, Adèle;Peigne, Maeliss;Bretault, Marion;Dagher-Hayeck, Benedicte;Perol, Sandrine;Droumaguet, Celine;Cavkaytar, Sabri;Nicolas-Bonne, Carole;Elloumi, Hanen;Khrouf, Mohamed;Rougier-LeMasle, Charlotte;Fradin, Melanie;Le Boette, Elsa;Luigi, Perrine;Guerrot, Anne-Marie;Ginglinger, Emmanuelle;Zampa, Amandine;Fauconnier, Anais;Auger, Nathalie;Paris, Françoise;Brischoux-Boucher, Elise;Cabrol, Christelle;Brun, Aurore;Guyon, Laura;Berard, Melanie;Riviere, Axelle;Gruchy, Nicolas;Odent, Sylvie;Gilbert-Dussardier, Brigitte;Isidor, Bertrand;Piard, Juliette;Lambert, Laetitia;Hamamah, Samir;Guedj, Anne Marie;Brac de la Perriere, Aude;Fernandez, Hervé;Raffin-Sanson, Marie-Laure;Polak, Michel;Letur, Hélène;Epelboin, Sylvie;Plu-Bureau, Genevieve;Wołczyński, Sławomir;Hieronimus, Sylvie;Aittomaki, Kristiina;Catteau-Jonard, Sophie;Misrahi, Micheline","Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine.","EBioMedicine","Netherlands","eng","Journal Article","Meiosis/DNA repair genes;Mitophagy;NF-KB;Personalized medicine;Post - translational regulation;Primary ovarian insufficiency","Female;Humans;Infertility;Mitomycins;NF-kappa B;Precision Medicine;Primary Ovarian Insufficiency","Female;Humans;Infertility;Mitomycins;NF-kappa B;Precision Medicine;Primary Ovarian Insufficiency","Primary Ovarian Insufficiency (POI), a public health problem, affects 1-3.7% of women under 40 yielding infertility and a shorter lifespan. Most causes are unknown. Recently, genetic causes were identified, mostly in single families. We studied an unprecedented large cohort of POI to unravel its molecular pathophysiology. 375 patients with 70 families were studied using targeted (88 genes) or whole exome sequencing with pathogenic/likely-pathogenic variant selection. Mitomycin-induced chromosome breakages were studied in patients' lymphocytes if necessary. A high-yield of 29.3% supports a clinical genetic diagnosis of POI. In addition, we found strong evidence of pathogenicity for nine genes not previously related to a Mendelian phenotype or POI: ELAVL2, NLRP11, CENPE, SPATA33, CCDC150, CCDC185, including DNA repair genes: C17orf53(HROB), HELQ, SWI5 yielding high chromosomal fragility. We confirmed the causal role of BRCA2, FANCM, BNC1, ERCC6, MSH4, BMPR1A, BMPR1B, BMPR2, ESR2, CAV1, SPIDR, RCBTB1 and ATG7 previously reported in isolated patients/families. In 8.5% of cases, POI is the only symptom of a multi-organ genetic disease. New pathways were identified: NF-kB, post-translational regulation, and mitophagy (mitochondrial autophagy), providing future therapeutic targets. Three new genes have been shown to affect the age of natural menopause supporting a genetic link. We have developed high-performance genetic diagnostic of POI, dissecting the molecular pathogenesis of POI and enabling personalized medicine to i) prevent/cure comorbidities for tumour/cancer susceptibility genes that could affect life-expectancy (37.4% of cases), or for genetically-revealed syndromic POI (8.5% of cases), ii) predict residual ovarian reserve (60.5% of cases). Genetic diagnosis could help to identify patients who may benefit from the promising in vitro activation-IVA technique in the near future, greatly improving its success in treating infertility. Université Paris Saclay, Agence Nationale de Biomédecine.","Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif, France.;Igenomix Turkey, İstanbul, Turkey; Institute of Science, Department of Bioengineering Yildiz Technical University, İstanbul, Turkey.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service d'Endocrinologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin/Port-Royal, 75005, Paris, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Faculty of Engineering and Architecture, Department of Biomedical Engineering, Beykent University, İstanbul, Turkey.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Aix Marseille Université, Assistance-Publique des Hôpitaux de Marseille (AP-HM), Service de Pédiatrie multidisciplinaire Hôpital de la Timone Enfants, 13385, Marseille Cedex 05, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre de Fertilité - Clinique de l'Atlantique La Rochelle, 17000, La Rochelle, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Üsküdar University, Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey.;Service de Gynécologie et d'Obstétrique, Centre Hospitalier Alpes Léman, 74130, Contamine-Sur-Arve, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France; Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service d'Endocrinologie-Diabétologie, Centre Hospitalier Antibes Juan Les Pins, 06600, Antibes, France.;Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics and reference center for developmental disorders, FHU G4 Génomique, F-76000 Rouen, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service d'Endocrinologie, Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Saint-Etienne, 42270, Saint-Priest-en-Jarez, France.;Service de génétique des tumeurs. Institut Gustave Roussy, 94805, Villejuif, France.;Département de Pédiatrie, Unité d'Endocrinologie-Gynécologie Pédiatrique, Hôpital A.-de-Villeneuve, Centre Hospitalier Universitaire Montpellier et Université Montpellier, 34090, Montpellier, France; Constitutif Sud, Centre de Référence Maladies Rares du Développement Génital, Hôpital Lapeyronie, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, 34090 Montpellier, France; INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, EA 7450 BioTARGen, FHU G4 Genomics, Caen, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France; Centre Hospitalier Universitaire de Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Université de Montpellier, Montpellier, France.;Service d'Endocrinologie et de Maladies Métaboliques, Centre Hospitalier Universitaire Nîmes, Université de Montpellier, 30029, Nîmes, France.;Fédération d'Endocrinologie, Centre de Référence des Maladies Rares du Développement Génital, Groupement Hospitalier Est, Hôpital Louis Pradel, 69002, Lyon, France.;Service de Gynecologie et d'Obstétrique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Faculté de médicine, Université Paris-Saclay, 94270 Le Kremlin Bicêtre, France; UVSQ, Inserm, CESP, Université Paris-Saclay, 94807 Villejuif, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Foch, 40 rue Worth 92 150 Suresnes, France; Service de Médecine de la Reproduction et Préservation de la Fertilité, Polyclinique de Navarre, 8, boulevard Hauterive, 64000 Pau, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.;Service de gynécologie médicale, orthogénie et sexologie, Centre Hospitalier Universitaire de Lille, Université de Lille, 59000 Lille, France.;Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif","NA",0,"2352-3964","EBioMedicine","EBioMedicine",2022,"2022","84","10.1016/j.ebiom.2022.104246","104246","","","36099812","36099812","PUBMED","Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif, France.;Igenomix Turkey, İstanbul, Turkey; Institute of Science, Department of Bioengineering Yildiz Technical University, İstanbul, Turkey.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service d'Endocrinologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin/Port-Royal, 75005, Paris, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Faculty of Engineering and Architecture, Department of Biomedical Engineering, Beykent University, İstanbul, Turkey.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Aix Marseille Université, Assistance-Publique des Hôpitaux de Marseille (AP-HM), Service de Pédiatrie multidisciplinaire Hôpital de la Timone Enfants, 13385, Marseille Cedex 05, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre de Fertilité - Clinique de l'Atlantique La Rochelle, 17000, La Rochelle, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Üsküdar University, Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey.;Service de Gynécologie et d'Obstétrique, Centre Hospitalier Alpes Léman, 74130, Contamine-Sur-Arve, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France; Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service d'Endocrinologie-Diabétologie, Centre Hospitalier Antibes Juan Les Pins, 06600, Antibes, France.;Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics and reference center for developmental disorders, FHU G4 Génomique, F-76000 Rouen, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service d'Endocrinologie, Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Saint-Etienne, 42270, Saint-Priest-en-Jarez, France.;Service de génétique des tumeurs. Institut Gustave Roussy, 94805, Villejuif, France.;Département de Pédiatrie, Unité d'Endocrinologie-Gynécologie Pédiatrique, Hôpital A.-de-Villeneuve, Centre Hospitalier Universitaire Montpellier et Université Montpellier, 34090, Montpellier, France; Constitutif Sud, Centre de Référence Maladies Rares du Développement Génital, Hôpital Lapeyronie, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, 34090 Montpellier, France; INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, EA 7450 BioTARGen, FHU G4 Genomics, Caen, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France; Centre Hospitalier Universitaire de Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Université de Montpellier, Montpellier, France.;Service d'Endocrinologie et de Maladies Métaboliques, Centre Hospitalier Universitaire Nîmes, Université de Montpellier, 30029, Nîmes, France.;Fédération d'Endocrinologie, Centre de Référence des Maladies Rares du Développement Génital, Groupement Hospitalier Est, Hôpital Louis Pradel, 69002, Lyon, France.;Service de Gynecologie et d'Obstétrique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Faculté de médicine, Université Paris-Saclay, 94270 Le Kremlin Bicêtre, France; UVSQ, Inserm, CESP, Université Paris-Saclay, 94807 Villejuif, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Foch, 40 rue Worth 92 150 Suresnes, France; Service de Médecine de la Reproduction et Préservation de la Fertilité, Polyclinique de Navarre, 8, boulevard Hauterive, 64000 Pau, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.;Service de gynécologie médicale, orthogénie et sexologie, Centre Hospitalier Universitaire de Lille, Université de Lille, 59000 Lille, France.;Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif"
"Lasocki S;Capdevila X;Vielle B;Bijok B;Lahlou-Casulli M;Collange V;Grillot N;Danguy des Deserts M;Duchalais A;Delannoy B;Drugeon B;Bouzat P;David JS;Rony L;Loupec T;Léger M;Rineau E","Lasocki, Sigismond;Capdevila, Xavier;Vielle, Bruno;Bijok, Benjamin;Lahlou-Casulli, Maria;Collange, Vincent;Grillot, Nicolas;Danguy des Deserts, Marc;Duchalais, Alexis;Delannoy, Bertrand;Drugeon, Bertrand;Bouzat, Pierre;David, Jean-Stéphane;Rony, Louis;Loupec, Thibault;Léger, Maxime;Rineau, Emmanuel","Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 × 2 factorial, randomised, double-blind, controlled trial.","The Lancet. Haematology","England","eng","Randomized Controlled Trial","","Male;Adult;Humans;Female;Middle Aged;Aged;Aged, 80 and over;Tranexamic Acid;Hip Fractures;Blood Transfusion;Iron;Anemia;Hemoglobins;Double-Blind Method;Treatment Outcome","Male;Adult;Humans;Female;Middle Aged;Aged;Aged, 80 and over;Tranexamic Acid;Hip Fractures;Blood Transfusion;Iron;Anemia;Hemoglobins;Double-Blind Method;Treatment Outcome","Anaemia and blood transfusion are associated with poor outcomes after hip fracture. We evaluated the efficacy of intravenous iron and tranexamic acid in reducing blood transfusions after hip fracture surgery. In this double-blind, randomised, 2 × 2 factorial trial, we recruited adults hospitalised for hip fractures in 12 medical centres in France who had preoperative haemoglobin concentrations between 9·5 and 13·0 g/dL. We randomly allocated participants (1:1:1:1), via a secure web-based service, to ferric derisomaltose (20 mg/kg intravenously) and tranexamic acid (1 g bolus followed by 1 g over 8 h intravenously at inclusion and 3 g topically during surgery), iron plus placebo (normal saline), tranexamic acid plus placebo, or double placebo. Unmasked nurses administered study drugs; participants and other clinical and research staff remained masked to treatment allocation. The primary outcome was the percentage of patients transfused during hospitalisation (or by day 30). The primary analysis included all randomised patients. This study is registered on ClinicalTrials.gov (NCT02972294) and is closed to new participants. Of 413 patients (51-104 years old, median [IQR] 86 [78-91], 312 [76%] women, 101 [24%] men), 104 received iron plus tranexamic acid, 103 iron plus placebo, 103 tranexamic acid plus placebo, and 103 double placebo between March 31, 2017 and June 18, 2021 (study stopped early for efficacy after the planned interim analysis done on the first 390 patients included on May 25, 2021). Data for the primary outcome were available for all participants. Among patients on double placebo, 31 (30%) were transfused versus 16 (15%) on both drugs (relative risk 0·51 [98·3% CI 0·27-0·97]; p=0·012). 27 (26%) participants on iron (0·81 [0·50-1·29]; p=0·28) and 28 (27%) on tranexamic acid (0·85 [0·54-1·33]; p=0·39) were transfused. 487 adverse events were reported with similar event rates among the groups; among prespecified safety endpoints, severe postoperative anaemia (haemoglobin <8 g/dL) was more frequent in the double placebo group. Main common adverse event were sepsis, pneumonia, and urinary infection, with similar rates among all groups. In patients hospitalised for hip fracture surgery with a haemoglobin concentration 9·5-13·0 g/dL, preoperative infusion of ferric derisomaltose plus tranexamic acid reduced the risk of blood transfusion by 50%. Our results suggest that combining treatments from two different pillars improves patient blood-management programmes. Either treatment alone did not reduce transfusion rates, but we might not have had the power to detect it. French Ministry of Health, HiFIT trial.","Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département de Biostatistiques, Centre Hospitalier Universitaire d'Angers, Angers, France.;Centre Hospitalier Universitaire de Lille, Pôle d'anesthésie-réanimation, Lille, France.;Department of Anesthesiology, Critical Care Medicine and Perioperative Medicine, Rennes University Hospital and School of Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anesthesiology, Médipole Lyon Villeurbanne, Lyon, France.;Nantes Université, Centre Hospitalier Universitaire de Nantes, Service d'Anesthésie Réanimation Chirurgicale, Immunologie et Infectiologie, Nantes, France.;Pôle Bloc Anesthésie Réanimation Urgences, Hôpital d'Instruction des Armées Clermont-Tonnerre, INSERM, Université de Bretagne Occidentale, Brest, France.;Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.;Department of Anesthesiology and Intensive Care Medicine, Ramsay Sante, Sauvegarde Clinic, Lyon, France.;Service des Urgences-SAMU-SMUR, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Université Grenoble Alpes, Inserm, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.;Service d'Anesthésie Réanimation, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre Bénite and Research on Healthcare Performance, Inserm, University Claude Bernard Lyon, Lyon, France.;Département de Chirurgie osseuse, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.","NA",0,"2352-3026","Lancet Haematol","Lancet Haematol",2023,"2023","10","10.1016/S2352-3026(23)00163-1","e747-e755","","","37524101","37524101","PUBMED","Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département de Biostatistiques, Centre Hospitalier Universitaire d'Angers, Angers, France.;Centre Hospitalier Universitaire de Lille, Pôle d'anesthésie-réanimation, Lille, France.;Department of Anesthesiology, Critical Care Medicine and Perioperative Medicine, Rennes University Hospital and School of Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anesthesiology, Médipole Lyon Villeurbanne, Lyon, France.;Nantes Université, Centre Hospitalier Universitaire de Nantes, Service d'Anesthésie Réanimation Chirurgicale, Immunologie et Infectiologie, Nantes, France.;Pôle Bloc Anesthésie Réanimation Urgences, Hôpital d'Instruction des Armées Clermont-Tonnerre, INSERM, Université de Bretagne Occidentale, Brest, France.;Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.;Department of Anesthesiology and Intensive Care Medicine, Ramsay Sante, Sauvegarde Clinic, Lyon, France.;Service des Urgences-SAMU-SMUR, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Université Grenoble Alpes, Inserm, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.;Service d'Anesthésie Réanimation, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre Bénite and Research on Healthcare Performance, Inserm, University Claude Bernard Lyon, Lyon, France.;Département de Chirurgie osseuse, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France."
"Houben NAM;Fustolo-Gunnink S;Fijnvandraat K;Caram-Deelder C;Carrascosa MA;Beuchée A;Brække K;Cardona F;Debeer A;Domingues S;Ghirardello S;Grizelj R;Hadžimuratovic E;Heiring C;Krivec JL;Malý J;Matasova K;Moore CM;Muehlbacher T;Szabó M;Szczapa T;Zaharie G;de Jager J;Reibel-Georgi NJ;New HV;Stanworth SJ;Deschmann E;Roehr CC;Dame C;le Cessie S;van der Bom J;Lopriore E","Houben, Nina A M;Fustolo-Gunnink, Suzanne;Fijnvandraat, Karin;Caram-Deelder, Camila;Carrascosa, Marta Aguar;Beuchée, Alain;Brække, Kristin;Cardona, Francesco;Debeer, Anne;Domingues, Sara;Ghirardello, Stefano;Grizelj, Ruza;Hadžimuratovic, Emina;Heiring, Christian;Krivec, Jana Lozar;Malý, Jan;Matasova, Katarina;Moore, Carmel Maria;Muehlbacher, Tobias;Szabó, Miklos;Szczapa, Tomasz;Zaharie, Gabriela;de Jager, Justine;Reibel-Georgi, Nora Johanna;New, Helen V;Stanworth, Simon J;Deschmann, Emöke;Roehr, Charles C;Dame, Christof;le Cessie, Saskia;van der Bom, Johanna;Lopriore, Enrico","Red Blood Cell Transfusion in European Neonatal Intensive Care Units, 2022 to 2023.","JAMA network open","United States","eng","Journal Article","","Humans;Erythrocyte Transfusion;Infant, Newborn;Intensive Care Units, Neonatal;Europe;Prospective Studies;Female;Male;Infant, Premature","Humans;Erythrocyte Transfusion;Infant, Newborn;Intensive Care Units, Neonatal;Europe;Prospective Studies;Female;Male;Infant, Premature","Red blood cell (RBC) transfusions are frequently administered to preterm infants born before 32 weeks of gestation in the neonatal intensive care unit (NICU). Two randomized clinical trials (Effects of Transfusion Thresholds on Neurocognitive Outcomes of Extremely Low-Birth-Weight Infants [ETTNO] and Transfusion of Prematures [TOP]) found that liberal RBC transfusion thresholds are nonsuperior to restrictive thresholds, but the extent to which these results have been integrated into clinical practice since publication in 2020 is unknown. To describe neonatal RBC transfusion practice in Europe. This international prospective observational cohort study collected data between September 1, 2022, and August 31, 2023, with a 6-week observation period per center, from 64 NICUs in 22 European countries. Participants included 1143 preterm infants born before 32 weeks of gestation. Admission to the NICU. Study outcome measures included RBC transfusion prevalence rates, cumulative incidence, indications, pretransfusion hemoglobin (Hb) levels, volumes, and transfusion rates, Hb increment, and adverse effects of RBC transfusion. A total of 1143 preterm infants were included (641 male [56.1%]; median gestational age at birth, 28 weeks plus 2 days [IQR, 26 weeks plus 2 days to 30 weeks plus 2 days]; median birth weight, 1030 [IQR, 780-1350] g), of whom 396 received 1 or more RBC transfusions, totaling 903 transfusions. Overall RBC transfusion prevalence rate during postnatal days 1 to 28 was 3.4 transfusion days per 100 admission days, with considerable variation across countries, only partly explained by patient mix. By day 28, 36.5% (95% CI, 31.6%-41.5%) of infants had received at least 1 transfusion. Most transfusions were given based on a defined Hb threshold (748 [82.8%]). Hemoglobin levels before transfusions indicated for threshold were below the restrictive thresholds set by ETTNO in 324 of 729 transfusions (44.4%) and TOP in 265 of 729 (36.4%). Conversely, they were between restrictive and liberal thresholds in 352 (48.3%) and 409 (56.1%) transfusions, respectively, and above liberal thresholds in 53 (7.3%) and 55 (7.5%) transfusions, respectively. Most transfusions given based on threshold had volumes of 15 mL/kg (470 of 738 [63.7%]) and were administered over 3 hours (400 of 738 [54.2%]), but there was substantial variation in dose and duration. In this cohort study of very preterm infants, most transfusions indicated for threshold were given for pretransfusion Hb levels above restrictive transfusion thresholds evaluated in recent trials. These results underline the need to optimize practices and for implementation research to support uptake of evidence.","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Sanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Centro Materno-Infantil do Norte-Unidade Local de Saúde de Santo António, Porto, Portugal.;Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Králové, Hradec Králové, Czech Republic.;Jessenius Faculty of Medicine, University Hospital Martin, Martin, Slovakia.;School of Medicine, University College Dublin, Dublin, Ireland.;National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Neonatology, Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.;Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.;Women's and Children's Division, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2024,"2024","7","10.1001/jamanetworkopen.2024.34077","e2434077","","","39298172","39298172","PUBMED","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Sanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Centro Materno-Infantil do Norte-Unidade Local de Saúde de Santo António, Porto, Portugal.;Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Králové, Hradec Králové, Czech Republic.;Jessenius Faculty of Medicine, University Hospital Martin, Martin, Slovakia.;School of Medicine, University College Dublin, Dublin, Ireland.;National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Neonatology, Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.;Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.;Women's and Children's Division, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands."
"Siefker-Radtke AO;Matsubara N;Park SH;Huddart RA;Burgess EF;Özgüroğlu M;Valderrama BP;Laguerre B;Basso U;Triantos S;Akapame S;Kean Y;Deprince K;Mukhopadhyay S;Loriot Y","Siefker-Radtke, A O;Matsubara, N;Park, S H;Huddart, R A;Burgess, E F;Özgüroğlu, M;Valderrama, B P;Laguerre, B;Basso, U;Triantos, S;Akapame, S;Kean, Y;Deprince, K;Mukhopadhyay, S;Loriot, Y","Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Randomized Controlled Trial","FGFR;erdafitinib;metastatic urothelial cancer;overall survival;pembrolizumab;safety","Humans;Carcinoma, Transitional Cell;Urinary Bladder Neoplasms;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Pyrazoles;Quinoxalines","Humans;Carcinoma, Transitional Cell;Urinary Bladder Neoplasms;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Pyrazoles;Quinoxalines","Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFRalt) who progressed after platinum-containing chemotherapy. FGFR-altered tumours are enriched in luminal 1 subtype and may have limited clinical benefit from anti-programmed death-(ligand) 1 [PD-(L)1] treatment. This cohort in the randomized, open-label phase III THOR study assessed erdafitinib versus pembrolizumab in anti-PD-(L)1-naive patients with mUC. Patients ≥18 years with unresectable advanced/mUC, with select FGFRalt, disease progression on one prior treatment, and who were anti-PD-(L)1-naive were randomized 1 : 1 to receive erdafitinib 8 mg once daily with pharmacodynamically guided uptitration to 9 mg or pembrolizumab 200 mg every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The intent-to-treat population (median follow-up 33 months) comprised 175 and 176 patients in the erdafitinib and pembrolizumab arms, respectively. There was no statistically significant difference in OS between erdafitinib and pembrolizumab [median 10.9 versus 11.1 months, respectively; hazard ratio (HR) 1.18; 95% confidence interval (CI) 0.92-1.51; P = 0.18]. Median PFS for erdafitinib and pembrolizumab was 4.4 and 2.7 months, respectively (HR 0.88; 95% CI 0.70-1.10). ORR was 40.0% and 21.6% (relative risk 1.85; 95% CI 1.32-2.59) and median duration of response was 4.3 and 14.4 months for erdafitinib and pembrolizumab, respectively. 64.7% and 50.9% of patients in the erdafitinib and pembrolizumab arms had ≥1 grade 3-4 adverse events (AEs); 5 (2.9%) and 12 (6.9%) patients, respectively, had AEs that led to death. Erdafitinib and pembrolizumab had similar median OS in this anti-PD-(L)1-naive, FGFR-altered mUC population. Outcomes with pembrolizumab were better than assumed and aligned with previous reports in non- FGFR-altered populations. Safety results were consistent with the known profiles for erdafitinib and pembrolizumab in this patient population.","Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston;Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.;Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA.;Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.;Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Beerse, Belgium.;Janssen Research & Development, Raritan, USA.;Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2023,"2024","35","10.1016/j.annonc.2023.10.003","107-117","","","37871702","37871702","PUBMED","Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston;Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.;Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA.;Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.;Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Beerse, Belgium.;Janssen Research & Development, Raritan, USA.;Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France."
"Hossain SI;de Goër de Herve J;Hassan MS;Martineau D;Petrosyan E;Corbin V;Beytout J;Lebert I;Durand J;Carravieri I;Brun-Jacob A;Frey-Klett P;Baux E;Cazorla C;Eldin C;Hansmann Y;Patrat-Delon S;Prazuck T;Raffetin A;Tattevin P;Vourc'h G;Lesens O;Nguifo EM","Hossain, Sk Imran;de Goër de Herve, Jocelyn;Hassan, Md Shahriar;Martineau, Delphine;Petrosyan, Evelina;Corbin, Violaine;Beytout, Jean;Lebert, Isabelle;Durand, Jonas;Carravieri, Irene;Brun-Jacob, Annick;Frey-Klett, Pascale;Baux, Elisabeth;Cazorla, Céline;Eldin, Carole;Hansmann, Yves;Patrat-Delon, Solene;Prazuck, Thierry;Raffetin, Alice;Tattevin, Pierre;Vourc'h, Gwenaël;Lesens, Olivier;Nguifo, Engelbert Mephu","Exploring convolutional neural networks with transfer learning for diagnosing Lyme disease from skin lesion images.","Computer methods and programs in biomedicine","Ireland","eng","Journal Article","CNN;Erythema migrans;Explainability;Lyme disease;Transfer learning","France;Humans;Lyme Disease;Machine Learning;Neural Networks, Computer;Skin Diseases","France;Humans;Lyme Disease;Machine Learning;Neural Networks, Computer;Skin Diseases","Lyme disease which is one of the most common infectious vector-borne diseases manifests itself in most cases with erythema migrans (EM) skin lesions. Recent studies show that convolutional neural networks (CNNs) perform well to identify skin lesions from images. Lightweight CNN based pre-scanner applications for resource-constrained mobile devices can help users with early diagnosis of Lyme disease and prevent the transition to a severe late form thanks to appropriate antibiotic therapy. Also, resource-intensive CNN based robust computer applications can assist non-expert practitioners with an accurate diagnosis. The main objective of this study is to extensively analyze the effectiveness of CNNs for diagnosing Lyme disease from images and to find out the best CNN architectures considering resource constraints. First, we created an EM dataset with the help of expert dermatologists from Clermont-Ferrand University Hospital Center of France. Second, we benchmarked this dataset for twenty-three CNN architectures customized from VGG, ResNet, DenseNet, MobileNet, Xception, NASNet, and EfficientNet architectures in terms of predictive performance, computational complexity, and statistical significance. Third, to improve the performance of the CNNs, we used custom transfer learning from ImageNet pre-trained models as well as pre-trained the CNNs with the skin lesion dataset HAM10000. Fourth, for model explainability, we utilized Gradient-weighted Class Activation Mapping to visualize the regions of input that are significant to the CNNs for making predictions. Fifth, we provided guidelines for model selection based on predictive performance and computational complexity. Customized ResNet50 architecture gave the best classification accuracy of 84.42% ±1.36, AUC of 0.9189±0.0115, precision of 83.1%±2.49, sensitivity of 87.93%±1.47, and specificity of 80.65%±3.59. A lightweight model customized from EfficientNetB0 also performed well with an accuracy of 83.13%±1.2, AUC of 0.9094±0.0129, precision of 82.83%±1.75, sensitivity of 85.21% ±3.91, and specificity of 80.89%±2.95. All the trained models are publicly available at https://dappem.limos.fr/download.html, which can be used by others for transfer learning and building pre-scanners for Lyme disease. Our study confirmed the effectiveness of even some lightweight CNNs for building Lyme disease pre-scanner mobile applications to assist people with an initial self-assessment and referring them to expert dermatologist for further diagnosis.","Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Inserm, Neuro-Dol, CNRS 6023 Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;CPIE Champenoux, F-54280 Champenoux, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;INRAE, US 1371 Laboratory of Excellence ARBRE, Centre INRAE Grand Est-Nancy, Champenoux F-54280, France.;Infectious Diseases Department, University Hospital of Nancy, Nancy, France.;Infectious Disease Department, University Hospital of Saint Etienne, Saint-Etienne, France.;IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires, 67000 Strasbourg, France.;Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Tick-Borne Diseases Reference Center, North region, Department of Infectious Diseases, Hospital of Villeneuve-Saint-Georges, 40 allée de la Source, 94190 Villeneuve-Saint-Georges; ESGBOR, European Study Group for Lyme Borreliosis.;Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Infectious and Tropical Diseases Department, CRIOA, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6023, Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand","NA",0,"1872-7565","Comput Methods Programs Biomed","Comput Methods Programs Biomed",2021,"2022","215","10.1016/j.cmpb.2022.106624","106624","","","35051835","35051835","PUBMED","Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Inserm, Neuro-Dol, CNRS 6023 Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;CPIE Champenoux, F-54280 Champenoux, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;INRAE, US 1371 Laboratory of Excellence ARBRE, Centre INRAE Grand Est-Nancy, Champenoux F-54280, France.;Infectious Diseases Department, University Hospital of Nancy, Nancy, France.;Infectious Disease Department, University Hospital of Saint Etienne, Saint-Etienne, France.;IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires, 67000 Strasbourg, France.;Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Tick-Borne Diseases Reference Center, North region, Department of Infectious Diseases, Hospital of Villeneuve-Saint-Georges, 40 allée de la Source, 94190 Villeneuve-Saint-Georges; ESGBOR, European Study Group for Lyme Borreliosis.;Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Infectious and Tropical Diseases Department, CRIOA, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6023, Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand"
"Lorscheider J;Signori A;Subramaniam S;Benkert P;Vukusic S;Trojano M;Hillert J;Glaser A;Hyde R;Spelman T;Magyari M;Elberling F;Pontieri L;Koch-Henriksen N;Sørensen PS;Gerlach O;Prat A;Girard M;Eichau S;Grammond P;Horakova D;Ramo-Tello C;Roos I;Buzzard K;Lechner Scott J;Sánchez-Menoyo JL;Alroughani R;Prévost J;Kuhle J;Gray O;Mathey G;Michel L;Ciron J;De Sèze J;Maillart E;Ruet A;Labauge P;Zephir H;Kwiatkowski A;van der Walt A;Kalincik T;Butzkueven H","Lorscheider, Johannes;Signori, Alessio;Subramaniam, Suvitha;Benkert, Pascal;Vukusic, Sandra;Trojano, Maria;Hillert, Jan;Glaser, Anna;Hyde, Robert;Spelman, Tim;Magyari, Melinda;Elberling, Frederik;Pontieri, Luigi;Koch-Henriksen, Nils;Sørensen, Per Soelberg;Gerlach, Oliver;Prat, Alexandre;Girard, Marc;Eichau, Sara;Grammond, Pierre;Horakova, Dana;Ramo-Tello, Cristina;Roos, Izanne;Buzzard, Katherine;Lechner Scott, Jeanette;Sánchez-Menoyo, José Luis;Alroughani, Raed;Prévost, Julie;Kuhle, Jens;Gray, Orla;Mathey, Guillaume;Michel, Laure;Ciron, Jonathan;De Sèze, Jérôme;Maillart, Elisabeth;Ruet, Aurelie;Labauge, Pierre;Zephir, Helene;Kwiatkowski, Arnaud;van der Walt, Anneke;Kalincik, Tomas;Butzkueven, Helmut","Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.","Journal of neurology, neurosurgery, and psychiatry","England","eng","Journal Article","MULTIPLE SCLEROSIS","","","Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories. Within the framework of the Big MS Data network, we merged data from the Observatoire Français de la Sclérose en Plaques, the Swedish and Italian MS registries, and MSBase. We identified patients with PPMS that started DMT or were never treated during the observed period. Subpopulations with comparable baseline characteristics were selected by propensity score matching. Disability outcomes were analysed in time-to-recurrent event analyses, which were repeated in subclasses with different disability trajectories determined by latent class mixed models. Of the 3243 included patients, we matched 739 treated and 1330 untreated patients with a median follow-up of 3 years after pairwise censoring. No difference in the risk of confirmed disability worsening (CDW) was observed between the groups in the fully matched dataset (HR 1.11, 95% CI 0.97 to 1.23, p=0.127). However, we found a lower risk for CDW among the class of treated patients with an aggressive disability trajectory (n=360, HR 0.68, 95% CI 0.50 to 0.92, p=0.014). In line with previous studies, our data suggest that DMT does not ameliorate disability worsening in PPMS, in general. However, we observed a beneficial effect of DMT on disability worsening in patients with aggressive predicted disability trajectories.","Department of Neurology, University Hospital Basel, Basel;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;Department of Health Sciences, Section of Biostatistics, University of Genoa, Genova, Italy.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Lyon, France.;Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France.;Eugène Devic EDMUS Foundation against multiple sclerosis, Lyon, France.;Department of Translational Biomedicine and Neurosciences - DiBraiN, University of Bari ""Aldo Moro"", Bari, Italy.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Independent Healthcare and Real-World Evidence Consultant, Zug, Switzerland.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;MSBase Foundation, Melbourne, Victoria, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands.;School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hospital Universitario Virgen Macarena, Sevilla, Spain.;Hotel-Dieu de Levis, Levis, Quebec, Canada.;Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.;Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurosciences, Box Hill Hospital, Box Hill, Victoria, Australia.;Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.;Hunter New England Health, John Hunter Hospital, Newcastle, New South Wales, Australia.;Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.;Neurology, Galdakao Hospital, Spain, Spain.;Amiri Hospital, Kuwait City, Kuwait.;Centre Integre de Sante et de Services Sociaux des Laurentides, Saint-Jerome, Quebec, Canada.;Department of Neurology, University Hospital Basel, Basel, Switzerland.;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;South Eastern HSC Trust, Belfast, UK.;Department of Neurology, Nancy University Hospital, Université de Lorraine, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neurology and Clinical Investigation Center, CHU de Strasbourg and University of Strasbourg, Strasbourg, France.;Neurology, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.;Service de Neurologie, CHU de Bordeaux, Bordeaux, France.;Neurocentre Magendie, Université de Bordeaux, Bordeaux, France.;CHU de Montpellier, MS Unit, University of Montpellier (MUSE), Montpellier, France.;CHU Lille, CRCSEP Lille, Université de Lille, Lille, France.;Department of Neurology, Hôpital Saint Vincent de Paul, Lille, France.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.","NA",0,"1468-330X","J Neurol Neurosurg Psychiatry","J Neurol Neurosurg Psychiatry",2024,"2024",NA,"10.1136/jnnp-2024-334700",NA,"","","39643429","39643429","PUBMED","Department of Neurology, University Hospital Basel, Basel;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;Department of Health Sciences, Section of Biostatistics, University of Genoa, Genova, Italy.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Lyon, France.;Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France.;Eugène Devic EDMUS Foundation against multiple sclerosis, Lyon, France.;Department of Translational Biomedicine and Neurosciences - DiBraiN, University of Bari ""Aldo Moro"", Bari, Italy.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Independent Healthcare and Real-World Evidence Consultant, Zug, Switzerland.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;MSBase Foundation, Melbourne, Victoria, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands.;School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hospital Universitario Virgen Macarena, Sevilla, Spain.;Hotel-Dieu de Levis, Levis, Quebec, Canada.;Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.;Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurosciences, Box Hill Hospital, Box Hill, Victoria, Australia.;Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.;Hunter New England Health, John Hunter Hospital, Newcastle, New South Wales, Australia.;Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.;Neurology, Galdakao Hospital, Spain, Spain.;Amiri Hospital, Kuwait City, Kuwait.;Centre Integre de Sante et de Services Sociaux des Laurentides, Saint-Jerome, Quebec, Canada.;Department of Neurology, University Hospital Basel, Basel, Switzerland.;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;South Eastern HSC Trust, Belfast, UK.;Department of Neurology, Nancy University Hospital, Université de Lorraine, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neurology and Clinical Investigation Center, CHU de Strasbourg and University of Strasbourg, Strasbourg, France.;Neurology, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.;Service de Neurologie, CHU de Bordeaux, Bordeaux, France.;Neurocentre Magendie, Université de Bordeaux, Bordeaux, France.;CHU de Montpellier, MS Unit, University of Montpellier (MUSE), Montpellier, France.;CHU Lille, CRCSEP Lille, Université de Lille, Lille, France.;Department of Neurology, Hôpital Saint Vincent de Paul, Lille, France.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia."
"Thille AW;Monseau G;Coudroy R;Nay MA;Gacouin A;Decavèle M;Sonneville R;Beloncle F;Girault C;Dangers L;Lautrette A;Levrat Q;Rouzé A;Vivier E;Lascarrou JB;Ricard JD;Razazi K;Barberet G;Lebert C;Ehrmann S;Massri A;Bourenne J;Pradel G;Bailly P;Terzi N;Dellamonica J;Lacave G;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Monseau, Grégoire;Coudroy, Rémi;Nay, Mai-Anh;Gacouin, Arnaud;Decavèle, Maxens;Sonneville, Romain;Beloncle, François;Girault, Christophe;Dangers, Laurence;Lautrette, Alexandre;Levrat, Quentin;Rouzé, Anahita;Vivier, Emmanuel;Lascarrou, Jean-Baptiste;Ricard, Jean-Damien;Razazi, Keyvan;Barberet, Guillaume;Lebert, Christine;Ehrmann, Stephan;Massri, Alexandre;Bourenne, Jeremy;Pradel, Gael;Bailly, Pierre;Terzi, Nicolas;Dellamonica, Jean;Lacave, Guillaume;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","Non-invasive ventilation versus high-flow nasal oxygen for postextubation respiratory failure in ICU: a post-hoc analysis of a randomized clinical trial.","Critical care (London, England)","England","eng","Journal Article","Acute respiratory failure;Airway extubation;High-flow nasal oxygen;Noninvasive ventilation;Ventilator weaning","Aged;Aged, 80 and over;Airway Extubation;Female;Humans;Intensive Care Units;Kaplan-Meier Estimate;Length of Stay;Male;Middle Aged;Noninvasive Ventilation;Oxygen Inhalation Therapy;Respiratory Insufficiency","Aged;Aged, 80 and over;Airway Extubation;Female;Humans;Intensive Care Units;Kaplan-Meier Estimate;Length of Stay;Male;Middle Aged;Noninvasive Ventilation;Oxygen Inhalation Therapy;Respiratory Insufficiency","In intensive care units (ICUs), patients experiencing post-extubation respiratory failure have poor outcomes. The use of noninvasive ventilation (NIV) to treat post-extubation respiratory failure may increase the risk of death. This study aims at comparing mortality between patients treated with NIV alternating with high-flow nasal oxygen or high-flow nasal oxygen alone. Post-hoc analysis of a multicenter, randomized, controlled trial focusing on patients who experienced post-extubation respiratory failure within the 7 days following extubation. Patients were classified in the NIV group or the high-flow nasal oxygen group according to oxygenation strategy used after the onset of post-extubation respiratory failure. Patients reintubated within the first hour after extubation and those promptly reintubated without prior treatment were excluded. The primary outcome was mortality at day 28 after the onset of post-extubation respiratory failure. Among 651 extubated patients, 158 (25%) experienced respiratory failure and 146 were included in the analysis. Mortality at day 28 was 18% (15/84) using NIV alternating with high-flow nasal oxygen and 29% (18/62) with high flow nasal oxygen alone (difference, - 11% [95% CI, - 25 to 2]; p = 0.12). Among the 46 patients with hypercapnia at the onset of respiratory failure, mortality at day 28 was 3% (1/33) with NIV and 31% (4/13) with high-flow nasal oxygen alone (difference, - 28% [95% CI, - 54 to - 6]; p = 0.006). The proportion of patients reintubated 48 h after the onset of post-extubation respiratory failure was 44% (37/84) with NIV and 52% (32/62) with high-flow nasal oxygen alone (p = 0.21). In patients with post-extubation respiratory failure, NIV alternating with high-flow nasal oxygen might not increase the risk of death. Trial registration number The trial was registered at http://www.clinicaltrials.gov with the registration number NCT03121482 the 20th April 2017.","Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Rennes, France.;Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP 6 - Sorbonne, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat - Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de la Rochelle, Service de Réanimation, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, UMR IAME 1137, Sorbonne Paris Cité, Université Paris Diderot, Colombes, France.;Hôpitaux Universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, Service de Réanimation Médicale, Site Emile Muller, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERMU1042, HP2, Université Grenoble-Alpes, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.","NA",0,"1466-609X","Crit Care","Crit Care",2021,"2021","25","10.1186/s13054-021-03621-6","221","grant number 15-0060","Ministère des Affaires Sociales, de la Santé et des Droits des Femmes","34183053","34183053","PUBMED","Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Rennes, France.;Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP 6 - Sorbonne, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat - Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de la Rochelle, Service de Réanimation, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, UMR IAME 1137, Sorbonne Paris Cité, Université Paris Diderot, Colombes, France.;Hôpitaux Universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, Service de Réanimation Médicale, Site Emile Muller, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERMU1042, HP2, Université Grenoble-Alpes, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France."
"Allaume P;Rabilloud N;Turlin B;Bardou-Jacquet E;Loréal O;Calderaro J;Khene ZE;Acosta O;De Crevoisier R;Rioux-Leclercq N;Pecot T;Kammerer-Jacquet SF","Allaume, Pierre;Rabilloud, Noémie;Turlin, Bruno;Bardou-Jacquet, Edouard;Loréal, Olivier;Calderaro, Julien;Khene, Zine-Eddine;Acosta, Oscar;De Crevoisier, Renaud;Rioux-Leclercq, Nathalie;Pecot, Thierry;Kammerer-Jacquet, Solène-Florence","Artificial Intelligence-Based Opportunities in Liver Pathology-A Systematic Review.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","artificial intelligence;deep learning;digital pathology;hepatology;liver;performance metrics","","","Artificial Intelligence (AI)-based Deep Neural Networks (DNNs) can handle a wide range of applications in image analysis, ranging from automated segmentation to diagnostic and prediction. As such, they have revolutionized healthcare, including in the liver pathology field. The present study aims to provide a systematic review of applications and performances provided by DNN algorithms in liver pathology throughout the Pubmed and Embase databases up to December 2022, for tumoral, metabolic and inflammatory fields. 42 articles were selected and fully reviewed. Each article was evaluated through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, highlighting their risks of bias. DNN-based models are well represented in the field of liver pathology, and their applications are diverse. Most studies, however, presented at least one domain with a high risk of bias according to the QUADAS-2 tool. Hence, DNN models in liver pathology present future opportunities and persistent limitations. To our knowledge, this review is the first one solely focused on DNN-based applications in liver pathology, and to evaluate their bias through the lens of the QUADAS2 tool.","Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Liver Diseases CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Assistance Publique-Hôpitaux de Paris, Department of Pathology Henri Mondor, 94000 Créteil, France.;INSERM U955, Team Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers, 94000 Créteil, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Urology, CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Biosit Platform UAR 3480 CNRS US18 INSERM U955, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2023,"2023","13","10.3390/diagnostics13101799",NA,"","","37238283","37238283","PUBMED","Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Liver Diseases CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Assistance Publique-Hôpitaux de Paris, Department of Pathology Henri Mondor, 94000 Créteil, France.;INSERM U955, Team Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers, 94000 Créteil, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Urology, CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Biosit Platform UAR 3480 CNRS US18 INSERM U955, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France."
"Hraiech S;Yoshida T;Annane D;Duggal A;Fanelli V;Gacouin A;Heunks L;Jaber S;Sottile PD;Papazian L","Hraiech, Sami;Yoshida, Takeshi;Annane, Djillali;Duggal, Abhijit;Fanelli, Vito;Gacouin, Arnaud;Heunks, Leo;Jaber, Samir;Sottile, Peter D;Papazian, Laurent","Myorelaxants in ARDS patients.","Intensive care medicine","United States","eng","Journal Article","Corticosteroids;ECMO;Muscle relaxants;PEEP;Prone positioning;Protective ventilation;Sedation","Humans;Neuromuscular Blocking Agents;Respiration, Artificial;Respiratory Distress Syndrome;Tidal Volume;Ventilator-Induced Lung Injury","Humans;Neuromuscular Blocking Agents;Respiration, Artificial;Respiratory Distress Syndrome;Tidal Volume;Ventilator-Induced Lung Injury","Neuromuscular blocking agents (NMBAs) inhibit patient-initiated active breath and the risk of high tidal volumes and consequent high transpulmonary pressure swings, and minimize patient/ ventilator asynchrony in acute respiratory distress syndrome (ARDS). Minimization of volutrauma and ventilator-induced lung injury (VILI) results in a lower incidence of barotrauma, improved oxygenation and a decrease in circulating proinflammatory markers. Recent randomized clinical trials did not reveal harmful muscular effects during a short course of NMBAs. The use of NMBAs should be considered during the early phase of severe ARDS for patients to facilitate lung protective ventilation or prone positioning only after optimising mechanical ventilation and sedation. The use of NMBAs should be integrated in a global strategy including the reduction of tidal volume, the rational use of PEEP, prone positioning and the use of a ventilatory mode allowing spontaneous ventilation as soon as possible. Partial neuromuscular blockade should be evaluated in future trials.","Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille, France.;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille, France.;The Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.;School of Medicine Simone Veil, Lab of Infection and Inflammation, U1173, RHU-RECORDS, FHU SEPSIS, INSERM, Université Paris Saclay, UVSQ, Hôpital Raymond Poincaré (APHP), 104 boulevard Raymond Poincaré, 92380, Garches, France.;Department of Critical Care, Respiratory Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, 44195, USA.;Department of Surgical Sciences, Anaesthesia and Intensive Care Medicine, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, Inserm-CIC-1414, Université Rennes I, IFR 140, F-35033, Rennes, France.;Department of Intensive Care Medicine, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands.;Réanimation Chirurgicale, Centre Hospitalier Universitaire de Montpellier, Hôpital St-Eloi, Montpellier, France.;Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.;Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille","NA",0,"1432-1238","Intensive Care Med","Intensive Care Med",2020,"2020","46","10.1007/s00134-020-06297-8","2357-2372","K23 HL145011","NHLBI NIH HHS","33159530","33159530","PUBMED","Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille, France.;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille, France.;The Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.;School of Medicine Simone Veil, Lab of Infection and Inflammation, U1173, RHU-RECORDS, FHU SEPSIS, INSERM, Université Paris Saclay, UVSQ, Hôpital Raymond Poincaré (APHP), 104 boulevard Raymond Poincaré, 92380, Garches, France.;Department of Critical Care, Respiratory Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, 44195, USA.;Department of Surgical Sciences, Anaesthesia and Intensive Care Medicine, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, Inserm-CIC-1414, Université Rennes I, IFR 140, F-35033, Rennes, France.;Department of Intensive Care Medicine, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands.;Réanimation Chirurgicale, Centre Hospitalier Universitaire de Montpellier, Hôpital St-Eloi, Montpellier, France.;Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.;Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille"
"Drillet G;Pastoret C;Moignet A;Lamy T;Marchand T","Drillet, Gaëlle;Pastoret, Cédric;Moignet, Aline;Lamy, Thierry;Marchand, Tony","Toward a Better Classification System for NK-LGL Disorders.","Frontiers in oncology","Switzerland","eng","Journal Article","KIR phenotype;NK cells;STAT3;chronic lymphoproliferative disorders of NK cells;large granular lymphocyte leukemia","","","Large granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by a clonal expansion of T-lineage lymphocyte or natural killer (NK) cells in 85 and 15% of cases respectively. T and NK large granular leukemia share common pathophysiology, clinical and biological presentation. The disease is characterized by cytopenia and a frequent association with autoimmune manifestations. Despite an indolent course allowing a watch and wait attitude in the majority of patients at diagnosis, two third of the patient will eventually need a treatment during the course of the disease. Unlike T lymphocyte, NK cells do not express T cell receptor making the proof of clonality difficult. Indeed, the distinction between clonal and reactive NK-cell expansion observed in several situations such as autoimmune diseases and viral infections is challenging. Advances in our understanding of the pathogenesis with the recent identification of recurrent mutations provide new tools to prove the clonality. In this review, we will discuss the pathophysiology of NK large granular leukemia, the recent advances in the diagnosis and therapeutic strategies.","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;CIC 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2021,"2022","12","10.3389/fonc.2022.821382","821382","","","35178350","35178350","PUBMED","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;CIC 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France."
"Moinard-Butot F;Saint-Martin C;Pflumio C;Carton M;Jacot W;Cottu PH;Diéras V;Dalenc F;Goncalves A;Debled M;Patsouris A;Mouret-Reynier MA;Vanlemmens L;Leheurteur M;Emile G;Ferrero JM;Desmoulins I;Uwer L;Eymard JC;Cheaib B;Courtinard C;Bachelot T;Chevrot M;Petit T","Moinard-Butot, Fabien;Saint-Martin, Caroline;Pflumio, Carole;Carton, Matthieu;Jacot, William;Cottu, Paul-Henri;Diéras, Véronique;Dalenc, Florence;Goncalves, Anthony;Debled, Marc;Patsouris, Anne;Mouret-Reynier, Marie-Ange;Vanlemmens, Laurence;Leheurteur, Marianne;Emile, George;Ferrero, Jean-Marc;Desmoulins, Isabelle;Uwer, Lionel;Eymard, Jean-Christophe;Cheaib, Bianca;Courtinard, Coralie;Bachelot, Thomas;Chevrot, Michaël;Petit, Thierry","Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Dual HER2 blockade;Lapatinib;Metastatic breast cancer;Overall survival;Progression-free survival;T-DM1","Ado-Trastuzumab Emtansine;Adolescent;Adult;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Lapatinib;Receptor, ErbB-2;Retrospective Studies;Taxoids;Trastuzumab","Ado-Trastuzumab Emtansine;Adolescent;Adult;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Lapatinib;Receptor, ErbB-2;Retrospective Studies;Taxoids;Trastuzumab","Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and lapatinib plus capecitabine beyond, without formal evaluation of these strategies. ESME Data Platform (NCT03275311) included individual data from all patients aged ≥18 years, in whom first-line treatment for metastatic breast cancer (MBC) was initiated between January 1, 2008 and December 31, 2016 in one of the 18 French Comprehensive Cancer Centers. The efficacy of T-DM1 and lapatinib plus capecitabine combination, following double blockade associating trastuzumab and pertuzumab were evaluated in this national real-life database. Eligibility criteria were: female, MBC, HER2+ tumor, first-line taxane-based chemotherapy and dual HER2-blockage by trastuzumab plus pertuzumab. Cohort A received second-line T-DM1, and Cohort B second-line T-DM1 and third or fourth-line lapatinib plus capecitabine. Cohort A comprised 233 patients, and Cohort B 47 patients. Median progression-free survival (PFS) was 7.1 months in Cohort A and 4.6 months in Cohort B. Median overall survival were 36.7 months and 12.9 months, respectively. PFS was significantly dependent on the preceding treatment line's duration. In cohort A, HER2 expression status was a significant predictive factor of PFS. First-line trastuzumab plus pertuzumab do not markedly diminish T-DM1's efficacy in second-line. Similarly, sequential treatment with trastuzumab plus pertuzumab then T-DM1 does not noticeably modify the efficacy of lapatinib plus capecitabine.","Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.","NA",0,"1532-3080","Breast","Breast",2021,"2022","63","10.1016/j.breast.2022.03.004","54-60","","","35299035","35299035","PUBMED","Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France."
"Lefebvre C;Bachelot T;Filleron T;Pedrero M;Campone M;Soria JC;Massard C;Lévy C;Arnedos M;Lacroix-Triki M;Garrabey J;Boursin Y;Deloger M;Fu Y;Commo F;Scott V;Lacroix L;Dieci MV;Kamal M;Diéras V;Gonçalves A;Ferrerro JM;Romieu G;Vanlemmens L;Mouret Reynier MA;Théry JC;Le Du F;Guiu S;Dalenc F;Clapisson G;Bonnefoi H;Jimenez M;Le Tourneau C;André F","Lefebvre, Celine;Bachelot, Thomas;Filleron, Thomas;Pedrero, Marion;Campone, Mario;Soria, Jean-Charles;Massard, Christophe;Lévy, Christelle;Arnedos, Monica;Lacroix-Triki, Magali;Garrabey, Julie;Boursin, Yannick;Deloger, Marc;Fu, Yu;Commo, Frédéric;Scott, Véronique;Lacroix, Ludovic;Dieci, Maria Vittoria;Kamal, Maud;Diéras, Véronique;Gonçalves, Anthony;Ferrerro, Jean-Marc;Romieu, Gilles;Vanlemmens, Laurence;Mouret Reynier, Marie-Ange;Théry, Jean-Christophe;Le Du, Fanny;Guiu, Séverine;Dalenc, Florence;Clapisson, Gilles;Bonnefoi, Hervé;Jimenez, Marta;Le Tourneau, Christophe;André, Fabrice","Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.","PLoS medicine","United States","eng","Journal Article","","Breast Neoplasms;Exome;Female;Humans;Mutation;Neoplasm Metastasis;Retrospective Studies;Sequence Analysis, DNA","Breast Neoplasms;Exome;Female;Humans;Mutation;Neoplasm Metastasis;Retrospective Studies;Sequence Analysis, DNA","Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9-155], p = 1.2e-12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2 negative (HER2-) mBCs (19%). HR+/HER2- mBC presented a high prevalence of mutations on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and TSC2) as compared to HR+/HER2- eBC (respectively 6% and 0.7%, p = 0.0004). Other actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8), NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant increase in APOBEC-mediated mutagenesis in HR+/HER2- metastatic tumors as compared to primary TCGA samples (p < 2e-16). The main limitations of this study include the absence of bone metastases and the size of the cohort, which might not have allowed the identification of rare mutations and their effect on survival. This work reports the results of the analysis of the first large-scale study on mutation profiles of mBC. This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations.","INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Inserm U1052, Lyon, France.;Biostatistics Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;R&D UNICANCER, Paris, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Translational research laboratory and biobank, Gustave Roussy, Villejuif, France.;Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.;Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Clinical Research, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;UNICANCER Biobanking Center, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, INSERM U916, Bordeaux, France.;R&D UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;EA7285, Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.","NA",0,"1549-1676","PLoS Med","PLoS Med",2016,"2016","13","10.1371/journal.pmed.1002201","e1002201","","","28027327","28027327","PUBMED","INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Inserm U1052, Lyon, France.;Biostatistics Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;R&D UNICANCER, Paris, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Translational research laboratory and biobank, Gustave Roussy, Villejuif, France.;Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.;Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Clinical Research, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;UNICANCER Biobanking Center, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, INSERM U916, Bordeaux, France.;R&D UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;EA7285, Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France."
"Codoni G;Kirchner T;Engel B;Villamil AM;Efe C;Stättermayer AF;Weltzsch JP;Sebode M;Bernsmeier C;Lleo A;Gevers TJ;Kupčinskas L;Castiella A;Pinazo J;De Martin E;Bobis I;Sandahl TD;Pedica F;Invernizzi F;Del Poggio P;Bruns T;Kolev M;Semmo N;Bessone F;Giguet B;Poggi G;Ueno M;Jang H;Elpek GÖ;Soylu NK;Cerny A;Wedemeyer H;Vergani D;Mieli-Vergani G;Lucena MI;Andrade RJ;Zen Y;Taubert R;Terziroli Beretta-Piccoli B","Codoni, Greta;Kirchner, Theresa;Engel, Bastian;Villamil, Alejandra Maria;Efe, Cumali;Stättermayer, Albert Friedrich;Weltzsch, Jan Philipp;Sebode, Marcial;Bernsmeier, Christine;Lleo, Ana;Gevers, Tom Jg;Kupčinskas, Limas;Castiella, Agustin;Pinazo, Jose;De Martin, Eleonora;Bobis, Ingrid;Sandahl, Thomas Damgaard;Pedica, Federica;Invernizzi, Federica;Del Poggio, Paolo;Bruns, Tony;Kolev, Mirjam;Semmo, Nasser;Bessone, Fernando;Giguet, Baptiste;Poggi, Guido;Ueno, Masayuki;Jang, Helena;Elpek, Gülsüm Özlem;Soylu, Neşe Karadağ;Cerny, Andreas;Wedemeyer, Heiner;Vergani, Diego;Mieli-Vergani, Giorgina;Lucena, M Isabel;Andrade, Raul J;Zen, Yoh;Taubert, Richard;Terziroli Beretta-Piccoli, Benedetta","Histological and serological features of acute liver injury after SARS-CoV-2 vaccination.","JHEP reports : innovation in hepatology","Netherlands","eng","Journal Article","AIH, autoimmune hepatitis;ALP, alkaline phosphatase;ALT, alanine aminotransferase;AMA, anti-mitochondrial antibody;ANA, anti-nuclear antibody;AST, aspartate aminotransferase;COVID-19, coronavirus disease 2019;DILI, drug-induced liver injury;IAIHG, International Autoimmune Hepatitis Group;IFT, indirect immunofluorescence;LKM, liver kidney microsomal;LT, liver transplantation;PCA, parietal cell antigen;SARS-CoV-2 vaccines;SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2;SLA, soluble liver antigen;SMA, anti-smooth muscle antibody;ULN, upper limit of normal;acute liver injury;autoimmune liver serology;liver histology;pIgG, polyreactive IgG","","","Liver injury with autoimmune features after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is increasingly reported. We investigated a large international cohort of individuals with acute hepatitis arising after SARS-CoV-2 vaccination, focusing on histological and serological features. Individuals without known pre-existing liver diseases and transaminase levels ≥5x the upper limit of normal within 3 months after any anti-SARS-CoV-2 vaccine, and available liver biopsy were included. Fifty-nine patients were recruited; 35 females; median age 54 years. They were exposed to various combinations of mRNA, vectorial, inactivated and protein-based vaccines. Liver histology showed predominantly lobular hepatitis in 45 (76%), predominantly portal hepatitis in 10 (17%), and other patterns in four (7%) cases; seven had fibrosis Ishak stage ≥3, associated with more severe interface hepatitis. Autoimmune serology, centrally tested in 31 cases, showed anti-antinuclear antibody in 23 (74%), anti-smooth muscle antibody in 19 (61%), anti-gastric parietal cells in eight (26%), anti-liver kidney microsomal antibody in four (13%), and anti-mitochondrial antibody in four (13%) cases. Ninety-one percent were treated with steroids ± azathioprine. Serum transaminase levels improved in all cases and were normal in 24/58 (41%) after 3 months, and in 30/46 (65%) after 6 months. One patient required liver transplantation. Of 15 patients re-exposed to SARS-CoV-2 vaccines, three relapsed. Acute liver injury arising after SARS-CoV-2 vaccination is frequently associated with lobular hepatitis and positive autoantibodies. Whether there is a causal relationship between liver damage and SARS-CoV-2 vaccines remains to be established. A close follow-up is warranted to assess the long-term outcomes of this condition. Cases of liver injury after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) have been published. We investigated a large international cohort of individuals with acute hepatitis after SARS-CoV-2 vaccination, focusing on liver biopsy findings and autoantibodies: liver biopsy frequently shows inflammation of the lobule, which is typical of recent injury, and autoantibodies are frequently positive. Whether there is a causal relationship between liver damage and SARS-CoV-2 vaccines remains to be established. Close follow-up is warranted to assess the long-term outcome of this condition.","Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;HIBA, Buenos Aires, Argentina.;Harran University, Şanlıurfa, Turkey.;Medical University of Vienna, Wien, Austria.;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.;IRCCS Humanitas Research Hospital Milan, Milan, Italy.;Humanitas University, Pieve Emanuele, Milan, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Maastricht University Medical Center, Maastricht, Netherlands.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Lithuanian University of Health Sciences, Kaunas, Lituania.;Donostia University Hospital, Donostia, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Hépatologie et Transplantation Hépatique, Hôpital Paul Brousse, Villejuif, France.;Städtisches Krankenhaus Kiel, Kiel, Germany.;Aarhus University Hospital, Aarhus, Denmark.;Ospedale San Raffaele, Milano, Italy.;Ospedale San Raffaele, Milano, Italy.;Policlinico San Marco, Zingonia, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Hospital RWTH Aachen, Aachen, Germany.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;University of Rosario School of Medicine, Rosario, Argentina.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Istituti Clinici Pavia-Vigevano UO Epatologia Oncologica, Vigevano, Italy.;Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.;Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.;Department of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Australia.;Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Turkey.;Department of Pathology, Inonu University Faculty of Medicine, Malatya 44280, Turkey.;Epatocentro Ticino, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Epatocentro Ticino, Lugano, Switzerland.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.","NA",0,"2589-5559","JHEP Rep","JHEP Rep",2022,"2023","5","10.1016/j.jhepr.2022.100605","100605","","","36440259","36440259","PUBMED","Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;HIBA, Buenos Aires, Argentina.;Harran University, Şanlıurfa, Turkey.;Medical University of Vienna, Wien, Austria.;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.;IRCCS Humanitas Research Hospital Milan, Milan, Italy.;Humanitas University, Pieve Emanuele, Milan, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Maastricht University Medical Center, Maastricht, Netherlands.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Lithuanian University of Health Sciences, Kaunas, Lituania.;Donostia University Hospital, Donostia, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Hépatologie et Transplantation Hépatique, Hôpital Paul Brousse, Villejuif, France.;Städtisches Krankenhaus Kiel, Kiel, Germany.;Aarhus University Hospital, Aarhus, Denmark.;Ospedale San Raffaele, Milano, Italy.;Ospedale San Raffaele, Milano, Italy.;Policlinico San Marco, Zingonia, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Hospital RWTH Aachen, Aachen, Germany.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;University of Rosario School of Medicine, Rosario, Argentina.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Istituti Clinici Pavia-Vigevano UO Epatologia Oncologica, Vigevano, Italy.;Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.;Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.;Department of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Australia.;Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Turkey.;Department of Pathology, Inonu University Faculty of Medicine, Malatya 44280, Turkey.;Epatocentro Ticino, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Epatocentro Ticino, Lugano, Switzerland.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK."
"Martin-Blondel G;Lescure FX;Assoumou L;Charpentier C;Chapplain JM;Perpoint T;Grouteau G;Cordel H;Pialoux G;Pacanowski J;Thy M;Bauvois A;Laureillard D;Hamrouni F;Algarte-Genin M;Poissy J;Descamps D;Costagliola D","Martin-Blondel, Guillaume;Lescure, François-Xavier;Assoumou, Lambert;Charpentier, Charlotte;Chapplain, Jean-Marc;Perpoint, Thomas;Grouteau, Gaspard;Cordel, Hugues;Pialoux, Gilles;Pacanowski, Jérome;Thy, Michael;Bauvois, Adeline;Laureillard, Didier;Hamrouni, Fadia;Algarte-Genin, Michèle;Poissy, Julien;Descamps, Diane;Costagliola, Dominique","Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.","BMC infectious diseases","England","eng","Journal Article","COVID-19;SARS-CoV-2;Severity;Variant of concern Alpha","Aged;COVID-19;Cohort Studies;Female;Hospitalization;Humans;Male;Retrospective Studies;SARS-CoV-2","Aged;COVID-19;Cohort Studies;Female;Hospitalization;Humans;Male;Retrospective Studies;SARS-CoV-2","The impact of the variant of concern (VOC) Alpha on the severity of COVID-19 has been debated. We report our analysis in France. We conducted an exposed/unexposed cohort study with retrospective data collection, comparing patients infected by VOC Alpha to contemporaneous patients infected by historical lineages. Participants were matched on age (± 2.5 years), sex and region of hospitalization. The primary endpoint was the proportion of hospitalized participants with severe COVID-19, defined as a WHO-scale > 5 or by the need of a non-rebreather mask, occurring up to day 29 after admission. We used a logistic regression model stratified on each matched pair and accounting for factors known to be associated with the severity of the disease. We included 650 pairs of patients hospitalized between Jan 1, 2021, and Feb 28, 2021, in 47 hospitals. Median age was 70 years and 61.3% of participants were male. The proportion of participants with comorbidities was high in both groups (85.0% vs 90%, p = 0.004). Infection by VOC Alpha was associated with a higher odds of severe COVID-19 (41.7% vs 38.5%-aOR = 1.33 95% CI [1.03-1.72]). Infection by the VOC Alpha was associated with a higher odds of severe COVID-19.","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse;Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Service de Médecine Interne, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;University of Lille, Inserm U1285, CHU Lille, Pôle de Médecine Intensive Réanimation, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.","NA",0,"1471-2334","BMC Infect Dis","BMC Infect Dis",2021,"2022","22","10.1186/s12879-022-07508-x","540","","","35698029","35698029","PUBMED","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse;Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Service de Médecine Interne, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;University of Lille, Inserm U1285, CHU Lille, Pôle de Médecine Intensive Réanimation, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France."
"Bannay A;Bories M;Le Corre P;Riou C;Lemordant P;Van Hille P;Chazard E;Dode X;Cuggia M;Bouzillé G","Bannay, Aurélie;Bories, Mathilde;Le Corre, Pascal;Riou, Christine;Lemordant, Pierre;Van Hille, Pascal;Chazard, Emmanuel;Dode, Xavier;Cuggia, Marc;Bouzillé, Guillaume","Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case.","JMIR medical informatics","Canada","eng","Journal Article","administrative claims;big data;data linking;data warehousing;drug interactions;health care;statins","","","Linking different sources of medical data is a promising approach to analyze care trajectories. The aim of the INSHARE (Integrating and Sharing Health Big Data for Research) project was to provide the blueprint for a technological platform that facilitates integration, sharing, and reuse of data from 2 sources: the clinical data warehouse (CDW) of the Rennes academic hospital, called eHOP (entrepôt Hôpital), and a data set extracted from the French national claim data warehouse (Système National des Données de Santé [SNDS]). This study aims to demonstrate how the INSHARE platform can support big data analytic tasks in the health field using a pharmacovigilance use case based on statin consumption and statin-drug interactions. A Spark distributed cluster-computing framework was used for the record linkage procedure and all analyses. A semideterministic record linkage method based on the common variables between the chosen data sources was developed to identify all patients discharged after at least one hospital stay at the Rennes academic hospital between 2015 and 2017. The use-case study focused on a cohort of patients treated with statins prescribed by their general practitioner or during their hospital stay. The whole process (record linkage procedure and use-case analyses) required 88 minutes. Of the 161,532 and 164,316 patients from the SNDS and eHOP CDW data sets, respectively, 159,495 patients were successfully linked (98.74% and 97.07% of patients from SNDS and eHOP CDW, respectively). Of the 16,806 patients with at least one statin delivery, 8293 patients started the consumption before and continued during the hospital stay, 6382 patients stopped statin consumption at hospital admission, and 2131 patients initiated statins in hospital. Statin-drug interactions occurred more frequently during hospitalization than in the community (3800/10,424, 36.45% and 3253/14,675, 22.17%, respectively; P<.001). Only 121 patients had the most severe level of statin-drug interaction. Hospital stay burden (length of stay and in-hospital mortality) was more severe in patients with statin-drug interactions during hospitalization. This study demonstrates the added value of combining and reusing clinical and claim data to provide large-scale measures of drug-drug interaction prevalence and care pathways outside hospitals. It builds a path to move the current health care system toward a Learning Health System using knowledge generated from research on real-world health data.","Université de Lorraine, Centre Hospitalier Régional Universitaire de Nancy, Centre national de la recherche scientifique, Inria, Laboratoire lorrain de recherche en informatique et ses applications, Nancy, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Inserm, Ecole des hautes études en santé publique, Institut de recherche en santé, environnement et travail, UMR_S 1085, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Centre National Hospitalier d'Information sur le Médicament, Paris, France.;Department of Pharmacy, Hospices Civils de Lyon, University Hospital, Lyon, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.","NA",0,"2291-9694","JMIR Med Inform","JMIR Med Inform",2021,"2021","9","10.2196/29286","e29286","","","34898457","34898457","PUBMED","Université de Lorraine, Centre Hospitalier Régional Universitaire de Nancy, Centre national de la recherche scientifique, Inria, Laboratoire lorrain de recherche en informatique et ses applications, Nancy, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Inserm, Ecole des hautes études en santé publique, Institut de recherche en santé, environnement et travail, UMR_S 1085, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Centre National Hospitalier d'Information sur le Médicament, Paris, France.;Department of Pharmacy, Hospices Civils de Lyon, University Hospital, Lyon, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France."
"Rugo HS;Finn RS;Diéras V;Ettl J;Lipatov O;Joy AA;Harbeck N;Castrellon A;Iyer S;Lu DR;Mori A;Gauthier ER;Bartlett CH;Gelmon KA;Slamon DJ","Rugo, H S;Finn, R S;Diéras, V;Ettl, J;Lipatov, O;Joy, A A;Harbeck, N;Castrellon, A;Iyer, S;Lu, D R;Mori, A;Gauthier, E R;Bartlett, C Huang;Gelmon, K A;Slamon, D J","Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.","Breast cancer research and treatment","Netherlands","eng","Clinical Trial, Phase III","Breast cancer;Cyclin-dependent kinase inhibitor;ER+;HER2−;Letrozole;Palbociclib","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Double-Blind Method;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen;Treatment Outcome","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Double-Blind Method;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen;Treatment Outcome","In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.","Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Department of Medical Oncology, Institut Curie, Paris, France.;Centre Eugène Marquis, Rennes, France.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia.;Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.;Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany.;Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA.;Patient and Health Impact, Pfizer Inc, New York, NY, USA.;Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.;Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy.;Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA.;Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA.;Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.","NA",0,"1573-7217","Breast Cancer Res Treat","Breast Cancer Res Treat",2018,"2019","174","10.1007/s10549-018-05125-4","719-729","","","30632023","30632023","PUBMED","Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Department of Medical Oncology, Institut Curie, Paris, France.;Centre Eugène Marquis, Rennes, France.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia.;Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.;Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany.;Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA.;Patient and Health Impact, Pfizer Inc, New York, NY, USA.;Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.;Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy.;Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA.;Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA.;Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA."
"Dalenc F;Lusque A;De La Motte Rouge T;Pistilli B;Brain E;Pasquier D;Debled M;Thery JC;Gonçalves A;Desmoulins I;Levy C;Uwer L;Ferrero JM;Eymard JC;Mouret-Reynier MA;Patsouris A;Frenel JS;Petit T;Chevrot M;Bachelot T;Guiu S","Dalenc, Florence;Lusque, Amélie;De La Motte Rouge, Thibault;Pistilli, Barbara;Brain, Etienne;Pasquier, David;Debled, Marc;Thery, Jean-Christophe;Gonçalves, Anthony;Desmoulins, Isabelle;Levy, Christelle;Uwer, Lionel;Ferrero, Jean-Marc;Eymard, Jean-Christophe;Mouret-Reynier, Marie-Ange;Patsouris, Anne;Frenel, Jean-Sébastien;Petit, Thierry;Chevrot, Michael;Bachelot, Thomas;Guiu, Séverine","Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Invasive ductal carcinoma;Invasive lobular carcinoma;Metastatic breast cancer;Overall survival","Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Prognosis;Retrospective Studies","Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Prognosis;Retrospective Studies","The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics. Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20-1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07-1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64-0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08-1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67-1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.","Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Saint-Cloud and Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-Paul Papin, Angers, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-René Gauducheau, Nantes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real Worl Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","164","10.1016/j.ejca.2021.12.031","70-79","","","35176614","35176614","PUBMED","Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Saint-Cloud and Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-Paul Papin, Angers, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-René Gauducheau, Nantes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real Worl Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier"
"Crabol Y;Poiree S;Bougnoux ME;Maunoury C;Barete S;Zeller V;Arvieux C;Pineau S;Amazzough K;Lecuit M;Lanternier F;Lortholary O","Crabol, Yoann;Poiree, Sylvain;Bougnoux, Marie-Elisabeth;Maunoury, Christophe;Barete, Stéphane;Zeller, Valérie;Arvieux, Cédric;Pineau, Samuel;Amazzough, Karima;Lecuit, Marc;Lanternier, Fanny;Lortholary, Olivier","Last generation triazoles for imported eumycetoma in eleven consecutive adults.","PLoS neglected tropical diseases","United States","eng","Case Reports","","Adolescent;Adult;Antifungal Agents;Child;Exophiala;Fluorodeoxyglucose F18;Fusarium;Humans;Madurella;Magnetic Resonance Imaging;Male;Mycetoma;Positron-Emission Tomography;Proteoglycans;Retrospective Studies;Skin;Treatment Outcome;Triazoles;Voriconazole;Young Adult;beta-Glucans","Adolescent;Adult;Antifungal Agents;Child;Exophiala;Fluorodeoxyglucose F18;Fusarium;Humans;Madurella;Magnetic Resonance Imaging;Male;Mycetoma;Positron-Emission Tomography;Proteoglycans;Retrospective Studies;Skin;Treatment Outcome;Triazoles;Voriconazole;Young Adult;beta-Glucans","Optimal management of eumycetoma, a severely debilitating chronic progressive fungal infection of skin, disseminating to bone and viscera, remains challenging. Especially, optimal antifungal treatment and duration are ill defined. We conducted a monocentric retrospective study of 11 imported cases of eumycetoma treated by voriconazole or posaconazole for at least 6 months. Response to treatment was assessed through evolution of clinical and magnetic resonance imaging (MRI). (1→3) ß-D-glucan (BG) and positron emission tomography using [18F] fluorodeoxyglucose (PET/CT) results were also assessed. Identified species were Fusarium solani complex (n = 3); Madurella mycetomatis, (n = 3), and Exophiala jeanselmei, (n = 1). Moreover, two coelomycetes and one phaeohyphomycetes strains without species identification were retrieved. Serum BG and PET/CT were abnormal in 7/8 and 6/6 patients tested, respectively. Patients received last generation azoles for a mean duration of 25.9±18 months. Complete response (major clinical and MRI improvement) was observed in 5/11 patients, partial response (minor MRI improvement or stable MRI findings) in 5 and failure (MRI evidence of disease progression) in one, with a 73±39 [6-132] months mean follow-up. Relapse occurred in 2 patients after treatment discontinuation. Optimal outcome was associated with fungal species, initiation of last generation triazole therapy (<65 months since first symptoms), negative serum BG and PET/CT normalization. MRI, PET/CT and serum BG appear as promising tools to assess optimal time of antifungal treatment for eumycetoma.","Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Service d'Imagerie Médicale, Hôpital Necker-Enfants malades, Paris, France.;Laboratoire de parasito-mycologie, Hôpital Universitaire Necker-Enfants malades, CNRS URA3012, Paris, France.;Unité de Médecine Nucléaire et TEP, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France.;Service de Dermatologie, Hôpital Tenon, APHP, Université Pierre et Marie Curie, Paris, France.;Service de Médecine Interne, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Service de maladies infectieuses et réanimation médicale du Centre hospitalier universitaire de Rennes, Rennes, France.;Hôpital Universitaire de Nantes, Service des Maladies Infectieuses et Tropicales, Nantes, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Biologie des Infections, Institut Pasteur, Inserm U1117, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Mycologie Moléculaire, Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.","NA",0,"1935-2735","PLoS Negl Trop Dis","PLoS Negl Trop Dis",2014,"2014","8","10.1371/journal.pntd.0003232","e3232","","","25299610","25299610","PUBMED","Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Service d'Imagerie Médicale, Hôpital Necker-Enfants malades, Paris, France.;Laboratoire de parasito-mycologie, Hôpital Universitaire Necker-Enfants malades, CNRS URA3012, Paris, France.;Unité de Médecine Nucléaire et TEP, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France.;Service de Dermatologie, Hôpital Tenon, APHP, Université Pierre et Marie Curie, Paris, France.;Service de Médecine Interne, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Service de maladies infectieuses et réanimation médicale du Centre hospitalier universitaire de Rennes, Rennes, France.;Hôpital Universitaire de Nantes, Service des Maladies Infectieuses et Tropicales, Nantes, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Biologie des Infections, Institut Pasteur, Inserm U1117, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Mycologie Moléculaire, Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France."
"Rousseau N;Lebreton O;Masse H;Maucourant Y;Pipelart V;Clement M;Le Lez ML;Khanna RK;Pepin M;Eude Y;Le Meur G;Weber M;Ducloyer JB","Rousseau, Nicolas;Lebreton, Olivier;Masse, Hélène;Maucourant, Yann;Pipelart, Valentin;Clement, Manon;Le Lez, Marie-Laure;Khanna, Raoul Kanav;Pepin, Maxime;Eude, Yannick;Le Meur, Guylène;Weber, Michel;Ducloyer, Jean-Baptiste","Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study.","Ophthalmology and therapy","England","eng","Journal Article","Corticosteroid implant;DME;Dexamethasone;Diabetes complications;Diabetic macular oedema;Fluocinolone acetonide;Intravitreal injection;Retinal diseases","","","The aim of this study was to assess the efficacy and safety of fluocinolone acetonide implant (FAci) injected 1 month after the last dexamethasone intravitreal implant (DEXi) in chronic diabetic macular oedema (DME) patients. Retrospective multicentric study conducted in pseudophakic patients with chronic DME frequently treated with dexamethasone intravitreal implant (DEXi; time to DME recurrence ≤ 6 months), receiving FAci 1 month after the last DEXi, with at least a 6-month follow-up. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure (IOP) and additional treatments were assessed on the day of FAci injection (M0), 1 (M1) and 3 months (M3) later and then every 3 months. A total of 41 eyes from 34 patients were included. At M0, patients' mean age was 68.7 ± 9.8 years, the mean DME duration was 63.9 ± 22.9 months, the mean interval between two DEXi was 14.2 ± 3.3 weeks. M12 data were available for 71% of patients. At baseline, the mean BCVA, CMT and IOP were 63.2 ± 16.6 letters, 299.4 ± 103.3 µm, and 16.2 ± 4.5 mmHg, respectively, and remained stable during the follow-up. At M12, 14% of patients required additional intravitreal treatments. In pseudophakic patients with chronic DME showing good response to DEXi but requiring repeated injections every < 6 months, switching to FAci 1 month after the last DEXi was effective and safe. Further prospective randomized controlled studies are needed to confirm these findings, and to determine the best interval between the last DEXi and the first FAci.","Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'ophtalmologie, Rennes, France.;Centre Hospitalier Le Mans, Service d'ophtalmologie, Le Mans, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, Tours, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, UMR 1253, iBrain, Tours, France.;Centre Hospitalier Universitaire d'Angers, Service d'ophtalmologie, Angers, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes","NA",0,"2193-8245","Ophthalmol Ther","Ophthalmol Ther",2023,"2023","12","10.1007/s40123-023-00749-2","2781-2792","No award number. Horus Pharma© only funded the publication fees. Horus did not fund the study, only the English proofreading of the manuscript.","Horus Pharma","37369907","37369907","PUBMED","Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'ophtalmologie, Rennes, France.;Centre Hospitalier Le Mans, Service d'ophtalmologie, Le Mans, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, Tours, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, UMR 1253, iBrain, Tours, France.;Centre Hospitalier Universitaire d'Angers, Service d'ophtalmologie, Angers, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes"
"Reizine F;Grégoire M;Lesouhaitier M;Coirier V;Gauthier J;Delaloy C;Dessauge E;Creusat F;Uhel F;Gacouin A;Dessauge F;Le Naoures C;Moreau C;Bendavid C;Daniel Y;Petitjean K;Bordeau V;Lamaison C;Piau C;Cattoir V;Roussel M;Fromenty B;Michelet C;Le Tulzo Y;Zmijewski J;Thibault R;Cogné M;Tarte K;Tadié JM","Reizine, Florian;Grégoire, Murielle;Lesouhaitier, Mathieu;Coirier, Valentin;Gauthier, Juliette;Delaloy, Céline;Dessauge, Elise;Creusat, Florent;Uhel, Fabrice;Gacouin, Arnaud;Dessauge, Frédéric;Le Naoures, Cécile;Moreau, Caroline;Bendavid, Claude;Daniel, Yoann;Petitjean, Kilian;Bordeau, Valérie;Lamaison, Claire;Piau, Caroline;Cattoir, Vincent;Roussel, Mikael;Fromenty, Bernard;Michelet, Christian;Le Tulzo, Yves;Zmijewski, Jaroslaw;Thibault, Ronan;Cogné, Michel;Tarte, Karin;Tadié, Jean-Marc","Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction.","Proceedings of the National Academy of Sciences of the United States of America","United States","eng","Journal Article","T cell;citrulline;mitochondria;sepsis","Animals;Arginine;Biological Availability;Citrulline;Cytokines;Disease Models, Animal;Female;Immune Tolerance;Immunosuppression Therapy;Lymphocyte Activation;Mice;Mice, Inbred C57BL;Mitochondria;Myeloid-Derived Suppressor Cells;Sepsis;T-Lymphocytes;T-Lymphocytes, Regulatory","Animals;Arginine;Biological Availability;Citrulline;Cytokines;Disease Models, Animal;Female;Immune Tolerance;Immunosuppression Therapy;Lymphocyte Activation;Mice;Mice, Inbred C57BL;Mitochondria;Myeloid-Derived Suppressor Cells;Sepsis;T-Lymphocytes;T-Lymphocytes, Regulatory","Severe sepsis induces a sustained immune dysfunction associated with poor clinical behavior. In particular, lymphopenia along with increased lymphocyte apoptosis and decreased lymphocyte proliferation, enhanced circulating regulatory T cells (Treg), and the emergence of myeloid-derived suppressor cells (MDSCs) have all been associated with persistent organ dysfunction, secondary infections, and late mortality. The mechanisms involved in MDSC-mediated T cell dysfunction during sepsis share some features with those described in malignancies such as arginine deprivation. We hypothesized that increasing arginine availability would restore T cell function and decrease sepsis-induced immunosuppression. Using a mouse model of sepsis based on cecal ligation and puncture and secondary pneumonia triggered by methicillin-resistant   inoculation, we demonstrated that citrulline administration was more efficient than arginine in increasing arginine plasma levels and restoring T cell mitochondrial function and proliferation while reducing sepsis-induced Treg and MDSC expansion. Because there is no specific therapeutic strategy to restore immune function after sepsis, we believe that our study provides evidence for developing citrulline-based clinical studies in sepsis.","Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;PEGASE, INRAE, Institut Agro, 35590 Saint Gilles, France.;Laboratoire d'anatomie pathologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Centre National de Référence de la Résistance aux Antibiotique (laboratoire associé ""Entérocoques""), Centre Hospitalier Universitaire de Rennes, F-35043 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.;INSERM, Service d'Endocrinologie, Diabétologie et Nutrition, Institut National de Recherche Agronomoque, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.","NA",0,"1091-6490","Proc Natl Acad Sci U S A","Proc Natl Acad Sci U S A",2021,"2022","119","10.1073/pnas.2115139119",NA,"","","35173051","35173051","PUBMED","Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;PEGASE, INRAE, Institut Agro, 35590 Saint Gilles, France.;Laboratoire d'anatomie pathologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Centre National de Référence de la Résistance aux Antibiotique (laboratoire associé ""Entérocoques""), Centre Hospitalier Universitaire de Rennes, F-35043 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.;INSERM, Service d'Endocrinologie, Diabétologie et Nutrition, Institut National de Recherche Agronomoque, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France."
"Coudert B;Pierga JY;Mouret-Reynier MA;Kerrou K;Ferrero JM;Petit T;Du FL;Dupré PF;Bachelot T;Gabelle P;Chauvet MP;Coeffic D;Barbe C;Prevost JB;Paintaud G;Thibault G;Ferhat A;Dupin J;Berriolo-Riedinger A;Arnould L","Coudert, Bruno;Pierga, Jean-Yves;Mouret-Reynier, Marie-Ange;Kerrou, Kaldoun;Ferrero, Jean-Marc;Petit, Thierry;Du, Fanny Le;Dupré, Pierre-François;Bachelot, Thomas;Gabelle, Philippe;Chauvet, Marie-Pierre;Coeffic, David;Barbe, Catherine;Prevost, Jean-Briac;Paintaud, Gilles;Thibault, Gilles;Ferhat, Abdennour;Dupin, Julien;Berriolo-Riedinger, Alina;Arnould, Laurent","Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.","EClinicalMedicine","England","eng","Journal Article","Bevacizumab;Early pet assessment;Her-2 positive breast cancer;Long-term follow-up;Neoadjuvant;Positron emission tomography;pathological complete response;Δsuvmax","","","The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes. Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomised (2:1) to neoadjuvant therapy with (Group A) or without (Group B) bevacizumab for cycles 3-6. All patients received one further cycle of trastuzumab before surgery plus adjuvant trastuzumab (11 cycles). 142 patients were randomized and treated (PET responders,   = 69; Group A,   = 48; Group B,   = 25). 5-year disease-free survival rates were 90.5% (95% CI: 80.0-95.6%) in PET responders, 90.2% (95% CI: 75.9-96.2%) in Group A, and 76.0% (95% CI: 54.2-88.4%) in Group B. However, no difference was observed between randomised arms in a sensitivity analysis. During adjuvant therapy, the incidence of Grade ≥3 (Group A: 25.6%; Group B 12.5%) and serious adverse events (Group A: 18.6%; Group B 12.5%) was higher in Group A vs Group B, but with no apparent effect on cardiac events. In patients with HER2-positive breast cancer, an intervention based on early PET assessment and improvement of pCR does not modify disease-free survival. Roche France.","Centre Georges-Francois Leclerc, Dijon, France.;Institut Curie, Université de Paris, Paris, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hopital Tenon, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Paul Strauss, Strasbourg, France.;Centre Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire Augustin-Morvan, Brest, France.;Centre Léon Berard, Lyon, France.;Institut Daniel Hollard, Grenoble, France.;Centre Oscar Lambret, Lille, France.;Polyclinique Courlancy, Institut du Cancer Courlancy Reims, France.;CHU Bretonneau, Tours, France.;Centre Pierre Curie, Beuvry, France.;Université de Tours, CHRU de Tours, Tours, France.;Université de Tours, CHRU de Tours, Tours, France.;Roche France S.A.S., Boulogne Billancourt, France.;Roche France S.A.S., Boulogne Billancourt, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Georges-Francois Leclerc, Dijon, France.","NA",0,"2589-5370","EClinicalMedicine","EClinicalMedicine",2020,"2020","28","10.1016/j.eclinm.2020.100566","100566","","","33205032","33205032","PUBMED","Centre Georges-Francois Leclerc, Dijon, France.;Institut Curie, Université de Paris, Paris, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hopital Tenon, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Paul Strauss, Strasbourg, France.;Centre Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire Augustin-Morvan, Brest, France.;Centre Léon Berard, Lyon, France.;Institut Daniel Hollard, Grenoble, France.;Centre Oscar Lambret, Lille, France.;Polyclinique Courlancy, Institut du Cancer Courlancy Reims, France.;CHU Bretonneau, Tours, France.;Centre Pierre Curie, Beuvry, France.;Université de Tours, CHRU de Tours, Tours, France.;Université de Tours, CHRU de Tours, Tours, France.;Roche France S.A.S., Boulogne Billancourt, France.;Roche France S.A.S., Boulogne Billancourt, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Georges-Francois Leclerc, Dijon, France."
"Monet M;Poët M;Tauzin S;Fouqué A;Cophignon A;Lagadic-Gossmann D;Vacher P;Legembre P;Counillon L","Monet, Michael;Poët, Mallorie;Tauzin, Sébastien;Fouqué, Amélie;Cophignon, Auréa;Lagadic-Gossmann, Dominique;Vacher, Pierre;Legembre, Patrick;Counillon, Laurent","The cleaved FAS ligand activates the Na(+)/H(+) exchanger NHE1 through Akt/ROCK1 to stimulate cell motility.","Scientific reports","England","eng","Journal Article","","Cell Line;Cell Movement;Fas Ligand Protein;Humans;Phosphorylation;Proto-Oncogene Proteins c-akt;Protons;Signal Transduction;Sodium-Hydrogen Exchanger 1;rho-Associated Kinases;rhoA GTP-Binding Protein","Cell Line;Cell Movement;Fas Ligand Protein;Humans;Phosphorylation;Proto-Oncogene Proteins c-akt;Protons;Signal Transduction;Sodium-Hydrogen Exchanger 1;rho-Associated Kinases;rhoA GTP-Binding Protein","Transmembrane CD95L (Fas ligand) can be cleaved to release a promigratory soluble ligand, cl-CD95L, which can contribute to chronic inflammation and cancer cell dissemination. The motility signaling pathway elicited by cl-CD95L remains poorly defined. Here, we show that in the presence of cl-CD95L, CD95 activates the Akt and RhoA signaling pathways, which together orchestrate an allosteric activation of the Na(+)/H(+) exchanger NHE1. Pharmacologic inhibition of Akt or ROCK1 independently blocks the cl-CD95L-induced migration. Confirming these pharmacologic data, disruption of the Akt and ROCK1 phosphorylation sites on NHE1 decreases cell migration in cells exposed to cl-CD95L. Together, these findings demonstrate that NHE1 is a novel molecular actor in the CD95 signaling pathway that drives the cl-CD95L-induced cell migration through both the Akt and RhoA signaling pathways.","Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Université de Bordeaux, Inserm U1045, 146 rue Léo Saignat, 33046 Bordeaux, France.;Bergonié Cancer Institute, 33000 Bordeaux, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2015,"2016","6","10.1038/srep28008","28008","","","27302366","27302366","PUBMED","Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Université de Bordeaux, Inserm U1045, 146 rue Léo Saignat, 33046 Bordeaux, France.;Bergonié Cancer Institute, 33000 Bordeaux, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France."
"Zhang-Yin JT;Girard A;Bertaux M","Zhang-Yin, Jules Tianyu;Girard, Antoine;Bertaux, Marc","What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review.","Cancers","Switzerland","eng","Journal Article","PCNSL;[18F]FDG;[18F]FDOPA;[18F]FET;[68Ga]Ga-DOTA-SSTR;brain metastases;glioma;meningioma","","","PET imaging is being increasingly used to supplement MRI in the clinical management of brain tumors. The main radiotracers implemented in clinical practice include [ F]FDG, radiolabeled amino acids ([ C]MET, [ F]FDOPA, [ F]FET) and [ Ga]Ga-DOTA-SSTR, targeting glucose metabolism, L-amino-acid transport and somatostatin receptors expression, respectively. This review aims at addressing the current place and perspectives of brain PET imaging for patients who suffer from primary or secondary brain tumors, at diagnosis and during follow-up. A special focus is given to the following: radiolabeled amino acids PET imaging for tumor characterization and follow-up in gliomas; the role of amino acid PET and [ F]FDG PET for detecting brain metastases recurrence; [ Ga]Ga-DOTA-SSTR PET for guiding treatment in meningioma and particularly before targeted radiotherapy.","Department of Nuclear Medicine, Clinique Sud Luxembourg, 486762 Arlon, Belgium.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2021,"2022","14","10.3390/cancers14040879",NA,"","","35205625","35205625","PUBMED","Department of Nuclear Medicine, Clinique Sud Luxembourg, 486762 Arlon, Belgium.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France."
"Sawyer E;Roylance R;Petridis C;Brook MN;Nowinski S;Papouli E;Fletcher O;Pinder S;Hanby A;Kohut K;Gorman P;Caneppele M;Peto J;Dos Santos Silva I;Johnson N;Swann R;Dwek M;Perkins KA;Gillett C;Houlston R;Ross G;De Ieso P;Southey MC;Hopper JL;Provenzano E;Apicella C;Wesseling J;Cornelissen S;Keeman R;Fasching PA;Jud SM;Ekici AB;Beckmann MW;Kerin MJ;Marme F;Schneeweiss A;Sohn C;Burwinkel B;Guénel P;Truong T;Laurent-Puig P;Kerbrat P;Bojesen SE;Nordestgaard BG;Nielsen SF;Flyger H;Milne RL;Perez JI;Menéndez P;Benitez J;Brenner H;Dieffenbach AK;Arndt V;Stegmaier C;Meindl A;Lichtner P;Schmutzler RK;Lochmann M;Brauch H;Fischer HP;Ko YD;Nevanlinna H;Muranen TA;Aittomäki K;Blomqvist C;Bogdanova NV;Dörk T;Lindblom A;Margolin S;Mannermaa A;Kataja V;Kosma VM;Hartikainen JM;Chenevix-Trench G;Lambrechts D;Weltens C;Van Limbergen E;Hatse S;Chang-Claude J;Rudolph A;Seibold P;Flesch-Janys D;Radice P;Peterlongo P;Bonanni B;Volorio S;Giles GG;Severi G;Baglietto L;McLean CA;Haiman CA;Henderson BE;Schumacher F;Le Marchand L;Simard J;Goldberg MS;Labrèche F;Dumont M;Kristensen V;Winqvist R;Pylkäs K;Jukkola-Vuorinen A;Kauppila S;Andrulis IL;Knight JA;Glendon G;Mulligan AM;Devillee P;Tollenaar RA;Seynaeve CM;Kriege M;Figueroa J;Chanock SJ;Sherman ME;Hooning MJ;Hollestelle A;van den Ouweland AM;van Deurzen CH;Li J;Czene K;Humphreys K;Cox A;Cross SS;Reed MW;Shah M;Jakubowska A;Lubinski J;Jaworska-Bieniek K;Durda K;Swerdlow A;Ashworth A;Orr N;Schoemaker M;Couch FJ;Hallberg E;González-Neira A;Pita G;Alonso MR;Tessier DC;Vincent D;Bacot F;Bolla MK;Wang Q;Dennis J;Michailidou K;Dunning AM;Hall P;Easton D;Pharoah P;Schmidt MK;Tomlinson I;Garcia-Closas M","Sawyer, Elinor;Roylance, Rebecca;Petridis, Christos;Brook, Mark N;Nowinski, Salpie;Papouli, Efterpi;Fletcher, Olivia;Pinder, Sarah;Hanby, Andrew;Kohut, Kelly;Gorman, Patricia;Caneppele, Michele;Peto, Julian;Dos Santos Silva, Isabel;Johnson, Nichola;Swann, Ruth;Dwek, Miriam;Perkins, Katherine-Anne;Gillett, Cheryl;Houlston, Richard;Ross, Gillian;De Ieso, Paolo;Southey, Melissa C;Hopper, John L;Provenzano, Elena;Apicella, Carmel;Wesseling, Jelle;Cornelissen, Sten;Keeman, Renske;Fasching, Peter A;Jud, Sebastian M;Ekici, Arif B;Beckmann, Matthias W;Kerin, Michael J;Marme, Federick;Schneeweiss, Andreas;Sohn, Christof;Burwinkel, Barbara;Guénel, Pascal;Truong, Therese;Laurent-Puig, Pierre;Kerbrat, Pierre;Bojesen, Stig E;Nordestgaard, Børge G;Nielsen, Sune F;Flyger, Henrik;Milne, Roger L;Perez, Jose Ignacio Arias;Menéndez, Primitiva;Benitez, Javier;Brenner, Hermann;Dieffenbach, Aida Karina;Arndt, Volker;Stegmaier, Christa;Meindl, Alfons;Lichtner, Peter;Schmutzler, Rita K;Lochmann, Magdalena;Brauch, Hiltrud;Fischer, Hans-Peter;Ko, Yon-Dschun;Nevanlinna, Heli;Muranen, Taru A;Aittomäki, Kristiina;Blomqvist, Carl;Bogdanova, Natalia V;Dörk, Thilo;Lindblom, Annika;Margolin, Sara;Mannermaa, Arto;Kataja, Vesa;Kosma, Veli-Matti;Hartikainen, Jaana M;Chenevix-Trench, Georgia;Lambrechts, Diether;Weltens, Caroline;Van Limbergen, Erik;Hatse, Sigrid;Chang-Claude, Jenny;Rudolph, Anja;Seibold, Petra;Flesch-Janys, Dieter;Radice, Paolo;Peterlongo, Paolo;Bonanni, Bernardo;Volorio, Sara;Giles, Graham G;Severi, Gianluca;Baglietto, Laura;McLean, Catriona A;Haiman, Christopher A;Henderson, Brian E;Schumacher, Fredrick;Le Marchand, Loic;Simard, Jacques;Goldberg, Mark S;Labrèche, France;Dumont, Martine;Kristensen, Vessela;Winqvist, Robert;Pylkäs, Katri;Jukkola-Vuorinen, Arja;Kauppila, Saila;Andrulis, Irene L;Knight, Julia A;Glendon, Gord;Mulligan, Anna Marie;Devillee, Peter;Tollenaar, Rob A E M;Seynaeve, Caroline M;Kriege, Mieke;Figueroa, Jonine;Chanock, Stephen J;Sherman, Mark E;Hooning, Maartje J;Hollestelle, Antoinette;van den Ouweland, Ans M W;van Deurzen, Carolien H M;Li, Jingmei;Czene, Kamila;Humphreys, Keith;Cox, Angela;Cross, Simon S;Reed, Malcolm W R;Shah, Mitul;Jakubowska, Anna;Lubinski, Jan;Jaworska-Bieniek, Katarzyna;Durda, Katarzyna;Swerdlow, Anthony;Ashworth, Alan;Orr, Nicholas;Schoemaker, Minouk;Couch, Fergus J;Hallberg, Emily;González-Neira, Anna;Pita, Guillermo;Alonso, M Rosario;Tessier, Daniel C;Vincent, Daniel;Bacot, Francois;Bolla, Manjeet K;Wang, Qin;Dennis, Joe;Michailidou, Kyriaki;Dunning, Alison M;Hall, Per;Easton, Doug;Pharoah, Paul;Schmidt, Marjanka K;Tomlinson, Ian;Garcia-Closas, Montserrat","Genetic predisposition to in situ and invasive lobular carcinoma of the breast.","PLoS genetics","United States","eng","Journal Article","","Breast Neoplasms;Carcinoma in Situ;Carcinoma, Lobular;Case-Control Studies;Female;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Polymorphism, Single Nucleotide","Breast Neoplasms;Carcinoma in Situ;Carcinoma, Lobular;Case-Control Studies;Female;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Polymorphism, Single Nucleotide","Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09-1.18), P = 6.0 × 10(-10); P-het for ILC vs IDC ER+ tumors = 1.8 × 10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P<0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11, rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although there is some heterogeneity between ER+ lobular and ER+ IDC tumors. These data provide evidence for overlapping, but distinct etiological pathways within ER+ breast cancer between morphological subtypes.","Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Biomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;Department of Pathology, The University of Melbourne, Melbourne, Australia.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;NIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.;Centre Eugène Marquis, Department of Medical Oncology, Rennes, France.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.;Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.;Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Saarland Cancer Registry, Saarbrücken, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Institute of Human Genetics, Technische Universität, Munich, Germany.;Centre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.;Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.;Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.;Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.;Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.;Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.;Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;Department of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.;Peter MacCallum Cancer Center, Melbourne, Australia.;Vesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Unit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Department of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.;Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.;Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.;Laboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.;Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.;Human Genetics Division, Genome Institute of Singapore, Singapore.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.;Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.","NA",0,"1553-7404","PLoS Genet","PLoS Genet",2013,"2014","10","10.1371/journal.pgen.1004285","e1004285","U01 CA69417;UM1 CA164920;U01 CA069467;2010NOVPR61;R01 CA128978;R01 CA132839;090532/Z/09/Z;U01 CA069417;CA54281;U01 CA069638;16563;10124;CA63464;C490/A10124;P50 CA116201;16565;C1287/A12014;R01 CA063464;090532;16561;R01 CA054281;U01 CA69638;U01 CA063464;U01 CA098758;CA132839;CA098758;16459;C1287/A10118;U01 CA69467;R37 CA054281","NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Breast Cancer Now;NCI NIH HHS;NCI NIH HHS;Wellcome Trust;Wellcome Trust;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;Cancer Research UK;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;Wellcome Trust;Cancer Research UK;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;NCI NIH HHS","24743323","24743323","PUBMED","Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Biomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;Department of Pathology, The University of Melbourne, Melbourne, Australia.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;NIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.;Centre Eugène Marquis, Department of Medical Oncology, Rennes, France.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.;Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.;Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Saarland Cancer Registry, Saarbrücken, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Institute of Human Genetics, Technische Universität, Munich, Germany.;Centre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.;Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.;Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.;Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.;Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.;Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.;Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;Department of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.;Peter MacCallum Cancer Center, Melbourne, Australia.;Vesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Unit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Department of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.;Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.;Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.;Laboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.;Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.;Human Genetics Division, Genome Institute of Singapore, Singapore.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.;Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."
"Arun BK;Han HS;Kaufman B;Wildiers H;Friedlander M;Ayoub JP;Puhalla SL;Bell-McGuinn KM;Bach BA;Kundu MG;Ratajczak CK;Maag D;Diéras V","Arun, Banu K;Han, Hyo S;Kaufman, Bella;Wildiers, Hans;Friedlander, Michael;Ayoub, Jean-Pierre;Puhalla, Shannon L;Bell-McGuinn, Katherine M;Bach, Bruce A;Kundu, Madan G;Ratajczak, Christine K;Maag, David;Diéras, Véronique","Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","BRCA;Breast cancer;Chemotherapy;PARP inhibitor","Adult;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Genes, BRCA1;Genes, BRCA2;Germ-Line Mutation;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2","Adult;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Genes, BRCA1;Genes, BRCA2;Germ-Line Mutation;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2","Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and ≤2 lines of previous cytotoxic therapy for metastatic disease in BROCADE3. A pre-planned subgroup analysis evaluated efficacy and safety in patients without previous cytotoxic therapy for metastatic disease. Patients were randomised 2:1 to receive veliparib (120 mg orally BID) or placebo on days -2 to 5. Carboplatin (AUC 6) was administered on day 1, and paclitaxel (80 mg/m ) on days 1, 8 and 15 (21-day cycles). Patients discontinuing carboplatin-paclitaxel for reasons besides progression could continue veliparib/placebo monotherapy (300 mg BID, increasing to 400 mg BID if tolerated) until progression. The primary end-point was PFS assessed by investigator. Of 509 patients in the intention-to-treat population (98.6% female; mean age 47, standard deviation 11), 413 (81%) had no previous cytotoxic therapy for metastatic disease (274, veliparib; 139, placebo). In the first-line subgroup, median PFS was 16.6 months (95% confidence interval [CI] 13.4-18.7) versus 13.1 months (95% CI 11.4-14.5) for the veliparib versus control groups (hazard ratio 0.70, 95% CI 0.54-0.89, P = .004). More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group. Adverse events unrelated to progression leading to study drug discontinuation occurred in 25 (9.1%) and 8 (5.8%) patients. Veliparib with carboplatin-paclitaxel led to durable disease control among first-line patients, suggesting a benefit of this treatment approach in early lines. NCT02163694.","Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX;Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.;Department of Oncology, Breast Oncology Institute, Sheba Medical Center, Tel-Aviv, Israel.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.;Department of Hematology and Oncology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Hematology/Oncology, Department of Medicine, UPMC Cancer Centers, Pittsburgh, PA, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Department of Medical Oncology, Institut Curie, Paris, France, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","154","10.1016/j.ejca.2021.05.037","35-45","","","34243076","34243076","PUBMED","Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX;Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.;Department of Oncology, Breast Oncology Institute, Sheba Medical Center, Tel-Aviv, Israel.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.;Department of Hematology and Oncology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Hematology/Oncology, Department of Medicine, UPMC Cancer Centers, Pittsburgh, PA, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Department of Medical Oncology, Institut Curie, Paris, France, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France."
"Cinotti R;Roquilly A;Chopin A;Martin FP;Morato Y;Lerebourg C;Moyer JD;Huet O;Lasocki S;Cohen B;Dahyot-Fizelier C;Chalard K;Seguin P;Chenet A;Perrouin-Verbe B;Sinha D;Asehnoune K;Feuillet F;Sébille V","Cinotti, Raphaël;Roquilly, Antoine;Chopin, Alice;Martin, Florian Pierre;Morato, Yoanna;Lerebourg, Céline;Moyer, Jean Denis;Huet, Olivier;Lasocki, Sigismond;Cohen, Benjamin;Dahyot-Fizelier, Claire;Chalard, Kevin;Seguin, Philippe;Chenet, Amandine;Perrouin-Verbe, Brigitte;Sinha, Debajyoti;Asehnoune, Karim;Feuillet, Fanny;Sébille, Véronique","Relationship between health-related quality-of-life and functional outcome 6 months after moderate to severe TBI.","Annals of physical and rehabilitation medicine","Netherlands","eng","Letter","Functional outcome;GOS-extended;Health-related quality of life;Post-intensive care syndrome;SF-36;Traumatic brain injury","Humans;Brain Injuries, Traumatic;Quality of Life","Humans;Brain Injuries, Traumatic;Quality of Life","NA","CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris.;Centre Hospitalier Universitaire de Brest, Anaesthesia and Intensive Care Unit, Brest, France.;Centre Hospitalier Universitaire d'Angers, Anaesthesia and Intensive Care Unit, Angers, France.;Centre Hospitalier Universitaire de Tours, Anaesthesia and Intensive Care Unit, Tours, France.;Centre Hospitalier Universitaire de Potiers, Anaesthesia and Intensive Care Unit, Poitiers, France.;Centre Hospitalier Universitaire de Montpellier, Anaesthesia and Intensive Care Unit, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Anaesthesia and Intensive Care Unit, Rennes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Plateforme de Méthodologie et Biostatistique, Direction Recherche et Innovation, CHU Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.","NA",0,"1877-0665","Ann Phys Rehabil Med","Ann Phys Rehabil Med",2022,"2023","66","10.1016/j.rehab.2022.101715","101715","","","36652785","36652785","PUBMED","CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris.;Centre Hospitalier Universitaire de Brest, Anaesthesia and Intensive Care Unit, Brest, France.;Centre Hospitalier Universitaire d'Angers, Anaesthesia and Intensive Care Unit, Angers, France.;Centre Hospitalier Universitaire de Tours, Anaesthesia and Intensive Care Unit, Tours, France.;Centre Hospitalier Universitaire de Potiers, Anaesthesia and Intensive Care Unit, Poitiers, France.;Centre Hospitalier Universitaire de Montpellier, Anaesthesia and Intensive Care Unit, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Anaesthesia and Intensive Care Unit, Rennes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Plateforme de Méthodologie et Biostatistique, Direction Recherche et Innovation, CHU Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France."
"Alyamani N;Clementel E;Sargos P;Blanchard P;Supiot S;Ronchin P;Pommier P;Duberge T;Silva M;Hammoud Y;Hasbini A;Khalifa J;Gnep K;Scrase C;Saez J;Vieillevigne L;Christiaens M;Zilli T;Ribault H;Bossi A;Fizazi K;Andratschke N","Alyamani, Najlaa;Clementel, Enrico;Sargos, Paul;Blanchard, Pierre;Supiot, Stephane;Ronchin, Philippe;Pommier, Pascal;Duberge, Thomas;Silva, Marlon;Hammoud, Yasser;Hasbini, Ali;Khalifa, Jonathan;Gnep, Khemara;Scrase, Christopher;Saez, Jordi;Vieillevigne, Laure;Christiaens, Melissa;Zilli, Thomas;Ribault, Hélène;Bossi, Alberto;Fizazi, Karim;Andratschke, Nicolaus","Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","PEACE-1;Prostate cancer;Quality assurance;RTQA","","","Radiotherapy quality assurance (RTQA) is essential for ensuring adherence to trial protocols. This paper summarizes the individual case review (ICR) results from the PEACE-1 trial, a phase-III study investigates standard of care (androgen deprivation therapy with or without docetaxel) with or without local radiotherapy; and with or without abiraterone acetate plus prednisone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Participating institutions submitted radiotherapy (RT) plans for central review, assessing protocol compliance in target volume and organs at risk (OARs) delineation, as well as dose specifications. ICRs were conducted either retrospectively (r-ICRs), after starting RT, or prospectively (p-ICRs), before RT initiation. Case reviews were categorized as acceptable per protocol, acceptable variation, or unacceptable variation based on delineation and dose and plan parameters. Out of 585 patients in the RT arms, 527 (90%) had r-ICRs, primarily using intensity-modulated radiotherapy (IMRT). Delineation review approved 417 (87%) r-ICRs and 44 (92%) p-ICRs. The main reasons for unacceptable delineation were erroneous clinical target volume (CTV) delineation. In dose and plan reviews, 399 (96%) r-ICRs cases and 46 (96%) p-ICRs were approved, with unacceptable cases primarily due to PTV dose distribution issues. RTQA is crucial in prostate cancer trials, primarily for proper target volume delineation. It is recommended to omit r-ICRs due to resource demands and lack of impact on RTQA outcomes, using limited p-ICRs with early feedback for site deviations and reserving full p-ICRs for trails with new techniques or dose regimens. gov: NCT01957436.","European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;Department of Radiotherapy Institut Bergonie Bordeaux France.;Department of Radiation Oncology Institut Gustave Roussy University of Paris Saclay Villejuif France.;Department of Radiation Oncology Institut de Cancérologie de l'Ouest - site René Gauducheau Nantes France.;Department of Radiation Oncology Centre Azuréen de Cancérologie Mougins France.;Department of Radiation Oncology Centre Léon Bérard Lyon France; Department of Radiation Oncology Institut Curie Paris France.;Department of Radiation Oncology La Croix-Rouge française Centre Saint Louis Toulon France.;Department of Radiation Oncology Centre François Baclesse Caen France.;Department of Radiation Oncology CHU Jean-Minjoz Besançon France.;Department of Radiation Oncology CFRO-Clinique Pasteur Brest France.;Department of Radiation Oncology Oncopole Claudius Regaud Toulouse France.;Department of Radiation Oncology Centre Eugène Marquis Rennes France; Department of Radiation Oncology Centre Armoricain de Radiothérapie d'Imagerie et d'Oncologie Plérin France.;Department of Oncology North Wales Cancer Centre Betsi Cadwaladr University Health Board and Bangor University Bangor UK.;Department of Radiation Oncology Hospital Clínic de Barcelona Barcelona Spain.;Department of Medical Physics Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse Toulouse France.;Department of Radiation Oncology University Hospitals Leuven Leuven Belgium.;Department of Radiation Oncology Oncology Institute of Southern Switzerland EOC Bellinzona Switzerland; Faculty of Biomedical Sciences Università Della Svizzera Italiana (USI) Lugano Switzerland; Faculty of Medicine University of Geneva Geneva Switzerland.;UNICANCER Paris France.;Department of Radiation Oncology Institut Gustave Roussy Villejuif France.;Department of Cancer Medicine Institut Gustave Roussy University of Paris Saclay Villejuif France.;","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2024,"2025","206","10.1016/j.radonc.2025.110780","110780","","","39924002","39924002","PUBMED","European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;Department of Radiotherapy Institut Bergonie Bordeaux France.;Department of Radiation Oncology Institut Gustave Roussy University of Paris Saclay Villejuif France.;Department of Radiation Oncology Institut de Cancérologie de l'Ouest - site René Gauducheau Nantes France.;Department of Radiation Oncology Centre Azuréen de Cancérologie Mougins France.;Department of Radiation Oncology Centre Léon Bérard Lyon France; Department of Radiation Oncology Institut Curie Paris France.;Department of Radiation Oncology La Croix-Rouge française Centre Saint Louis Toulon France.;Department of Radiation Oncology Centre François Baclesse Caen France.;Department of Radiation Oncology CHU Jean-Minjoz Besançon France.;Department of Radiation Oncology CFRO-Clinique Pasteur Brest France.;Department of Radiation Oncology Oncopole Claudius Regaud Toulouse France.;Department of Radiation Oncology Centre Eugène Marquis Rennes France; Department of Radiation Oncology Centre Armoricain de Radiothérapie d'Imagerie et d'Oncologie Plérin France.;Department of Oncology North Wales Cancer Centre Betsi Cadwaladr University Health Board and Bangor University Bangor UK.;Department of Radiation Oncology Hospital Clínic de Barcelona Barcelona Spain.;Department of Medical Physics Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse Toulouse France.;Department of Radiation Oncology University Hospitals Leuven Leuven Belgium.;Department of Radiation Oncology Oncology Institute of Southern Switzerland EOC Bellinzona Switzerland; Faculty of Biomedical Sciences Università Della Svizzera Italiana (USI) Lugano Switzerland; Faculty of Medicine University of Geneva Geneva Switzerland.;UNICANCER Paris France.;Department of Radiation Oncology Institut Gustave Roussy Villejuif France.;Department of Cancer Medicine Institut Gustave Roussy University of Paris Saclay Villejuif France.;"
"Gigante E;Hobeika C;Le Bail B;Paradis V;Tougeron D;Lequoy M;Bouattour M;Blanc JF;Ganne-Carrié N;Tran H;Hollande C;Allaire M;Amaddeo G;Regnault H;Vigneron P;Ronot M;Elkrief L;Verset G;Trepo E;Zaanan A;Ziol M;Ningarhari M;Calderaro J;Edeline J;Nault JC","Gigante, Elia;Hobeika, Christian;Le Bail, Brigitte;Paradis, Valérie;Tougeron, David;Lequoy, Marie;Bouattour, Mohamed;Blanc, Jean-Frederic;Ganne-Carrié, Nathalie;Tran, Henri;Hollande, Clémence;Allaire, Manon;Amaddeo, Giuliana;Regnault, Hélène;Vigneron, Paul;Ronot, Maxime;Elkrief, Laure;Verset, Gontran;Trepo, Eric;Zaanan, Aziz;Ziol, Marianne;Ningarhari, Massih;Calderaro, Julien;Edeline, Julien;Nault, Jean-Charles","Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.","Liver cancer","Switzerland","eng","Journal Article","Cholangiocarcinoma;Hepatocellular carcinoma;Hepatocholangiocarcinoma;Platinum;Systemic treatment;Tyrosine kinase inhibitors","","","Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA. Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients with cHCC-CCA were compared with patients with hepatocellular carcinoma (HCC) treated by sorafenib (  = 117) and with intrahepatic cholangiocarcinoma (iCCA,   = 94) treated mainly by platinum-based chemotherapy using a frailty Cox model. The efficacy of TKIs and platinum-based chemotherapies in patients with cHCC-CCA was assessed using a doubly robust estimator. A total of 83 patients with cHCC-CCA were included and were predominantly male (72%) with underlying cirrhosis (55%). 67% of patients had extrahepatic metastases and 31% macrovascular tumor invasion. cHCC-CCAs were more often developed on cirrhosis (55.4%) than iCCA (26.6%) but less frequently than HCC (80.2%) (  < 0.001). Both HCC (36.8% and cHCC-CCA (66.2%) had less frequent extrahepatic metastases than iCCA (81%) (  < 0.001). Unadjusted overall survival (OS) was better in iCCA (13 months) compared to cHCC-CCA (12 months) and HCC (11 months) (  = 0.130). In multivariable analysis, after adjustment by a Cox frailty model, patients with cHCC-CCA had the same survival as HCC and iCCA (HR = 0.67, 95% CI: 0.37-1.22,   = 0.189 and HR = 0.66, 95% CI: 0.43-1.02,   = 0.064, respectively). ALBI score (HR = 2.15; 95% CI: 1.23-3.76;   = 0.009), ascites (HR = 3.45, 95% CI: 1.31-9.03,   = 0.013), and tobacco use (HR = 2.29, 95% CI: 1.08-4.87,   = 0.032) were independently associated with OS in patients with cHCC-CCA. Among patients with cHCC-CCA, 25 patients treated with TKI were compared with 54 patients who received platinum-based chemotherapies. Patients treated with TKI had a median OS of 8.3 months compared to 11.9 months for patients treated with platinum-based chemotherapy (  = 0.86). After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27-3.15,   = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44-3.49,   = 0.67). First-line systemic treatments with TKIs or platinum-based chemotherapies have similar efficacy in patients with unresectable/metastatic cHCC-CCA. The ALBI score predicts OS.","Service d'Hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.;Service d'Anatomo-Pathologie, Hôpital Beaujon, AP-HP, Clichy, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers, France.;Service d'Hépatologie, Hôpital Saint-Antoine, AP-HP, Paris, France.;Unité Oncologie Hépatique, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie et d'Oncologie digestive, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac: INSERM U1053, Université de Bordeaux, Bordeaux, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Cochin, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Radiologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépatologie HC, UMUH 1, CHRU Tours, Tours, France.;Department of Gastroenterology and Digestive Oncology, Erasme Hospital, Brussels, Belgium.;Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.;Service Hépato-gastro-entérologie et Oncologie digestive, Hôpital Européen Georges-Pompidou, Université de Paris, AP-HP centre, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France.;Service des Maladies de l'appareil digestif et nutrition-Hépatologie, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Service d'Anatomo-Pathologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Oncologie, Centre Eugène Marquis, Rennes, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.","NA",0,"2235-1795","Liver Cancer","Liver Cancer",2021,"2022","11","10.1159/000525488","460-473","","","36158591","36158591","PUBMED","Service d'Hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.;Service d'Anatomo-Pathologie, Hôpital Beaujon, AP-HP, Clichy, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers, France.;Service d'Hépatologie, Hôpital Saint-Antoine, AP-HP, Paris, France.;Unité Oncologie Hépatique, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie et d'Oncologie digestive, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac: INSERM U1053, Université de Bordeaux, Bordeaux, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Cochin, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Radiologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépatologie HC, UMUH 1, CHRU Tours, Tours, France.;Department of Gastroenterology and Digestive Oncology, Erasme Hospital, Brussels, Belgium.;Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.;Service Hépato-gastro-entérologie et Oncologie digestive, Hôpital Européen Georges-Pompidou, Université de Paris, AP-HP centre, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France.;Service des Maladies de l'appareil digestif et nutrition-Hépatologie, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Service d'Anatomo-Pathologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Oncologie, Centre Eugène Marquis, Rennes, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France."
"Benguerfi S;Thepault F;Lena H;Ricordel C","Benguerfi, Soraya;Thepault, Fanny;Lena, Hervé;Ricordel, Charles","Spontaneous splenic rupture as a rare complication of G-CSF injection.","BMJ case reports","England","eng","Case Reports","lung cancer (oncology);unwanted effects / adverse reactions","Adenocarcinoma;Adenocarcinoma of Lung;Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Brain Neoplasms;Female;Granulocyte Colony-Stimulating Factor;Humans;Injections;Laparoscopy;Lung Neoplasms;Middle Aged;Peritoneal Dialysis;Rupture, Spontaneous;Splenic Rupture;Syncope;Treatment Outcome","Adenocarcinoma;Adenocarcinoma of Lung;Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Brain Neoplasms;Female;Granulocyte Colony-Stimulating Factor;Humans;Injections;Laparoscopy;Lung Neoplasms;Middle Aged;Peritoneal Dialysis;Rupture, Spontaneous;Splenic Rupture;Syncope;Treatment Outcome","Splenic rupture is an infrequent and underdiagnosed side effect of granylocyte colony-stimulating factor (G-CSF). We report the case of a 54-year-old woman with brain and bone metastasis in a lung adenocarcinoma who was admitted for faintness 28 days after a G-CSF injection. Abdominal CT scan confirmed the diagnosis of splenic rupture. A conservative treatment was chosen using a peritoneal cleansing during laparoscopic surgery. Clinicians should be aware of this rare toxicity as it could be severe, but easily reversible using appropriate surgical treatment. Even if prognosis remains poor for patients with lung cancer, invasive procedures could be considered in this rapidly evolving setting, especially in case of reversible adverse event.","Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2018,"2018","2018","10.1136/bcr-2017-222561",NA,"","","29330272","29330272","PUBMED","Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France."
"Tao Y;Auperin A;Blanchard P;Alfonsi M;Sun XS;Rives M;Pointreau Y;Castelli J;Graff P;Wong Hee Kam S;Thariat J;Veresezan O;Heymann S;Renard-Oldrini S;Lafond C;Cornely A;Casiraghi O;Boisselier P;Lapeyre M;Biau J;Bourhis J","Tao, Yungan;Auperin, Anne;Blanchard, Pierre;Alfonsi, Marc;Sun, Xu-Shan;Rives, Michel;Pointreau, Yoann;Castelli, Joël;Graff, Pierre;Wong Hee Kam, Stéphanie;Thariat, Juliette;Veresezan, Ovidiu;Heymann, Steve;Renard-Oldrini, Sophie;Lafond, Cédrik;Cornely, Alexandre;Casiraghi, Odile;Boisselier, Pierre;Lapeyre, Michel;Biau, Julian;Bourhis, Jean","Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Clinical Trial, Phase III","Cisplatin;Concurrent chemoradiotherapy;Dose escalation;Head and neck cancer;IMRT;Intensity-modulated radiotherapy","Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Humans;Radiotherapy Dosage;Radiotherapy, Intensity-Modulated;Squamous Cell Carcinoma of Head and Neck","Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Humans;Radiotherapy Dosage;Radiotherapy, Intensity-Modulated;Squamous Cell Carcinoma of Head and Neck","Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT. The primary endpoint was locoregional progression (LRP). 188 patients were randomized: 85% oropharynx and 73% stage IVa. P16 status was documented for 137 oropharyngeal tumors with P16+ in 53 (39%) patients; and 90% were smokers. Median follow-up was 60.5 months. Xerostomia was markedly decreased in arm B (p < 0.0001). The 1-year grade ≥2 xerostomia (RTOG criteria) was 63% vs 23% and 3-year 45% vs 11% in arms A and B, respectively. Xerostomia LENT-SOMA scale was also reduced in arm B. Dose-escalated IMRT did not reduce LRP with an adjusted HR of 1.13 [95%CI = 0.64-1.98] (p = 0.68). Survival was not different (adjusted HR: 1.19 [95%CI = 0.78-1.81], p = 0.42). No interaction between p16 and treatment effect was found. Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.","Gustave-Roussy Cancer Campus Grand Paris, Villejuif;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Institut Sainte Catherine, Avignon, France.;Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.;Institut Claudius Regaud, Toulouse, France.;Centre Jean Bernard, Le Mans, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.;AP-HM Hôpital de la Timone, Marseille, France.;Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Clinique Sainte Anne, Strasbourg, France.;Centre Alexis Vautrin, Nancy, France.;Centre Jean Bernard, Le Mans, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.;Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2020,"2020","150","10.1016/j.radonc.2020.05.021","18-25","","","32417348","32417348","PUBMED","Gustave-Roussy Cancer Campus Grand Paris, Villejuif;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Institut Sainte Catherine, Avignon, France.;Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.;Institut Claudius Regaud, Toulouse, France.;Centre Jean Bernard, Le Mans, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.;AP-HM Hôpital de la Timone, Marseille, France.;Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Clinique Sainte Anne, Strasbourg, France.;Centre Alexis Vautrin, Nancy, France.;Centre Jean Bernard, Le Mans, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.;Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne"
"Luque Paz D;Jouneau S;Tattevin P;Ricordel C","Luque Paz, David;Jouneau, Stephane;Tattevin, Pierre;Ricordel, Charles","Pneumocystis in metastatic lung cancer, a pragmatic approach in support of prophylaxis.","BMJ case reports","England","eng","Case Reports","lung cancer (oncology);pneumonia (respiratory medicine)","Aged, 80 and over;Carcinoma, Non-Small-Cell Lung;Humans;Immunocompromised Host;Lung Neoplasms;Male;Pneumocystis;Pneumocystis carinii;Pneumonia, Pneumocystis","Aged, 80 and over;Carcinoma, Non-Small-Cell Lung;Humans;Immunocompromised Host;Lung Neoplasms;Male;Pneumocystis;Pneumocystis carinii;Pneumonia, Pneumocystis","Lung cancer prognosis has improved in the last decade, including in patients with brain metastasis. However, few of these patients who receive corticosteroids have a primary prophylaxis for   pneumonia (PJP). We report the case of an 80-year-old man diagnosed with non-small cell lung cancer and concomitant symptomatic brain metastases, treated with 50 mg/day of prednisolone without any prophylaxis, who presented an acute PJP. After 72 hours of unsuccessful treatment of PJP, the patient died. In our review of this case and the existing literature, we emphasise the importance of a wide use of prophylaxis for PJP, especially in advanced lung cancer treated with corticosteroid therapy. We discuss this issue and report current evidence for primary prophylaxis by trimethoprim-sulfamethoxazole.","Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2021,"2021","14","10.1136/bcr-2019-232895",NA,"","","34183310","34183310","PUBMED","Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes"
"Löfström U;Hage C;Savarese G;Donal E;Daubert JC;Lund LH;Linde C","Löfström, Ulrika;Hage, Camilla;Savarese, Gianluigi;Donal, Erwan;Daubert, Jean-Claude;Lund, Lars H;Linde, Cecilia","Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.","ESC heart failure","England","eng","Journal Article","Echocardiography;Framingham criteria;Heart failure with preserved ejection fraction;Natriuretic peptides;Prognosis","Aged;Aged, 80 and over;Female;Heart Failure;Hospitalization;Humans;Male;Prognosis;Prospective Studies;Stroke Volume","Aged;Aged, 80 and over;Female;Heart Failure;Hospitalization;Humans;Male;Prognosis;Prospective Studies;Stroke Volume","This study aims to assess prognostic impact of Framingham criteria for heart failure (FC-HF) in patients with stable heart failure (HF) with preserved ejection fraction (HFpEF). In the prospective Karolinska-Rennes (KaRen) study, we assessed stable HFpEF patients after an acute HF episode. We evaluated associations between the four descriptive models of HFpEF and the composite endpoint of all-cause mortality and HF hospitalization. The descriptive models were FC-HF alone, FC-HF + natriuretic peptides (NPs) according to the PARAGON trial, FC-HF + NPs + echocardiographic HFpEF criteria according to European Society of Cardiology HF guidelines, and FC-HF + NPs + echocardiographic criteria according to the PARAGON trial. Out of the 539 patients enrolled in KaRen, 438 returned for the stable state revisit after 4-8 weeks, 13 (2.4%) patients died before the planned follow-up, and 88 patients (16%) declined or were unable to return. Three hundred ninety-nine patients have FC registered at follow-up, and among these, the four descriptive models were met in 107 (27%), 82 (22%), 61 (21%), and 69 (22%) patients, and not met in 292 (73%). The 107 patients that had FC-HF at stable state (descriptive model 1) could also be part of the other models because all patients in models 1-4 had to fulfil the FC-HF. The patients in model 0 did not fulfil the criteria for FC-HF but could have single FC. Of single FC, only pleural effusion predicted the endpoint [hazard ratio (HR) 3.38, 95% confidence interval (CI) 1.47-7.76, P = 0.004]. Patients without FC-HF had better prognosis than patients meeting FC-HF. The unadjusted associations between the four HFpEF descriptive models and the endpoint were HR 1.54, 95% CI 1.14-2.09, P = 0.005; HR 1.71, 95% CI 1.24-2.36, P = 0.002; HR 1.95, 95% CI 1.36-2.81, P = 0.001; and HR 2.05, 95% CI 1.45-2.91, P < 0.001, for descriptive models 1-4, respectively. No descriptive model independently predicted the endpoint. In ambulatory HFpEF patients, a quarter met FC-HF, while most met NP and echocardiography criteria for HF. Residual FC-HF tended to be associated with increased risk for mortality and HF hospitalization, further strengthened by NPs and echocardiographic criteria, highlighting its role in clinical risk assessment.","Department of Cardiology, Capio St. Göran's Hospital, 112 81, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, University of Rennes 1, Rennes, France.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2019,"2019","6","10.1002/ehf2.12458","830-839","20110610;20090376;20110120;00556-2009;20110406;20080498;20100419;20080409;2013-23897-104604-23","Stockholm County Council;Stockholm County Council;Stockholm County Council;Stockholm County Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Research Council;Center for Gender Medicine Karolinska Institutet, Stockholm, Sweden;Medtronic Bakken Research Center, Maastricht, The Netherlands;Fédération Française de Cardiologie/Société Française de Cardiologie, France","31207140","31207140","PUBMED","Department of Cardiology, Capio St. Göran's Hospital, 112 81, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, University of Rennes 1, Rennes, France.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden."
"Batail JM;Corouge I;Combès B;Conan C;Guillery-Sollier M;Vérin M;Sauleau P;Le Jeune F;Gauvrit JY;Robert G;Barillot C;Ferre JC;Drapier D","Batail, J M;Corouge, I;Combès, B;Conan, C;Guillery-Sollier, M;Vérin, M;Sauleau, P;Le Jeune, F;Gauvrit, J Y;Robert, G;Barillot, C;Ferre, J C;Drapier, D","Apathy in depression: An arterial spin labeling perfusion MRI study.","Journal of psychiatric research","England","eng","Journal Article","Apathy;Arterial spin labeling;Depressive disorder;Neuroimaging;Perfusion MRI","Depression;Apathy;Prospective Studies;Magnetic Resonance Imaging;Perfusion;Cerebrovascular Circulation","Depression;Apathy;Prospective Studies;Magnetic Resonance Imaging;Perfusion;Cerebrovascular Circulation","Apathy, as defined as a deficit in goal-directed behaviors, is a critical clinical dimension in depression associated with chronic impairment. Little is known about its cerebral perfusion specificities in depression. To explore neurovascular mechanisms underpinning apathy in depression by pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI). Perfusion imaging analysis was performed on 90 depressed patients included in a prospective study between November 2014 and February 2017. Imaging data included anatomical 3D T1-weighted and perfusion pCASL sequences. A multiple regression analysis relating the quantified cerebral blood flow (CBF) in different regions of interest defined from the FreeSurfer atlas, to the Apathy Evaluation Scale (AES) total score was conducted. After confound adjustment (demographics, disease and clinical characteristics) and correction for multiple comparisons, we observed a strong negative relationship between the CBF in the left anterior cingulate cortex (ACC) and the AES score (standardized beta = -0.74, corrected p value = 0.0008). Our results emphasized the left ACC as a key region involved in apathy severity in a population of depressed participants. Perfusion correlates of apathy in depression evidenced in this study may contribute to characterize different phenotypes of depression.","Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Univ Rennes, LP3C (Laboratoire de Psychologie: Cognition, Comportement, Communication) - EA 1285, CC5000, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurophysiology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Centre Eugène Marquis, Department of Nuclear Medicine, F-35062, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.","NA",0,"1879-1379","J Psychiatr Res","J Psychiatr Res",2021,"2023","157","10.1016/j.jpsychires.2022.11.015","7-16","","","36427413","36427413","PUBMED","Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Univ Rennes, LP3C (Laboratoire de Psychologie: Cognition, Comportement, Communication) - EA 1285, CC5000, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurophysiology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Centre Eugène Marquis, Department of Nuclear Medicine, F-35062, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France."
"Hage C;Michaëlsson E;Kull B;Miliotis T;Svedlund S;Linde C;Donal E;Daubert JC;Gan LM;Lund LH","Hage, Camilla;Michaëlsson, Erik;Kull, Bengt;Miliotis, Tasso;Svedlund, Sara;Linde, Cecilia;Donal, Erwan;Daubert, Jean-Claude;Gan, Li-Ming;Lund, Lars H","Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients.","ESC heart failure","England","eng","Journal Article","Endothelial dysfunction;Heart failure with preserved ejection fraction;Microvascular inflammation;Myeloperoxidase;Prognosis","Aged;Biomarkers;Female;Heart Failure;Humans;Inflammation;Male;Middle Aged;Peroxidase;Stroke Volume","Aged;Biomarkers;Female;Heart Failure;Humans;Inflammation;Male;Middle Aged;Peroxidase;Stroke Volume","In heart failure (HF) with preserved ejection fraction (HFpEF), microvascular inflammation is proposed as an underlying mechanism. Myeloperoxidase (MPO) is associated with vascular dysfunction and prognosis in congestive HF. MPO, MPO-related biomarkers, and echocardiography were assessed in 86 patients, 4-8 weeks after presentation with acute HF (EF ≥ 45%), and in 46 healthy controls. Patients were followed up for median 579 days (Q1;Q3 276;1178) regarding the composite endpoint all-cause mortality or HF hospitalization. Patients were 73 years old, 51% were female, EF was 64% (Q1;Q3 58;68), E/e' was ratio 10.8 (8.3;14.0), and left atrial volume index (LAVI) was 43 mL/m  (38;52). Controls were 60 (57;62) years old (vs. patients; P < 0.001), 24% were female (P = 0.005), and left ventricular EF was 63% (59;66; P = 0.790). MPO was increased in HFpEF compared with controls, 101 (81;132) vs. 86 (74;101 ng/mL, P = 0.015), as was uric acid 369 (314;439) vs. 289 (252;328 μmol/L, P < 0.001), calprotectin, asymmetric dimethyl arginine (ADMA), and symmetric dimethyl arginine (SDMA), while arginine was decreased. MPO correlated with uric acid (r = 0.26; P = 0.016). In patients with E/e' > 14, uric acid and SDMA were elevated (421 vs. 344 μM, P = 0.012; 0.54 vs. 0.47 μM, P = 0.039, respectively), and MPO was 121 vs. 98 ng/mL (P = 0.090). The ratios of arginine/ADMA (112 vs. 162; P < 0.001) and ADMA/SDMA (1.36 vs. 1.17; P = 0.002) were decreased in HFpEF patients, suggesting reduced NO availability and increased enzymatic clearance of ADMA, respectively. Uric acid independently predicted the endpoint [hazard ratio (HR) 3.76 (95% CI 1.19-11.85; P = 0.024)] but not MPO [HR 1.48 (95% CI 0.70-3.14; P = 0.304)] or the other biomarkers. In HFpEF, MPO-dependent oxidative stress reflected by uric acid and calprotectin is increased, and SDMA is associated with diastolic dysfunction and uric acid with outcome. This suggests microvascular neutrophil involvement mirroring endothelial dysfunction, a central component of the HFpEF syndrome and a potential treatment target.","Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2019,"2020","7","10.1002/ehf2.12700","1534-1546","00556-2009;20110120;20080409;20100419;2013-23897-104604-23;NA","Stockholm County Council;Stockholm County Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Research Council;Center for Gender Medicine, Karolinska Institutet;Medtronic Bakken Research Center;Fédération Française de Cardiologie/Société Française de Cardiologie","32424988","32424988","PUBMED","Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden."
"Drillet G;Lhomme F;De Guibert S;Manson G;Houot R","Drillet, Gaëlle;Lhomme, Faustine;De Guibert, Sophie;Manson, Guillaume;Houot, Roch","Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists.","Blood advances","United States","eng","Journal Article","","Humans;Receptors, Thrombopoietin;Immunotherapy, Adoptive;Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic;Anemia","Humans;Receptors, Thrombopoietin;Immunotherapy, Adoptive;Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic;Anemia","NA","Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;INSERM U1236, Rennes, France.","NA",0,"2473-9537","Blood Adv","Blood Adv",2022,"2023","7","10.1182/bloodadvances.2022008066","537-540","","","35930692","35930692","PUBMED","Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;INSERM U1236, Rennes, France."
"Scherdel P;Botton J;Rolland-Cachera MF;Léger J;Pelé F;Ancel PY;Simon C;Castetbon K;Salanave B;Thibault H;Lioret S;Péneau S;Gusto G;Charles MA;Heude B","Scherdel, Pauline;Botton, Jérémie;Rolland-Cachera, Marie-Françoise;Léger, Juliane;Pelé, Fabienne;Ancel, Pierre Yves;Simon, Chantal;Castetbon, Katia;Salanave, Benoit;Thibault, Hélène;Lioret, Sandrine;Péneau, Sandrine;Gusto, Gaelle;Charles, Marie-Aline;Heude, Barbara","Should the WHO growth charts be used in France?","PloS one","United States","eng","Comparative Study","","Adolescent;Anthropometry;Body Weights and Measures;Child;Child, Preschool;Female;France;Growth Charts;Humans;Male;Prospective Studies;World Health Organization","Adolescent;Anthropometry;Body Weights and Measures;Child;Child, Preschool;Female;France;Growth Charts;Humans;Male;Prospective Studies;World Health Organization","Growth charts are an essential clinical tool for evaluating a child's health and development. The current French reference curves, published in 1979, have recently been challenged by the 2006 World Health Organization (WHO) growth charts. To evaluate and compare the growth of French children who were born between 1981 and 2007, with the WHO growth charts and the French reference curves currently used. Anthropometric measurements from French children, who participated in 12 studies, were analyzed: 82,151 measurements were available for 27,257 children in different age groups, from birth to 18 years. We calculated and graphically compared mean z-scores based on the WHO and French curves, for height, weight and Body Mass Index (BMI) according to age and sex. The prevalence of overweight using the WHO, the French and International Obesity Task Force definitions were compared. Our population of children was on average 0.5 standard deviations taller than the French reference population, from the first month of life until puberty age. Mean z-scores for height, weight and BMI were closer to zero based on the WHO growth charts than on the French references from infancy until late adolescence, except during the first six months. These differences not related to breastfeeding rates. As expected, the prevalence of overweight depended on the reference used, and differences varied according to age. The WHO growth charts may be appropriate for monitoring growth of French children, as the growth patterns in our large population of French children were closer to the WHO growth charts than to the French reference curves, from 6 months onwards. However, there were some limitations in the use of these WHO growth charts, and further investigation is needed.","INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; Univ. Paris-Sud, Laboratoire de biomathématique, Faculté de Pharmacie, Châtenay-Malabry, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;Univ. Paris Diderot, Sorbonne Paris Cité, Paris, AP-HP, Hôpital Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, Institut National de la Santé et de la Recherche Médicale, UMR 676, Paris, France.;Inserm UMR 1085 IRSET, Rennes, France; Université de Rennes 1, Faculté de Médecine, Rennes, France, Centre Hospitalier Universitaire de Rennes (CHU), Service d'Epidémiologie et de Santé Publique, Rennes, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Paris, France, Paris Descartes University, France.;Carmen, Inserm U1060, University of Lyon 1, INRA U1235, CRNH Rhône-Alpes, CENS, Lyon, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Univ. Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France, Inserm, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; French Agency for Food, Environmental and Occupational Health Safety (ANSES, ex-AFSSA, Dietary Survey Unit, Maisons-Alfort, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;IRSA, département Synergies, 37521 La Riche cedex, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.","NA",0,"1932-6203","PLoS One","PLoS One",2014,"2015","10","10.1371/journal.pone.0120806","e0120806","","","25761138","25761138","PUBMED","INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; Univ. Paris-Sud, Laboratoire de biomathématique, Faculté de Pharmacie, Châtenay-Malabry, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;Univ. Paris Diderot, Sorbonne Paris Cité, Paris, AP-HP, Hôpital Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, Institut National de la Santé et de la Recherche Médicale, UMR 676, Paris, France.;Inserm UMR 1085 IRSET, Rennes, France; Université de Rennes 1, Faculté de Médecine, Rennes, France, Centre Hospitalier Universitaire de Rennes (CHU), Service d'Epidémiologie et de Santé Publique, Rennes, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Paris, France, Paris Descartes University, France.;Carmen, Inserm U1060, University of Lyon 1, INRA U1235, CRNH Rhône-Alpes, CENS, Lyon, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Univ. Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France, Inserm, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; French Agency for Food, Environmental and Occupational Health Safety (ANSES, ex-AFSSA, Dietary Survey Unit, Maisons-Alfort, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;IRSA, département Synergies, 37521 La Riche cedex, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France."
"Llovet JM;Kudo M;Merle P;Meyer T;Qin S;Ikeda M;Xu R;Edeline J;Ryoo BY;Ren Z;Masi G;Kwiatkowski M;Lim HY;Kim JH;Breder V;Kumada H;Cheng AL;Galle PR;Kaneko S;Wang A;Mody K;Dutcus C;Dubrovsky L;Siegel AB;Finn RS","Llovet, Josep M;Kudo, Masatoshi;Merle, Philippe;Meyer, Tim;Qin, Shukui;Ikeda, Masafumi;Xu, Ruocai;Edeline, Julien;Ryoo, Baek-Yeol;Ren, Zhenggang;Masi, Gianluca;Kwiatkowski, Mariusz;Lim, Ho Yeong;Kim, Jee Hyun;Breder, Valeriy;Kumada, Hiromitsu;Cheng, Ann-Lii;Galle, Peter R;Kaneko, Shuichi;Wang, Anran;Mody, Kalgi;Dutcus, Corina;Dubrovsky, Leonid;Siegel, Abby B;Finn, Richard S","Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.","The Lancet. Oncology","England","eng","Randomized Controlled Trial","","Aged;Female;Humans;Male;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Hepatocellular;Double-Blind Method;Gastrointestinal Hemorrhage;Hepatorenal Syndrome;Liver Neoplasms;Middle Aged","Aged;Female;Humans;Male;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Hepatocellular;Double-Blind Method;Gastrointestinal Hemorrhage;Hepatorenal Syndrome;Liver Neoplasms;Middle Aged","Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, α-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0·019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0·002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov, NCT03713593, and is active but not recruiting. Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 66·0 years (IQR 57·0-72·0), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 32·1 months (IQR 29·4-35·3). Median overall survival was 21·2 months (95% CI 19·0-23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2-21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71-1·00; stratified log-rank p=0·023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 8·2 months (95% CI 6·4-8·4; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 8·0 months (6·3-8·2; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 0·87; 95% CI 0·73-1·02; stratified log-rank p=0·047). The most common treatment-related grade 3-4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]). In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck.","Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; August Pi i Sunyer Biomedical Research Institute, University of Barcelona Hospital Clinic Barcelona, Barcelona;Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.;Hepatology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Royal Free London NHS Foundation Trust, London, UK; University College London Cancer Institute, University College London, London, UK.;GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.;National Cancer Center Hospital East, Kashiwa, Japan.;Hunan Cancer Hospital, Changsha, Hunan, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Zhongshan Hospital, Fudan University, Shanghai, China.;Department of Translational Research and New Technologies in Medicine and Surgery, Division of Medical Oncology, Pisa University Hospital, Pisa, Italy.;Nicolaus Copernicus Provincial Hospital, Koszalin, Poland.;Samsung Medical Center, Seoul, South Korea.;Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.;N N Blokhin Russian Cancer Research Center, Moscow, Russia.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.;University Medical Center Mainz, Mainz, Germany.;Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.;Merck, Rahway, NJ, USA.;Eisai, Nutley, NJ, USA.;Eisai, Nutley, NJ, USA.;Merck, Rahway, NJ, USA.;Merck, Rahway, NJ, USA.;Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2023","24","10.1016/S1470-2045(23)00469-2","1399-1410","26813","Cancer Research UK","38039993","38039993","PUBMED","Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; August Pi i Sunyer Biomedical Research Institute, University of Barcelona Hospital Clinic Barcelona, Barcelona;Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.;Hepatology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Royal Free London NHS Foundation Trust, London, UK; University College London Cancer Institute, University College London, London, UK.;GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.;National Cancer Center Hospital East, Kashiwa, Japan.;Hunan Cancer Hospital, Changsha, Hunan, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Zhongshan Hospital, Fudan University, Shanghai, China.;Department of Translational Research and New Technologies in Medicine and Surgery, Division of Medical Oncology, Pisa University Hospital, Pisa, Italy.;Nicolaus Copernicus Provincial Hospital, Koszalin, Poland.;Samsung Medical Center, Seoul, South Korea.;Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.;N N Blokhin Russian Cancer Research Center, Moscow, Russia.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.;University Medical Center Mainz, Mainz, Germany.;Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.;Merck, Rahway, NJ, USA.;Eisai, Nutley, NJ, USA.;Eisai, Nutley, NJ, USA.;Merck, Rahway, NJ, USA.;Merck, Rahway, NJ, USA.;Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA."
"Chan SL;Schuler M;Kang YK;Yen CJ;Edeline J;Choo SP;Lin CC;Okusaka T;Weiss KH;Macarulla T;Cattan S;Blanc JF;Lee KH;Maur M;Pant S;Kudo M;Assenat E;Zhu AX;Yau T;Lim HY;Bruix J;Geier A;Guillén-Ponce C;Fasolo A;Finn RS;Fan J;Vogel A;Qin S;Riester M;Katsanou V;Chaudhari M;Kakizume T;Gu Y;Porta DG;Myers A;Delord JP","Chan, Stephen L;Schuler, Martin;Kang, Yoon-Koo;Yen, Chia-Jui;Edeline, Julien;Choo, Su Pin;Lin, Chia-Chi;Okusaka, Takuji;Weiss, Karl-Heinz;Macarulla, Teresa;Cattan, Stéphane;Blanc, Jean-Frederic;Lee, Kyung-Hun;Maur, Michela;Pant, Shubham;Kudo, Masatoshi;Assenat, Eric;Zhu, Andrew X;Yau, Thomas;Lim, Ho Yeong;Bruix, Jordi;Geier, Andreas;Guillén-Ponce, Carmen;Fasolo, Angelica;Finn, Richard S;Fan, Jia;Vogel, Arndt;Qin, Shukui;Riester, Markus;Katsanou, Vasiliki;Chaudhari, Monica;Kakizume, Tomoyuki;Gu, Yi;Porta, Diana Graus;Myers, Andrea;Delord, Jean-Pierre","A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.","Journal of experimental & clinical cancer research : CR","England","eng","Clinical Trial, Phase I","FGF19;FGFR4;Hepatocellular carcinoma;Immune checkpoint inhibitors;KLB;PD-1;PD-L1;Phase 1","Antibodies, Monoclonal, Humanized;Bayes Theorem;Biomarkers;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Piperazines;Pyridines","Antibodies, Monoclonal, Humanized;Bayes Theorem;Biomarkers;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Piperazines;Pyridines","Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab. Patients with HCC or other FGFR4/KLB expressing tumors were enrolled. Dose-escalation was guided by a Bayesian model. Phase 2 dose-expansion enrolled patients with HCC from Asian countries (group1), non-Asian countries (group2), and patients with other solid tumors expressing FGFR4 and KLB (group3). FGF401 and spartalizumab combination was evaluated in patients with HCC. Seventy-four patients were treated in the phase I with single-agent FGF401 at 50 to 150 mg. FGF401 displayed favorable PK characteristics and no food effect when dosed with low-fat meals. The RP2D was established as 120 mg qd. Six of 70 patients experienced grade 3 dose-limiting toxicities: increase in transaminases (n = 4) or blood bilirubin (n = 2). In phase 2, 30 patients in group 1, 36 in group 2, and 20 in group 3 received FGF401. In total, 8 patients experienced objective responses (1 CR, 7 PR; 4 each in phase I and phase II, respectively). Frequent adverse events (AEs) were diarrhea (73.8%), increased AST (47.5%), and ALT (43.8%). Increase in levels of C4, total bile acid, and circulating FGF19, confirmed effective FGFR4 inhibition. Twelve patients received FGF401 plus spartalizumab. RP2D was established as FGF401 120 mg qd and spartalizumab 300 mg Q3W; 2 patients reported PR. At biologically active doses, FGF401 alone or combined with spartalizumab was safe in patients with FGFR4/KLB-positive tumors including HCC. Preliminary clinical efficacy was observed. Further clinical evaluation of FGF401 using a refined biomarker strategy is warranted. NCT02325739 .","State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong;West German Cancer Center, University Hospital Essen, Germany & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Centre Eugène Marquis, Rennes, France and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;National Cancer Centre, Singapore, Singapore.;National Taiwan University Hospital, Taipei, Taiwan.;National Cancer Centre Hospital, Tokyo, Japan.;Salem Medical Center, Internal Medicine, Heidelberg, Germany.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quirón, Barcelona, Spain.;Chru de Lille, Lille, France.;CHU de Bordeaux Pessac, Bordeaux, France.;Seoul National University Hospital, Seoul, South Korea.;University Hospital of Modena, Modena, Italy.;MD Anderson Cancer Center, Houston, TX, USA.;Kindai University Hospital, Osaka, Japan.;Hôpital Saint-Eloi Montpellier, Montpellier, France.;Massachusetts General Hospital, Boston, MA, USA.;Jiahui International Cancer Center, Jiahui Health, Shanghai, China.;Queen Mary Hospital, Hong Kong, China.;Samsung Medical Center, Seoul, South Korea.;Barcelona clinic liver cancer (BCLC) Group, Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.;University Hospital Würzburg, Würzburg, Germany.;Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.;San Raffaele Hospital, Milan, Italy.;University of California, Los Angeles, California, USA.;Zhongshan Hospital, Fudan University, Shanghai, China.;Hannover Medical School, Hanover, Germany.;No. 81th PLA Hospital Nanjing, Jiangsu, China.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;IQVIA, Durham, North Carolina, USA.;Novartis Pharma K.K, Tokyo, Japan.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;IUCT Oncopole - Institut Claudius Regaud, Toulouse, France.","NA",0,"1756-9966","J Exp Clin Cancer Res","J Exp Clin Cancer Res",2022,"2022","41","10.1186/s13046-022-02383-5","189","","","35655320","35655320","PUBMED","State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong;West German Cancer Center, University Hospital Essen, Germany & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Centre Eugène Marquis, Rennes, France and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;National Cancer Centre, Singapore, Singapore.;National Taiwan University Hospital, Taipei, Taiwan.;National Cancer Centre Hospital, Tokyo, Japan.;Salem Medical Center, Internal Medicine, Heidelberg, Germany.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quirón, Barcelona, Spain.;Chru de Lille, Lille, France.;CHU de Bordeaux Pessac, Bordeaux, France.;Seoul National University Hospital, Seoul, South Korea.;University Hospital of Modena, Modena, Italy.;MD Anderson Cancer Center, Houston, TX, USA.;Kindai University Hospital, Osaka, Japan.;Hôpital Saint-Eloi Montpellier, Montpellier, France.;Massachusetts General Hospital, Boston, MA, USA.;Jiahui International Cancer Center, Jiahui Health, Shanghai, China.;Queen Mary Hospital, Hong Kong, China.;Samsung Medical Center, Seoul, South Korea.;Barcelona clinic liver cancer (BCLC) Group, Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.;University Hospital Würzburg, Würzburg, Germany.;Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.;San Raffaele Hospital, Milan, Italy.;University of California, Los Angeles, California, USA.;Zhongshan Hospital, Fudan University, Shanghai, China.;Hannover Medical School, Hanover, Germany.;No. 81th PLA Hospital Nanjing, Jiangsu, China.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;IQVIA, Durham, North Carolina, USA.;Novartis Pharma K.K, Tokyo, Japan.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;IUCT Oncopole - Institut Claudius Regaud, Toulouse, France."
"Thille AW;Coudroy R;Nay MA;Gacouin A;Decavèle M;Sonneville R;Beloncle F;Girault C;Dangers L;Lautrette A;Levrat Q;Rouzé A;Vivier E;Lascarrou JB;Ricard JD;Razazi K;Barberet G;Lebert C;Ehrmann S;Massri A;Bourenne J;Pradel G;Bailly P;Terzi N;Dellamonica J;Lacave G;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Coudroy, Rémi;Nay, Mai-Anh;Gacouin, Arnaud;Decavèle, Maxens;Sonneville, Romain;Beloncle, François;Girault, Christophe;Dangers, Laurence;Lautrette, Alexandre;Levrat, Quentin;Rouzé, Anahita;Vivier, Emmanuel;Lascarrou, Jean-Baptiste;Ricard, Jean-Damien;Razazi, Keyvan;Barberet, Guillaume;Lebert, Christine;Ehrmann, Stephan;Massri, Alexandre;Bourenne, Jeremy;Pradel, Gael;Bailly, Pierre;Terzi, Nicolas;Dellamonica, Jean;Lacave, Guillaume;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","Non-invasive ventilation alternating with high-flow nasal oxygen versus high-flow nasal oxygen alone after extubation in COPD patients: a post hoc analysis of a randomized controlled trial.","Annals of intensive care","Germany","eng","Journal Article","Airway extubation;Chronic obstructive pulmonary disease;High-flow nasal oxygen;Non-invasive ventilation;Weaning","","","Several randomized clinical trials have shown that non-invasive ventilation (NIV) applied immediately after extubation may prevent reintubation in patients at high-risk of extubation failure. However, most of studies included patients with chronic respiratory disorders as well as patients without underlying respiratory disease. To date, no study has shown decreased risk of reintubation with prophylactic NIV after extubation among patients with chronic obstructive pulmonary disease (COPD). We hypothesized that prophylactic NIV after extubation may decrease the risk of reintubation in COPD patients as compared with high-flow nasal oxygen. We performed a post hoc subgroup analysis of COPD patients included in a multicenter, randomized, controlled trial comparing prophylactic use of NIV alternating with high-flow nasal oxygen versus high-flow nasal oxygen alone immediately after extubation. Among the 651 patients included in the original study, 150 (23%) had underlying COPD including 86 patients treated with NIV alternating with high-flow nasal oxygen and 64 patients treated with high-flow nasal oxygen alone. The reintubation rate was 13% (11 out of 86 patients) with NIV and 27% (17 out of 64 patients) with high-flow nasal oxygen alone [difference, - 14% (95% CI - 27% to - 1%); p = 0.03]. Whereas reintubation rates were significantly lower with NIV than with high-flow nasal oxygen alone at 72 h and until ICU discharge, mortality in ICU did not differ between groups: 6% (5/86) with NIV vs. 9% (6/64) with high-flow nasal oxygen alone [difference - 4% (95% CI - 14% to 5%); p = 0.40]. In COPD patients, prophylactic NIV alternating with high-flow nasal oxygen significantly decreased the risk of reintubation compared with high-flow nasal oxygen alone. Trial registration The study was registered at http://www.clinicaltrials.gov with the trial registration number NCT03121482 (20 April 2017).","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers;Service de Médecine Intensive Réanimation, CHU de Poitiers, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Rennes, France.;Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.;Hôpital Bichat, Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université de Paris, INSERM U1148, Paris, France.;Département de Médecine Intensive Réanimation, Centre Hospitalier Universitaire D'Angers, Université d'Angers, Angers, France.;Département de Réanimation Médicale, Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, EA3830-GRHV, Rouen, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint Denis de la Réunion, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Service de Réanimation, Centre Hospitalier de La Rochelle, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, 59000, Lille, France.;Réanimation Polyvalente, Centre Hospitalier Saint-Joseph Saint-Luc, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Service de Réanimation Médicale, DHU A-TVB, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Site Emile Muller, Service de Réanimation Médicale, Groupe Hospitalier Régional Mulhouse Sud Alsace, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2020,"2021","11","10.1186/s13613-021-00823-7","30","grant number 15-0060","Direction de l'hospitalisation et de l'offre de Soins","33559765","33559765","PUBMED","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers;Service de Médecine Intensive Réanimation, CHU de Poitiers, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Rennes, France.;Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.;Hôpital Bichat, Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université de Paris, INSERM U1148, Paris, France.;Département de Médecine Intensive Réanimation, Centre Hospitalier Universitaire D'Angers, Université d'Angers, Angers, France.;Département de Réanimation Médicale, Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, EA3830-GRHV, Rouen, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint Denis de la Réunion, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Service de Réanimation, Centre Hospitalier de La Rochelle, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, 59000, Lille, France.;Réanimation Polyvalente, Centre Hospitalier Saint-Joseph Saint-Luc, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Service de Réanimation Médicale, DHU A-TVB, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Site Emile Muller, Service de Réanimation Médicale, Groupe Hospitalier Régional Mulhouse Sud Alsace, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France."
"Modesto A;Tougeron D;Tremolières P;Ronchin P;Jouve AD;Leignel DA;Vendrely V;Riou O;Martin-Babau J;Le Sourd S;Mirabel X;Leroy T;Huguet F;Montaigne L;Baumgaertner I;Deslandres M;Moyal E;Seva C;Selves J;Otal P;Pezzella V;Guimbaud R;Filleron T;Quéro L","Modesto, Anouchka;Tougeron, David;Tremolières, Pierre;Ronchin, Philippe;Jouve, Ariane Darut;Leignel, Delphine Argo;Vendrely, Véronique;Riou, Olivier;Martin-Babau, Jérôme;Le Sourd, Samuel;Mirabel, Xavier;Leroy, Thomas;Huguet, Florence;Montaigne, Lucile;Baumgaertner, Isabelle;Deslandres, Marion;Moyal, Elizabeth;Seva, Catherine;Selves, Janick;Otal, Philippe;Pezzella, Veronica;Guimbaud, Rosine;Filleron, Thomas;Quéro, Laurent","Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.","BMC cancer","England","eng","Clinical Trial Protocol","Anti-PD-L1;Chemo-radiotherapy;Esophagus carcinoma;Immunotherapy;Phase II;Randomized trial","Humans;Proteomics;Antineoplastic Combined Chemotherapy Protocols;Chemoradiotherapy;Carcinoma;Esophageal Neoplasms;Immunotherapy;Randomized Controlled Trials as Topic;Multicenter Studies as Topic;Clinical Trials, Phase II as Topic","Humans;Proteomics;Antineoplastic Combined Chemotherapy Protocols;Chemoradiotherapy;Carcinoma;Esophageal Neoplasms;Immunotherapy;Randomized Controlled Trials as Topic;Multicenter Studies as Topic;Clinical Trials, Phase II as Topic","In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains the standard of care resulting in a 2-year disease-free survival of 25% which deserves to be associated with new systemic strategies. In recent years, several immune checkpoint inhibitors (anti-PD1/anti-PD-L1, anti-Program-Death 1/anti-Program-Death ligand 1) have been approved for the treatment of various solid malignancies including metastatic esophageal cancer. As such, we hypothesized that the addition of an anti-PD-L1 to CRT would provide clinical benefit for patients with locally advanced oesophageal cancer. To assess the efficacy of the anti-PD-L1 durvalumab in combination with CRT and then as maintenance therapy we designed the randomized phase II ARION (Association of Radiochemotherapy with Immunotherapy in unresectable Oesophageal carciNoma- UCGI 33/PRODIGE 67). ARION is a multicenter, open-label, randomized, comparative phase II trial. Patients are randomly assigned in a 1:1 ratio in each arm with a stratification according to tumor stage, histology and centre. Experimental arm relies on CRT with 50 Gy in 25 daily fractions in combination with FOLFOX regimen administrated during and after radiotherapy every two weeks for a total of 6 cycles and durvalumab starting with CRT for a total of 12 infusions. Standard arm is CRT alone. Use of Intensity Modulated radiotherapy is mandatory. The primary endpoint is to increase progression-free survival at 12 months from 50 to 68% (HR = 0.55) (power 90%; one-sided alpha-risk, 10%). Progression will be defined with central external review of imaging. PD-L1 Combined Positivity Score on carcinoma cells and stromal immune cells of diagnostic biopsy specimen will be correlated to disease free survival. The study of gut microbiota will aim to determine if baseline intestinal bacteria correlates with tumor response. Proteomic analysis on blood samples will compare long-term responder after CRT with durvalumab to non-responder to identify biomarkers. Results of the present study will be of great importance to evaluate the impact of immunotherapy in combination with CRT and decipher immune response in this unmet need clinical situation. ClinicalTrials.gov, NCT: 03777813.Trial registration date: 5  December 2018.","Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse;Service d'hépato-Gastro-Entérologie, Centre Hospitalier Universitaire de Poitiers, 86000, Poitiers, France.;Institut de Cancérologie de L'Ouest: Angers Et Saint Herblain, Saint-herblain, France.;Hôpital Privé Arnault Tzanck- Centre Azuréen de Cancérologie, Mougins, France.;Institut de Cancérologie de Bourgogne, Dijon, France.;Groupe Hospitalier Bretagne Sud, Lorient, France.;CHU de Bordeaux, Bordeaux, France.;Centre Val d'Aurelle, Montpellier, France.;Centre Armoricain d'Oncologie CARIO, Plérin, France.;Centre Eugène Marquis, Renne, France.;Centre Oscar Lambret, Lille, France.;Nouvelle Clinique Des Dentellières, Valenciennes, France.;Radiation Oncology Department, Tenon Hospital, AP-HP,, Sorbonne University, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Hospitalo Universitaire Henri Mondor APHP, Créteil, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Pathology department, Centre Hospitalo Universitaire IUCT-Oncopole, Toulouse, France.;Imaging Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;UNICANCER, Paris, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Biostatistics Departement Institut Claudius Regaud Institut, Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Radiation Oncology Department, Saint Louis Hospital, AP-HP, Paris, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2022,"2023","23","10.1186/s12885-023-11227-0","966","","","37828434","37828434","PUBMED","Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse;Service d'hépato-Gastro-Entérologie, Centre Hospitalier Universitaire de Poitiers, 86000, Poitiers, France.;Institut de Cancérologie de L'Ouest: Angers Et Saint Herblain, Saint-herblain, France.;Hôpital Privé Arnault Tzanck- Centre Azuréen de Cancérologie, Mougins, France.;Institut de Cancérologie de Bourgogne, Dijon, France.;Groupe Hospitalier Bretagne Sud, Lorient, France.;CHU de Bordeaux, Bordeaux, France.;Centre Val d'Aurelle, Montpellier, France.;Centre Armoricain d'Oncologie CARIO, Plérin, France.;Centre Eugène Marquis, Renne, France.;Centre Oscar Lambret, Lille, France.;Nouvelle Clinique Des Dentellières, Valenciennes, France.;Radiation Oncology Department, Tenon Hospital, AP-HP,, Sorbonne University, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Hospitalo Universitaire Henri Mondor APHP, Créteil, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Pathology department, Centre Hospitalo Universitaire IUCT-Oncopole, Toulouse, France.;Imaging Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;UNICANCER, Paris, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Biostatistics Departement Institut Claudius Regaud Institut, Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Radiation Oncology Department, Saint Louis Hospital, AP-HP, Paris, France."
"Duffaud F;Italiano A;Bompas E;Rios M;Penel N;Mir O;Piperno-Neumann S;Chevreau C;Delcambre C;Bertucci F;Boudou-Rouquette P;Cancel M;Perrin C;Saada-Bouzid E;Monard L;Schiffler C;Chaigneau L;Hervieu A;Collard O;Bouvier C;Vidal V;Chabaud S;Blay JY","Duffaud, Florence;Italiano, Antoine;Bompas, Emannuelle;Rios, Maria;Penel, Nicolas;Mir, Olivier;Piperno-Neumann, Sophie;Chevreau, Christine;Delcambre, Corinne;Bertucci, François;Boudou-Rouquette, Pascaline;Cancel, Mathilde;Perrin, Christophe;Saada-Bouzid, Esma;Monard, Laure;Schiffler, Camille;Chaigneau, Loic;Hervieu, Alice;Collard, Olivier;Bouvier, Corinne;Vidal, Vincent;Chabaud, Sylvie;Blay, Jean-Yves","Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.","European journal of cancer (Oxford, England : 1990)","England","eng","Clinical Trial, Phase II","Metastatic chondrosarcoma;Progression after standard chemotherapy;Regorafenib","Adult;Aged;Antineoplastic Agents;Bone Neoplasms;Chondrosarcoma;Disease Progression;Double-Blind Method;Female;France;Humans;Male;Middle Aged;Phenylurea Compounds;Progression-Free Survival;Pyridines;Time Factors","Adult;Aged;Antineoplastic Agents;Bone Neoplasms;Chondrosarcoma;Disease Progression;Double-Blind Method;Female;France;Humans;Male;Middle Aged;Phenylurea Compounds;Progression-Free Survival;Pyridines;Time Factors","This multi-cohort trial explored the efficacy and safety of regorafenib for patients with advanced sarcomas of bone origin; this report details the cohort of patients with metastatic or locally advanced chondrosarcoma (CS), progressing after prior chemotherapy. Patients with CS, progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progressive disease. The primary endpoint was progression-free rate (PFR) at 12 weeks. With one-sided α of 0.05, and 80% power, at least 16/24 progression-free patients at 12 weeks were needed for success (P0 = 50%, P1 = 75%). From September 2014 to February 2019, 46 patients were included in the CS cohort, and 40 patients were evaluable for efficacy: 16 on placebo and 24 on regorafenib. Thirteen patients (54.2%; 95% CI [35.8%-[) were non-progressive at 12 weeks on regorafenib versus 5 (31.3%; 95% CI [13.2%-[);) on placebo. Median PFS was 19.9 weeks on regorafenib, and 8.0 on placebo. Fourteen placebo patients crossed over to regorafenib after progression. The most common grade ≥3 treatment-related adverse events on regorafenib included hypertension (12%), asthenia (8%), thrombocytopenia (8%) and diarrhoea (8%). One episode of fatal liver dysfunction occurred on regorafenib. Although the primary endpoint was not met statistically in this small randomised cohort, there is modest evidence to suggest that regorafenib might slow disease progression in patients with metastatic CS after the failure of prior chemotherapy. The trial is registered at ClinicalTrials.gov (NCT02389244).","Aix Marseille Univ, APHM Hopital La Timone, Medical Oncology Unit, Marseille;Medical Oncology Unit, Institut Bergonié, Bordeaux, France.;Medical Oncology Department, Centre René Gauducheau, Saint Herblain, France.;Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Unicancer, Paris, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Hospitalier Universitaire - Jean Minjoz Hospital, Besançon, France.;Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France.;Medical Oncology Department, Institut de Cancérologie Lucien Neuwirth, St Priest En Jarez, France.;Aix Marseille Univ, APHM Hopital La Timone, Pathology Department, Marseille, France.;Aix Marseille Univ, APHM Hopital La Timone, Radiology Department, Marseille, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","150","10.1016/j.ejca.2021.03.039","108-118","","","33895682","33895682","PUBMED","Aix Marseille Univ, APHM Hopital La Timone, Medical Oncology Unit, Marseille;Medical Oncology Unit, Institut Bergonié, Bordeaux, France.;Medical Oncology Department, Centre René Gauducheau, Saint Herblain, France.;Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Unicancer, Paris, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Hospitalier Universitaire - Jean Minjoz Hospital, Besançon, France.;Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France.;Medical Oncology Department, Institut de Cancérologie Lucien Neuwirth, St Priest En Jarez, France.;Aix Marseille Univ, APHM Hopital La Timone, Pathology Department, Marseille, France.;Aix Marseille Univ, APHM Hopital La Timone, Radiology Department, Marseille, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France."
"Cabrit N;Cheugoua-Zanetsie M;Tierney J;Thirion P;Nankivell M;Winter K;Yang H;Wijnhoven B;Vernerey D;Smithers BM;Piessen G;Nilsson M;Boonstra J;Ychou M;Law S;Cunningham D;Vathaire F;Stahl M;Urba S;Valmasoni M;Williaume D;Thomas J;Lordick F;Tepper J;Gebski V;Burmeister B;Paoletti X;Sandick JV;Fu J;Pignon JP;Ducreux M;Faron M;Michiels S","Cabrit, Nicolas;Cheugoua-Zanetsie, Maurice;Tierney, Jayne;Thirion, Pierre;Nankivell, Matthew;Winter, Kathryn;Yang, Hong;Wijnhoven, Bas;Vernerey, Dewi;Smithers, B Mark;Piessen, Guillaume;Nilsson, Magnus;Boonstra, Jurjen;Ychou, Marc;Law, Simon;Cunningham, David;Vathaire, Florent de;Stahl, Michael;Urba, Susan;Valmasoni, Michele;Williaume, Danièle;Thomas, Janine;Lordick, Florian;Tepper, Joel;Gebski, Val;Burmeister, Bryan;Paoletti, Xavier;Sandick, Johanna van;Fu, Jianhua;Pignon, Jean-Pierre;Ducreux, Michel;Faron, Matthieu;Michiels, Stefan","Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Chemotherapy;Esophageal cancer;Gastroesophageal junction;Individual patient data network meta-analysis;Preoperative;Radiotherapy;Surrogate endpoint","Humans;Esophageal Neoplasms;Neoadjuvant Therapy;Disease-Free Survival;Chemoradiotherapy;Male;Female;Esophagogastric Junction;Middle Aged;Aged;Randomized Controlled Trials as Topic;Esophagectomy;Chemoradiotherapy, Adjuvant;Chemotherapy, Adjuvant","Humans;Esophageal Neoplasms;Neoadjuvant Therapy;Disease-Free Survival;Chemoradiotherapy;Male;Female;Esophagogastric Junction;Middle Aged;Aged;Randomized Controlled Trials as Topic;Esophagectomy;Chemoradiotherapy, Adjuvant;Chemotherapy, Adjuvant","The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in the neoadjuvant treatment of esophageal (E) or gastroesophageal junctional (GEJ) carcinomas remains uncertain. To evaluate DFS as a surrogate end-point for OS in E/GEJ using the meta-analytical approach DESIGN, SETTING, AND PARTICIPANTS: individual patient data from an international meta-analysis on operable locally advanced E/GEJ, which including randomized trials comparing at least two of the neo-adjuvant treatment strategies: upfront surgery (S), chemotherapy followed by surgery (CS), and/or chemoradiotherapy followed by surgery (CRS). Individual (Kendall's tau) and trial-level (R2) correlations between DFS and OS were estimated using a Clayton copula. DFS and OS data were available for a total of 4518 pts: 2222 pts included in CS vs S, 1908 pts in CRS vs S, and 388 in CS vs CRS comparisons. 3440 patients had a DFS event and 3303 patients died. Kendall's tau was 0.73 [95 % CI 0.71 - 0.75] and R2 trial-level correlation was 0.95 [0.84 - 0.99] for CS vs S, Kendall's tau was 0.76 [0.74 - 0.77] and R2 was 0.96 [0.87 - 0.99] for CRS vs S, Kendall's tau was 0.87 [0.78 - 0.92] and R2 was 0.93 [0.43 - 1] for CRS vs CS. In a multistate model, the median time in the recurrence state was shorter in older vs more recent trials: mean time of 10.8 [10.2 - 11.4] vs 16.5 months [15.4-17.6]. DFS is a validated surrogate endpoint for OS in trials evaluating neoadjuvant chemotherapy or chemoradiotherapy in E/GEJ. DFS may be more useful as an endpoint when delays between recurrences and death become larger.","Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;St Luke's Radiation Oncology Network Dublin, Trinity College Dublin, Ireland; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Sun Yat-Sen University Cancer Center, Guangzhou, China; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Erasmus University Medical Center, Rotterdam, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CHRU Jean Minjoz, Besançon, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;University of Queensland, Princess Alexandra Hospital, Australia; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Univ. Lille, CNRS, Inserm, Chu Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille F-59000, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Leiden University Medical Center, Leiden, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Val d'Aurelles, Montpellier, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, UK; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Evang, Kliniken Essen-Mitte, Essen, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of Michigan, Ann Arbor, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Centre Eugène Marquis, Rennes, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Princess Alexandra Hospital, Woolloongabba, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Department of Oncology, University of Leipzig Medical Center, Leipzig, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of North Carolina School of Medicine, Chapel Hill, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; NHMRC, Sydney, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Institut Curie, Paris, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University Paris-Saclay, Medical Oncology Department, Gustave Roussy, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2024,"2025","218","10.1016/j.ejca.2025.115292","115292","","","39938127","39938127","PUBMED","Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;St Luke's Radiation Oncology Network Dublin, Trinity College Dublin, Ireland; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Sun Yat-Sen University Cancer Center, Guangzhou, China; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Erasmus University Medical Center, Rotterdam, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CHRU Jean Minjoz, Besançon, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;University of Queensland, Princess Alexandra Hospital, Australia; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Univ. Lille, CNRS, Inserm, Chu Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille F-59000, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Leiden University Medical Center, Leiden, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Val d'Aurelles, Montpellier, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, UK; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Evang, Kliniken Essen-Mitte, Essen, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of Michigan, Ann Arbor, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Centre Eugène Marquis, Rennes, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Princess Alexandra Hospital, Woolloongabba, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Department of Oncology, University of Leipzig Medical Center, Leipzig, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of North Carolina School of Medicine, Chapel Hill, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; NHMRC, Sydney, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Institut Curie, Paris, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University Paris-Saclay, Medical Oncology Department, Gustave Roussy, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif"
"Le Daré B;Boglione-Kerrien C;Reizine F;Gangneux JP;Bacle A","Le Daré, Brendan;Boglione-Kerrien, Christelle;Reizine, Florian;Gangneux, Jean-Pierre;Bacle, Astrid","Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.","Critical care (London, England)","England","eng","Journal Article","","Antifungal Agents;COVID-19;Drug Administration Schedule;Evidence-Based Medicine;Female;Humans;Male;Pulmonary Aspergillosis;Voriconazole","Antifungal Agents;COVID-19;Drug Administration Schedule;Evidence-Based Medicine;Female;Humans;Male;Pulmonary Aspergillosis;Voriconazole","NA","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes;INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Univ Rennes, Rennes;Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, 35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033, Rennes, France.;Faculté de Médecine, Biosit, Université Rennes 1, 35043, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.","NA",0,"1466-609X","Crit Care","Crit Care",2021,"2021","25","10.1186/s13054-021-03568-8","152","","","33879175","33879175","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes;INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Univ Rennes, Rennes;Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, 35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033, Rennes, France.;Faculté de Médecine, Biosit, Université Rennes 1, 35043, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France."
"Zheng J;Yu Y;Durairaj C;Diéras V;Finn RS;Wang DD","Zheng, Jenny;Yu, Yanke;Durairaj, Chandrasekar;Diéras, Véronique;Finn, Richard S;Wang, Diane D","Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib.","Targeted oncology","France","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Drug Tapering;Female;Humans;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyridines;Treatment Outcome","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Drug Tapering;Female;Humans;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyridines;Treatment Outcome","Palbociclib is indicated for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Exposure-response analyses were conducted to evaluate efficacy in Asian versus non-Asian patients and in patients with versus without dose reduction in PALOMA-2. PALOMA-2 compared palbociclib plus letrozole versus placebo plus letrozole in patients with ABC. Population pharmacokinetic analysis provided apparent palbociclib clearance (CL/F) for each patient. The time-varying exposure metric, C , was calculated using average dose intensity and CL/F at the time of each progression-free survival (PFS) event. A Cox proportional model characterized PFS and palbociclib C  relationships. Significant prognostic factors for PFS were identified by univariate analysis, which were subsequently included in multivariate analyses, in addition to the C  effect on PFS. PFS profiles in Asian/non-Asian patients and patients with/without dose reduction were simulated and compared using observed palbociclib exposures and established exposure-response relationships. Patients (n = 421) received palbociclib plus letrozole (Asian = 64, non-Asian = 357; no dose reduction = 272, dose reduction = 149). Based on univariate analyses, significant prognostic factors were Ki67 score, age, and baseline aspartate aminotransferase (BAST), tumor size, alkaline phosphatase, and albumin levels. In multivariate analysis, only Ki67 and BAST remained significant. Palbociclib exposure did not significantly affect PFS in either univariate (P = 0.12) or multivariate (P = 0.44) analyses. This analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians. NCT01740427.","Pharmacometrics, Global Product Development, Pfizer Inc, Col-D/006/D6400, 500 Arcola Rd., Collegeville, PA, 19426;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Department of Medical Oncology Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.","NA",0,"1776-260X","Target Oncol","Target Oncol",2020,"2021","16","10.1007/s11523-020-00771-5","69-76","","","33211314","33211314","PUBMED","Pharmacometrics, Global Product Development, Pfizer Inc, Col-D/006/D6400, 500 Arcola Rd., Collegeville, PA, 19426;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Department of Medical Oncology Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA."
"Presti D;Havas J;Soldato D;Lapidari P;Martin E;Pistilli B;Jouannaud C;Emile G;Rigal O;Fournier M;Soulie P;Mouret-Reynier MA;Tarpin C;Campone M;Guillermet S;Martin AL;Everhard S;Di Meglio A","Presti, D;Havas, J;Soldato, D;Lapidari, P;Martin, E;Pistilli, B;Jouannaud, C;Emile, G;Rigal, O;Fournier, M;Soulie, P;Mouret-Reynier, M-A;Tarpin, C;Campone, M;Guillermet, S;Martin, A-L;Everhard, S;Di Meglio, A","Factors associated with enrolment in clinical trials among women with early-stage breast cancer.","ESMO open","England","eng","Journal Article","breast neoplasms;clinical trial;quality of life;survivorship","Breast Neoplasms;Female;Humans;Prospective Studies;Quality of Life;Surveys and Questionnaires","Breast Neoplasms;Female;Humans;Prospective Studies;Quality of Life;Surveys and Questionnaires","Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer. We included 9516 patients with stage I-III breast cancer from the multicenter, prospective CANTO study (NCT01993498), followed-up until year 4 (Y4) post-diagnosis. We assessed factors associated with enrolment using multivariable logistic regression. In exploratory, propensity score matched analyses, we used multiple linear regression to evaluate the relationship of enrolment in clinical trials with the European Organisation for Research and Treatment of Cancer Quality Of Life (QoL) questionnaire (EORTC QLQ-C30) Summary Score and described clinical outcomes (distant disease event, invasive disease event, and death by any cause) according to enrolment. Overall, 1716 patients (18%) were enrolled in a clinical trial until Y4 post-diagnosis of breast cancer. Socioeconomic factors were not associated with enrolment. Centres of intermediate volume were most likely to enrol patients in clinical trials [versus low volume, odds ratio 1.45 (95% confidence interval (CI) 1.08-1.95), P = 0.0124]. Among 2118 propensity score matched patients, enrolment was associated with better QoL at Y4 (adjusted mean difference versus not enrolled 1.37, 95% CI 0.03-2.71, P = 0.0458), and clinical outcomes (enrolled versus not enrolled, distant disease event 7.3% versus 10.1%, P = 0.0206; invasive disease event 8.2% versus 10.5%, P = 0.0732; death by any cause 2.8% versus 3.7%, P = 0.2707). In this large study, one in five patients enrolled on a clinical trial until Y4 after diagnosis of early breast cancer. Geographical and centre-related factors were significantly associated with enrolment in clinical trials. Inclusion in clinical trials seemed associated with improved QoL and clinical outcomes. Access to innovation for early-stage breast cancer patients should be encouraged and facilitated by overcoming organizational and geographical barriers to recruitment.","INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Institut Jean Godinot, Reims, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologie de L'ouest -Paul Papin, Angers, France.;Centre Jean-Perrin, Clermont Ferrand, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif","NA",0,"2059-7029","ESMO Open","ESMO Open",2022,"2022","7","10.1016/j.esmoop.2022.100513","100513","","","35724624","35724624","PUBMED","INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Institut Jean Godinot, Reims, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologie de L'ouest -Paul Papin, Angers, France.;Centre Jean-Perrin, Clermont Ferrand, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif"
"Pasquier G;Bounhiol A;Robert Gangneux F;Zahar JR;Gangneux JP;Novara A;Bougnoux ME;Dannaoui E","Pasquier, Grégoire;Bounhiol, Agathe;Robert Gangneux, Florence;Zahar, Jean-Ralph;Gangneux, Jean Pierre;Novara, Ana;Bougnoux, Marie-Elisabeth;Dannaoui, Eric","A review of significance of Aspergillus detection in airways of ICU COVID-19 patients.","Mycoses","Germany","eng","Journal Article","Aspergillus fumigatus;COVID-19;SARS-CoV-2;colonisation;intensive care unit;invasive pulmonary aspergillosis;mortality","Adult;Aged;Aged, 80 and over;Antifungal Agents;Bronchoalveolar Lavage Fluid;COVID-19;Cause of Death;Female;Humans;Intensive Care Units;Invasive Pulmonary Aspergillosis;Male;Middle Aged;SARS-CoV-2","Adult;Aged;Aged, 80 and over;Antifungal Agents;Bronchoalveolar Lavage Fluid;COVID-19;Cause of Death;Female;Humans;Intensive Care Units;Invasive Pulmonary Aspergillosis;Male;Middle Aged;SARS-CoV-2","It is now well known that patients with SARS-CoV-2 infection admitted in ICU and mechanically ventilated are at risk of developing invasive pulmonary aspergillosis (IPA). Nevertheless, symptomatology of IPA is often atypical in mechanically ventilated patients, and radiological aspects in SARS-CoV-2 pneumonia and IPA are difficult to differentiate. In this context, the significance of the presence of Aspergillus in airway specimens (detected by culture, galactomannan antigen or specific PCR) remains to be fully understood. To decipher the relevance of the detection of Aspergillus, we performed a comprehensive review of all published cases of respiratory Aspergillus colonisation and IPA in COVID-19 patients. The comparison of patients receiving or not antifungal treatment allowed us to highlight the most important criteria for the decision to treat. The comparison of surviving and non-surviving patients made it possible to unveil criteria associated with mortality that should be taken into account in the treatment decision.","Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Infection Control Unit, Avicenne Hospital, Bobigny, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Medical Intensive Care Unit, Faculty of Medicine, Paris-Descartes University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Fungal biology and Pathogenicity. Institut Pasteur, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Dynamyc EA 7380, Paris-Créteil University, Créteil, France.","NA",0,"1439-0507","Mycoses","Mycoses",2021,"2021","64","10.1111/myc.13341","980-988","","","34143533","34143533","PUBMED","Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Infection Control Unit, Avicenne Hospital, Bobigny, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Medical Intensive Care Unit, Faculty of Medicine, Paris-Descartes University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Fungal biology and Pathogenicity. Institut Pasteur, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Dynamyc EA 7380, Paris-Créteil University, Créteil, France."
"Ren Z;Ducreux M;Abou-Alfa GK;Merle P;Fang W;Edeline J;Li Z;Wu L;Assenat E;Hu S;Rimassa L;Zhang T;Blanc JF;Pan H;Ross P;Yen CJ;Tran A;Shao G;Bouattour M;Chen Y;Meyer T;Hou J;Tougeron D;Bai Y;Hou MM;Meng Z;Wu J;Li V;Chica-Duque S;Cheng AL","Ren, Zhenggang;Ducreux, Michel;Abou-Alfa, Ghassan K;Merle, Philippe;Fang, Weijia;Edeline, Julien;Li, Zhiwei;Wu, Lihua;Assenat, Eric;Hu, Sheng;Rimassa, Lorenza;Zhang, Tao;Blanc, Jean-Frédéric;Pan, Hongming;Ross, Paul;Yen, Chia-Jui;Tran, Albert;Shao, Guoliang;Bouattour, Mohamed;Chen, Yajin;Meyer, Tim;Hou, Jinlin;Tougeron, David;Bai, Yuxian;Hou, Ming-Mo;Meng, Zhiqiang;Wu, John;Li, Vincent;Chica-Duque, Sandra;Cheng, Ann-Lii","Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.","Liver cancer","Switzerland","eng","Journal Article","Hepatocellular carcinoma;Immunotherapy;Pretreated patient population;Tislelizumab","","","Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. The multiregional phase 2 study RATIONALE-208 examined single-agent tislelizumab (200 mg intravenously every 3 weeks) in patients with advanced HCC with Child-Pugh A, Barcelona Clinic Liver Cancer stage B or C, and who had received one or more prior lines of systemic therapy. The primary endpoint was objective response rate (ORR), radiologically confirmed per Response Evaluation Criteria in Solid Tumors version 1.1 by the Independent Review Committee. Safety was assessed in patients who received ≥1 dose of tislelizumab. Between April 9, 2018, and February 27, 2019, 249 eligible patients were enrolled and treated. After a median study follow-up of 12.7 months, ORR was 13% (  = 32/249; 95% confidence interval [CI], 9-18), including five complete and 27 partial responses. The number of prior lines of therapy did not impact ORR (one prior line, 13% [95% CI, 8-20]; two or more prior lines, 13% [95% CI, 7-20]). Median duration of response was not reached. The disease control rate was 53%, and median overall survival was 13.2 months. Of the 249 total patients, grade ≥3 treatment-related adverse events were reported in 38 (15%) patients; the most common was liver transaminase elevations in 10 (4%) patients. Treatment-related adverse events led to treatment discontinuation in 13 (5%) patients or dose delay in 46 (19%) patients. No deaths were attributed to the treatment per investigator assessment. Tislelizumab demonstrated durable objective responses, regardless of the number of prior lines of therapy, and acceptable tolerability in patients with previously treated advanced HCC.","Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.;Medical Oncology Department, Gustave Roussy, INSERM U1279, Paris-Saclay University, Villejuif, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College at Cornell University, New York, New York, USA.;Department of Hepatology, Hospital La Croix-Rousse, Lyon, France.;Department of Medical Oncology, The First Affiliated Hospital Zhejiang University, Hangzhou, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Department of Oncology, CHRU Saint Eloi, Montpellier, France.;Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China.;Medical Oncology and Hematology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.;Abdominal Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Service Hépato-Gastroentérologie et Oncologie Digestive, Groupe Hospitalier Sud - Hôpital Haut Lévêque, Bordeaux, France.;Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.;Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust and Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.;Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Département Digestif, Université Côte d'Azur, Nice, France, and Centre Hospitalier Universitaire de Nice, Nice, France, and Centre Méditerranéen de Médecine Moléculaire, INSERUM U1065, Université Côte d'Azur, Nice, France.;Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.;Department of Digestive Oncology, APHP Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.;Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.;Academic Department of Oncology, Royal Free Hospital NHS Trust, Pond Street, London, UK.;State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Gastroenterology and Hepatology Department, University of Poitiers and Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.;Department of Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.;Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.;Biostatistics, BeiGene USA, Inc., Ridgefield Park, New Jersey, USA.;Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.;Clinical Development, BeiGene USA, Inc., San Mateo, California, USA.;Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.","NA",0,"2235-1795","Liver Cancer","Liver Cancer",2022,"2023","12","10.1159/000527175","72-84","P30 CA008748","NCI NIH HHS","36872927","36872927","PUBMED","Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.;Medical Oncology Department, Gustave Roussy, INSERM U1279, Paris-Saclay University, Villejuif, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College at Cornell University, New York, New York, USA.;Department of Hepatology, Hospital La Croix-Rousse, Lyon, France.;Department of Medical Oncology, The First Affiliated Hospital Zhejiang University, Hangzhou, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Department of Oncology, CHRU Saint Eloi, Montpellier, France.;Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China.;Medical Oncology and Hematology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.;Abdominal Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Service Hépato-Gastroentérologie et Oncologie Digestive, Groupe Hospitalier Sud - Hôpital Haut Lévêque, Bordeaux, France.;Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.;Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust and Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.;Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Département Digestif, Université Côte d'Azur, Nice, France, and Centre Hospitalier Universitaire de Nice, Nice, France, and Centre Méditerranéen de Médecine Moléculaire, INSERUM U1065, Université Côte d'Azur, Nice, France.;Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.;Department of Digestive Oncology, APHP Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.;Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.;Academic Department of Oncology, Royal Free Hospital NHS Trust, Pond Street, London, UK.;State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Gastroenterology and Hepatology Department, University of Poitiers and Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.;Department of Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.;Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.;Biostatistics, BeiGene USA, Inc., Ridgefield Park, New Jersey, USA.;Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.;Clinical Development, BeiGene USA, Inc., San Mateo, California, USA.;Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan."
"Guilhem-Ducléon G;Dalban C;Negrier S;Gravis G;Laguerre B;Chevreau C;Oudard S;Barthelemy P;Ladoire S;Boughalem E;Borchiellini D;Linassier C;Nenan S;Flippot R;Albiges L;Goupil MG","Guilhem-Ducléon, Guillemette;Dalban, Cécile;Negrier, Sylvie;Gravis, Gwenaelle;Laguerre, Brigitte;Chevreau, Christine;Oudard, Stéphane;Barthelemy, Philippe;Ladoire, Sylvain;Boughalem, Elouen;Borchiellini, Delphine;Linassier, Claude;Nenan, Soazig;Flippot, Ronan;Albiges, Laurence;Goupil, Marine Gross","Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.","Clinical genitourinary cancer","United States","eng","Journal Article","Advanced Renal Cell Carcinoma;Immune Checkpoint Inhibitor;Response;Survival analyses;Tyrosine Kinase Inhibitor","Humans;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Duration of Therapy;Vascular Endothelial Growth Factor A;Protein Kinase Inhibitors;Receptors, Vascular Endothelial Growth Factor;Cytokines;Retrospective Studies","Humans;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Duration of Therapy;Vascular Endothelial Growth Factor A;Protein Kinase Inhibitors;Receptors, Vascular Endothelial Growth Factor;Cytokines;Retrospective Studies","In metastatic renal clear cell carcinoma (ccRCC), vascular endothelial growth factor receptor (VEGFR) and immune checkpoint are 2 main therapeutic targets. We investigated the impact of duration exposure to antiangiogenic on immunotherapy clinical outcomes in metastatic ccRCC. Patients from NIVOREN trial who received nivolumab after only 1 prior antiangiogenic therapy were included. Response rate, clinical benefit, progression free survival (PFS) and overall survival (OS) were prospectively analyzed depending on the duration of the first line (< 6 months, ≥6 months) and exploratory in patients with long first line exposure (≥18 months). The circulating levels of 8 plasma proteins and cytokines at baseline were collected and compared according to first line antiangiogenic duration. Among 354 patients, 127 (36%) and 227 (64%) patients had received first line antiangiogenic for < 6months and ≥ 6months respectively. Respective duration of first line therapy was not associated with objective response to nivolumab (20.5% vs. 23.9%, P = .50), or PFS (HR 0.92; P = .421). Median OS was respectively 16.6 and 31.3 months in the <6 and ≥6 months subgroups respectively. Adjusted on international metastatic renal cell carcinoma database consortium risk, age and metastatic site, OS was longer in patients with longer treatment duration in the first line setting (HR 0.73; P = .017). Duration of first line VEGFR TKI was independent from circulating levels of 8 proteins and cytokines at nivolumab baseline. Nivolumab activity in second line is independent from first-line duration of VEGFR TKI. However, first line VEGFR TKI duration ≥ 6 months is associated with longer OS.","Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.;Department of Clinical Research and Innovation, Centre de Lutte Contre Le Cancer, Centre Léon Bérard, Lyon, France.;University Lyon I, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, CHU Bretonneau et Université de Tours, Tours, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux","NA",0,"1938-0682","Clin Genitourin Cancer","Clin Genitourin Cancer",2023,"2023","21","10.1016/j.clgc.2023.07.008","643-652","","","37635052","37635052","PUBMED","Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.;Department of Clinical Research and Innovation, Centre de Lutte Contre Le Cancer, Centre Léon Bérard, Lyon, France.;University Lyon I, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, CHU Bretonneau et Université de Tours, Tours, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux"
"Poissonnet V;Chabrillac E;Uro-Coste E;Woisard V;Moya-Plana A;Espitalier F;Castelli J;Dedieu T;Salas S;Garrel R;Baudouin R;Poissonnet G;Castain C;Barbut J;Mirghani H;Evrard D;Bouchain O;Marie JP;Orliac H;Ceruse P;Dufour X;Brenet E;Rambeau A;Herman P;Abu Shama Y;Bertolus C;Atallah S;Morinière S;Righini C;Mouawad F;Duflo S;Segier B;Vergez S","Poissonnet, Valentine;Chabrillac, Emilien;Uro-Coste, Emmanuelle;Woisard, Virginie;Moya-Plana, Antoine;Espitalier, Florent;Castelli, Joel;Dedieu, Thibault;Salas, Sébastien;Garrel, Renaud;Baudouin, Robin;Poissonnet, Gilles;Castain, Claire;Barbut, Jonathan;Mirghani, Haitham;Evrard, Diane;Bouchain, Olivier;Marie, Jean Paul;Orliac, Hélène;Ceruse, Philippe;Dufour, Xavier;Brenet, Esteban;Rambeau, Audrey;Herman, Philippe;Abu Shama, Yazan;Bertolus, Chloé;Atallah, Sarah;Morinière, Sylvain;Righini, Christian;Mouawad, François;Duflo, Suzy;Segier, Bertille;Vergez, Sébastien","Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study.","Oral oncology","England","eng","Journal Article","Locally-advanced stage;Minor salivary gland;Salivary gland carcinoma;Tongue;Totalglossectomy","Humans;Male;Female;Middle Aged;Tongue Neoplasms;Aged;Retrospective Studies;Salivary Gland Neoplasms;Adult;Neoplasm Staging;Aged, 80 and over","Humans;Male;Female;Middle Aged;Tongue Neoplasms;Aged;Retrospective Studies;Salivary Gland Neoplasms;Adult;Neoplasm Staging;Aged, 80 and over","Salivary carcinomas of the tongue represent a therapeutic challenge as their radical excision is particularly mutilating. We aimed to study the oncologic and functional outcomes of advanced stages salivary carcinomas of the tongue. This retrospective multicentric study, based on the French national network on rare head and neck cancers (REFCOR), included all patients with a T3-T4 salivary carcinoma of the tongue, diagnosed between January 2009 and December 2018. In total, 47 patients were included, of which 44.7 % underwent surgery. Histologies were mostly adenoid cystic carcinomas (61.7 %), followed by other adenocarcinomas (27.7 %) and mucoepidermoid carcinomas (10.6 %). Median follow-up duration was 63.9 months. In multivariable analysis, surgery was significantly associated with better Recurrence-Free Survival (HR = 0.23, 95 %CI [0.09;0.55]) and Local/Regional Recurrence-Free Survival (HR = 0.31, 95 %CI [0.10;0.95]). The rate of distant metastasis at the end of follow-up was 61.9 % in the surgical group and 57.7 % in the non-surgical group. The Distant Metastasis Free Survival was 54.9 % [38.3;68.7], without statistical difference between both groups. There were similar rates of definitive gastrostomies but the rate of normal oral diet at the last follow-up seemed higher in the surgery group (38.1 % vs 15.4 %). Radical surgery in that population mainly aims to improve local/regional control, which may result in better long-term swallowing functions. About half of these tumors may be associated with occult distant metastasis at initial presentation. More studies are warranted to establish the role of postoperative RT and non-surgical treatment with concurrent CRT.","Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Department of Anatomical Pathology, University Cancer Institute Toulouse, Toulouse France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Head and Neck Oncology Department, Gustave-Roussy Institute, Villejuif, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nantes, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Strasbourg, France.;AP-HM, Aix-Marseille University, Department of Medical Oncology, Marseille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Montpellier, France.;Otolaryngology, Head and Neck Surgery Department, Foch Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Head and Neck University Institute, Nice, France.;Department of Anatomical Pathology, Bordeaux University Hospital-CHU, F-33000, Bordeaux, France.;Otolaryngology, Head and Neck Surgery Department, Hospital of Toulon, France.;Otolaryngology, Head and Neck Surgery Department, George Pompidou European Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Bichat Hospital, Paris, France.;Head and Neck Surgery Department, CHU Sart Tilman, University Liege, Belgium.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Rouen, France.;Department of Radiation Therapy, University Hospital of Limoges, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lyon, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Poitiers, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Reims, France.;Oncology Department, François Baclesse Centre, Caen, France.;Otolaryngology, Head and Neck Surgery Department, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France.;Department of Oral and Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, France.;Head and Neck Surgery Department, Tenon Hospital, APHP, Sorbonne University, Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Tours, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Grenoble, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Point-à-Pitre, France.;Statistical Department, Institut Claudius Regaud, University Institute of Cancer, Toulouse, France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.","NA",0,"1879-0593","Oral Oncol","Oral Oncol",2024,"2024","159","10.1016/j.oraloncology.2024.107072","107072","","","39432991","39432991","PUBMED","Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Department of Anatomical Pathology, University Cancer Institute Toulouse, Toulouse France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Head and Neck Oncology Department, Gustave-Roussy Institute, Villejuif, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nantes, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Strasbourg, France.;AP-HM, Aix-Marseille University, Department of Medical Oncology, Marseille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Montpellier, France.;Otolaryngology, Head and Neck Surgery Department, Foch Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Head and Neck University Institute, Nice, France.;Department of Anatomical Pathology, Bordeaux University Hospital-CHU, F-33000, Bordeaux, France.;Otolaryngology, Head and Neck Surgery Department, Hospital of Toulon, France.;Otolaryngology, Head and Neck Surgery Department, George Pompidou European Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Bichat Hospital, Paris, France.;Head and Neck Surgery Department, CHU Sart Tilman, University Liege, Belgium.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Rouen, France.;Department of Radiation Therapy, University Hospital of Limoges, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lyon, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Poitiers, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Reims, France.;Oncology Department, François Baclesse Centre, Caen, France.;Otolaryngology, Head and Neck Surgery Department, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France.;Department of Oral and Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, France.;Head and Neck Surgery Department, Tenon Hospital, APHP, Sorbonne University, Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Tours, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Grenoble, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Point-à-Pitre, France.;Statistical Department, Institut Claudius Regaud, University Institute of Cancer, Toulouse, France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France."
"Van der Voort V;Legros R;Albouys J;Lepetit H;Wallenhorst T;Pioche M;Jacques J","Van der Voort, Véronique;Legros, Romain;Albouys, Jérémie;Lepetit, Hugo;Wallenhorst, Timothée;Pioche, Mathieu;Jacques, Jérémie","Multi-strategy endoscopic submucosal dissection of a challenging lesion.","Endoscopy","Germany","eng","Journal Article","","","","NA","Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Rennes, Site de Pontchaillou, Rennes, France.;Department of Gastroenterology and Hepatology, Hôpital Edouard Herriot, Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.","NA",0,"1438-8812","Endoscopy","Endoscopy",2025,"2025","57","10.1055/a-2517-1878","E114-E115","","","39914475","39914475","PUBMED","Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Rennes, Site de Pontchaillou, Rennes, France.;Department of Gastroenterology and Hepatology, Hôpital Edouard Herriot, Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France."
"Favier M;Brischoux-Boucher E;Pyle LC;Mottet N;Auber-Lenoir M;Cattin J;Dahlen E;Cabrol C;Arbez-Gindre F;Attié-Bitach T;Boute O;Devisme L;Trost D;Boughalem A;Chitayat D;Prasov L;Chorin O;Rein-Rothschild A;Kassif E;Weissbach T;Hendon LG;Adam MP;Quelin C;Jaillard S;Mary L;Aukema SM;Heijligers M;de Die-Smulders C;Stegmann S;Badalato L;Ben-Yehuda A;Beneteau C;Forey PL;Kuentz P;Piard J","Favier, Maud;Brischoux-Boucher, Elise;Pyle, Louise C;Mottet, Nicolas;Auber-Lenoir, Marion;Cattin, Julie;Dahlen, Eric;Cabrol, Christelle;Arbez-Gindre, Francine;Attié-Bitach, Tania;Boute, Odile;Devisme, Louise;Trost, Detlef;Boughalem, Aicha;Chitayat, David;Prasov, Lev;Chorin, Odelia;Rein-Rothschild, Annick;Kassif, Eran;Weissbach, Tal;Hendon, Laura Godfrey;Adam, Margaret P;Quelin, Chloé;Jaillard, Sylvie;Mary, Laura;Aukema, Sietse M;Heijligers, Malou;de Die-Smulders, Christine;Stegmann, Sander;Badalato, Lauren;Ben-Yehuda, Adi;Beneteau, Claire;Forey, Pierre-Louis;Kuentz, Paul;Piard, Juliette","Fetal Presentation of MYRF-Related Cardiac Urogenital Syndrome: An Emerging and Challenging Prenatal Diagnosis.","Prenatal diagnosis","England","eng","Journal Article","","Humans;Female;Pregnancy;Heart Defects, Congenital;Urogenital Abnormalities;Male;Ultrasonography, Prenatal;Adult;Prenatal Diagnosis;Infant, Newborn","Humans;Female;Pregnancy;Heart Defects, Congenital;Urogenital Abnormalities;Male;Ultrasonography, Prenatal;Adult;Prenatal Diagnosis;Infant, Newborn","MYRF-related cardiac-urogenital syndrome (MYRF-CUGS) is a rare condition associated with heterozygous MYRF variants. The description of MYRF-CUGS phenotype is mostly based on postnatal cases and 36 affected individuals have been published so far. We aim now to delineate the prenatal phenotype of MYRF-CUGS by reporting clinical data from fetuses and neonates with a pathogenic MYRF variant. Detailed radiographic, pathological, clinical, and molecular data from 12 prenatal cases were collected through an international collaborative study. Adding the five fetuses previously published, we were able to study a cohort of 17 cases. Main ultrasound-accessible manifestations of MYRF-CUGS include congenital heart defects (13/17, 76%), congenital diaphragmatic hernia (10/17, 59%) and disorders of sexual differentiation in 46, XY fetuses (7/14; 50%). Postnatal examination and/or autopsy data highlighted additional birth defects and neurological findings with a large spectrum of severity. Molecular results revealed ten previously unpublished variants, one missense and nine predicted truncating variants (three frameshift, three nonsense and three splice site variants). We report the first prenatal cohort of MYRF-CUGS, allowing us to further characterize the variable expressivity of this rare disorder in fetuses. Severe congenital anomalies with a poor prognosis are more frequent than previously described in postnatal cases. Our data suggest that MYRF-CUGS is characterized by a recurrent recognizable malformative association, accessible to prenatal diagnosis, with a significant intrafamilial phenotypic variability making genetic counseling challenging.","Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département de Radiologie, Imagerie pédiatrique, prénatale et sénologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Anatomie et cytologie pathologiques, Foetopathologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Laboratoire de biologie médicale multisites SeqOIA, Assistance Publique Hôpitaux de Paris, Paris, France.;Institut Imagine, INSERM U1163, Université Paris Descartes, Paris, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Mount Sinai Hospital, University of Toronto, Toronto, Canada.;Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.;Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;Mississippi Medical Center, Jackson, Mississippi, USA.;Division of Genetic Medicine, Seattle Children's Hospital, Seattle, Washington, USA.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Medical Genetics, Carl von Ossietzky University, Oldenburg, Germany.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Pediatrics, Kingstone General Hospital, Queen's University, Kingston, Canada.;Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Grenoble, Université de Grenoble, Grenoble, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.","NA",0,"1097-0223","Prenat Diagn","Prenat Diagn",2024,"2024","44","10.1002/pd.6700","1647-1658","K08 EY032098","NEI NIH HHS","39542847","39542847","PUBMED","Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département de Radiologie, Imagerie pédiatrique, prénatale et sénologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Anatomie et cytologie pathologiques, Foetopathologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Laboratoire de biologie médicale multisites SeqOIA, Assistance Publique Hôpitaux de Paris, Paris, France.;Institut Imagine, INSERM U1163, Université Paris Descartes, Paris, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Mount Sinai Hospital, University of Toronto, Toronto, Canada.;Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.;Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;Mississippi Medical Center, Jackson, Mississippi, USA.;Division of Genetic Medicine, Seattle Children's Hospital, Seattle, Washington, USA.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Medical Genetics, Carl von Ossietzky University, Oldenburg, Germany.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Pediatrics, Kingstone General Hospital, Queen's University, Kingston, Canada.;Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Grenoble, Université de Grenoble, Grenoble, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France."
"Kristensen DM;Desdoits-Lethimonier C;Mackey AL;Dalgaard MD;De Masi F;Munkbøl CH;Styrishave B;Antignac JP;Le Bizec B;Platel C;Hay-Schmidt A;Jensen TK;Lesné L;Mazaud-Guittot S;Kristiansen K;Brunak S;Kjaer M;Juul A;Jégou B","Kristensen, David Møbjerg;Desdoits-Lethimonier, Christèle;Mackey, Abigail L;Dalgaard, Marlene Danner;De Masi, Federico;Munkbøl, Cecilie Hurup;Styrishave, Bjarne;Antignac, Jean-Philippe;Le Bizec, Bruno;Platel, Christian;Hay-Schmidt, Anders;Jensen, Tina Kold;Lesné, Laurianne;Mazaud-Guittot, Séverine;Kristiansen, Karsten;Brunak, Søren;Kjaer, Michael;Juul, Anders;Jégou, Bernard","Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism.","Proceedings of the National Academy of Sciences of the United States of America","United States","eng","Journal Article","endocrine disruption;endocrinology;hypogonadism;ibuprofen;reproduction","Adult;Analgesics, Non-Narcotic;Cell Line;Gene Expression;Humans;Hypogonadism;Ibuprofen;In Vitro Techniques;Leydig Cells;Luteinizing Hormone;Male;Middle Aged;Prostaglandins;Sertoli Cells;Testosterone","Adult;Analgesics, Non-Narcotic;Cell Line;Gene Expression;Humans;Hypogonadism;Ibuprofen;In Vitro Techniques;Leydig Cells;Luteinizing Hormone;Male;Middle Aged;Prostaglandins;Sertoli Cells;Testosterone","Concern has been raised over increased male reproductive disorders in the Western world, and the disruption of male endocrinology has been suggested to play a central role. Several studies have shown that mild analgesics exposure during fetal life is associated with antiandrogenic effects and congenital malformations, but the effects on the adult man remain largely unknown. Through a clinical trial with young men exposed to ibuprofen, we show that the analgesic resulted in the clinical condition named ""compensated hypogonadism,"" a condition prevalent among elderly men and associated with reproductive and physical disorders. In the men, luteinizing hormone (LH) and ibuprofen plasma levels were positively correlated, and the testosterone/LH ratio decreased. Using adult testis explants exposed or not exposed to ibuprofen, we demonstrate that the endocrine capabilities from testicular Leydig and Sertoli cells, including testosterone production, were suppressed through transcriptional repression. This effect was also observed in a human steroidogenic cell line. Our data demonstrate that ibuprofen alters the endocrine system via selective transcriptional repression in the human testes, thereby inducing compensated hypogonadism.","Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Biology, Faculty of Science, University of Copenhagen, 2100 Copenhagen, Denmark.;Institute of Metagenomics, BGI-Shenzhen, Shenzhen 518083, China.;Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark;EDMaRC (International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health), Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.","NA",0,"1091-6490","Proc Natl Acad Sci U S A","Proc Natl Acad Sci U S A",2018,"2018","115","10.1073/pnas.1715035115","E715-E724","","","29311296","29311296","PUBMED","Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Biology, Faculty of Science, University of Copenhagen, 2100 Copenhagen, Denmark.;Institute of Metagenomics, BGI-Shenzhen, Shenzhen 518083, China.;Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark;EDMaRC (International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health), Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France."
"Boissière C;Bacle A;Pelletier R;Le Bouedec D;Gicquel T;Lurton Y;Le Daré B","Boissière, Camille;Bacle, Astrid;Pelletier, Romain;Le Bouedec, Diane;Gicquel, Thomas;Lurton, Yves;Le Daré, Brendan","In vitro assessment of isopropanol leakage from antiseptic barrier caps into commonly used needleless connectors.","Infection control and hospital epidemiology","United States","eng","Journal Article","","Infant, Newborn;Humans;Child;2-Propanol;Catheters, Indwelling;Equipment Contamination;Anti-Infective Agents, Local","Infant, Newborn;Humans;Child;2-Propanol;Catheters, Indwelling;Equipment Contamination;Anti-Infective Agents, Local","Needleless connectors (NCs) can be disinfected using antiseptic barrier caps (ABCs) to reduce the risk of catheter-related bloodstream infections. However, recent evidence suggests that isopropanol can leak from the ABC into the NC, posing concern about their safe use. We sought to determine in vitro which ABC and NC parameters influence the leakage of isopropanol through the infusion circuit. We assessed 13 NCs and 4 ABCs available in the European market. In vitro circuits consisting of an isopropanol cap, a NC, and an 11-cm catheter line were created. The circuits were left in place for 1 to 7 days at room temperature to assess the kinetics of isopropanol leakage. Isopropanol content in ABC and in circuit flushing solutions (5 mL NaCl 0.9%) after exposure to the cap were measured using gas chromatography with a flame ionization detector. The leakage of isopropanol from the cap to the NC was dependent on the NC, but not the cap. The NC mechanism did not predict the leakage of isopropanol. The Q-Syte NC exhibited the most isopropanol leakage (7.01±1.03 mg and 28.32±2.62 mg at 24 hours and 7 days, respectively), whereas the Caresite NC had the lowest isopropanol leakage at 7 days (1.69±0.01 mg). The use of isopropanol ABCs can cause isopropanol leakage into the catheter circuit according to NC parameters. Caution should be exercised when using these devices, especially in the pediatric and neonatal population.","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail), Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.","NA",0,"1559-6834","Infect Control Hosp Epidemiol","Infect Control Hosp Epidemiol",2024,"2024","45","10.1017/ice.2023.285","576-582","","","38213184","38213184","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail), Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France."
"Gendronneau M;Kérourédan O;Taque S;Sixou JL;Bonnaure-Mallet M","Gendronneau, M;Kérourédan, O;Taque, S;Sixou, J L;Bonnaure-Mallet, M","Dental abnormalities and preventive oral care in Schimke immuno-osseous dysplasia.","European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry","England","eng","Case Reports","","Anodontia;Arteriosclerosis;Cariostatic Agents;Child;Child, Preschool;Dental Pulp;Fatal Outcome;Fluorides;Follow-Up Studies;Humans;Immunologic Deficiency Syndromes;Male;Nephrotic Syndrome;Oral Health;Osteochondrodysplasias;Pit and Fissure Sealants;Primary Immunodeficiency Diseases;Pulmonary Embolism;Tooth Abnormalities;Tooth Crown;Tooth Discoloration;Tooth Diseases;Tooth Root;Toothbrushing","Anodontia;Arteriosclerosis;Cariostatic Agents;Child;Child, Preschool;Dental Pulp;Fatal Outcome;Fluorides;Follow-Up Studies;Humans;Immunologic Deficiency Syndromes;Male;Nephrotic Syndrome;Oral Health;Osteochondrodysplasias;Pit and Fissure Sealants;Primary Immunodeficiency Diseases;Pulmonary Embolism;Tooth Abnormalities;Tooth Crown;Tooth Discoloration;Tooth Diseases;Tooth Root;Toothbrushing","Schimke immuno-osseous dysplasia (SIOD) is a rare, severe, autosomal recessive disorder that results in spondyloepiphyseal dysplasia, renal dysfunction, immunodeficiency, facial dysmorphism and growth failure. Little is known about oral features associated with SIOD. Some of the dental anomalies encountered are specific to SIOD and have only been reported in individuals with SIOD. This paper describes the clinical and radiographic dental manifestations of SIOD in two Caucasian brothers. Both lived to be about 10 years old. After a variety of symptoms were reported, a diagnosis of SIOD was finally made when the brothers were, respectively, 5 and 8 years old. At that time, dental anomalies, such as dyschromia, bulbous crowns, short and thin roots, had not been taken into account to establish the diagnosis. However, knowledge of the dental features characteristic of this disease could have helped make the diagnosis. Although both were caries- and periodontal disease-free, special attention was focused on prevention, including dietary counselling, plaque control, oral hygiene instructions and the use of fluoridated toothpaste. The two patients were followed every 6 months, for over 2 years (until their death), by both a private dentist and a university hospital dentist, which helped them maintain good oral health. Oral hygiene was assessed at each appointment and fissure sealants were placed by the private practitioner on their first permanent molars. This report describes dental anomalies specific to SIOD that could facilitate diagnosis. Clinicians and dentists should work in collaboration to diagnose and treat children with SIOD. These patients require regular and specific dental management because of their fragile health and their characteristic dental anomalies. Ideally, preventive visits should be scheduled every 6 months in addition to curative visits as needed.","Université Européenne de Bretagne, Université de Rennes 1 and Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"1996-9805","Eur Arch Paediatr Dent","Eur Arch Paediatr Dent",2013,"2014","15","10.1007/s40368-013-0099-3","217-21","","","24327104","24327104","PUBMED","Université Européenne de Bretagne, Université de Rennes 1 and Centre Hospitalier Universitaire de Rennes, Rennes, France."
"Obacz J;Archambeau J;Lafont E;Nivet M;Martin S;Aubry M;Voutetakis K;Pineau R;Boniface R;Sicari D;Pelizzari-Raymundo D;Ghukasyan G;McGrath E;Vlachavas EI;Le Gallo M;Le Reste PJ;Barroso K;Fainsod-Levi T;Obiedat A;Granot Z;Tirosh B;Samal J;Pandit A;Négroni L;Soriano N;Monnier A;Mosser J;Chatziioannou A;Quillien V;Chevet E;Avril T","Obacz, Joanna;Archambeau, Jérôme;Lafont, Elodie;Nivet, Manon;Martin, Sophie;Aubry, Marc;Voutetakis, Konstantinos;Pineau, Raphael;Boniface, Rachel;Sicari, Daria;Pelizzari-Raymundo, Diana;Ghukasyan, Gevorg;McGrath, Eoghan;Vlachavas, Efstathios-Iason;Le Gallo, Matthieu;Le Reste, Pierre Jean;Barroso, Kim;Fainsod-Levi, Tanya;Obiedat, Akram;Granot, Zvi;Tirosh, Boaz;Samal, Juhi;Pandit, Abhay;Négroni, Luc;Soriano, Nicolas;Monnier, Annabelle;Mosser, Jean;Chatziioannou, Aristotelis;Quillien, Véronique;Chevet, Eric;Avril, Tony","IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.","Neuro-oncology","England","eng","Journal Article","ER stress;IRE1;chemokines;glioblastoma;inflammation","Glioblastoma;Humans;Mice;Endoribonucleases;Animals;Protein Serine-Threonine Kinases;Signal Transduction;Brain Neoplasms;Myeloid Cells;Unfolded Protein Response;Tumor Microenvironment;Tumor Cells, Cultured;Endoplasmic Reticulum Stress","Glioblastoma;Humans;Mice;Endoribonucleases;Animals;Protein Serine-Threonine Kinases;Signal Transduction;Brain Neoplasms;Myeloid Cells;Unfolded Protein Response;Tumor Microenvironment;Tumor Cells, Cultured;Endoplasmic Reticulum Stress","Intrinsic or environmental stresses trigger the accumulation of improperly folded proteins in the endoplasmic reticulum (ER), leading to ER stress. To cope with this, cells have evolved an adaptive mechanism named the unfolded protein response (UPR) which is hijacked by tumor cells to develop malignant features. Glioblastoma (GB), the most aggressive and lethal primary brain tumor, relies on UPR to sustain growth. We recently showed that IRE1 alpha (referred to IRE1 hereafter), 1 of the UPR transducers, promotes GB invasion, angiogenesis, and infiltration by macrophage. Hence, high tumor IRE1 activity in tumor cells predicts a worse outcome. Herein, we characterized the IRE1-dependent signaling that shapes the immune microenvironment toward monocytes/macrophages and neutrophils. We used human and mouse cellular models in which IRE1 was genetically or pharmacologically invalidated and which were tested in vivo. Publicly available datasets from GB patients were also analyzed to confirm our findings. We showed that IRE1 signaling, through both the transcription factor XBP1s and the regulated IRE1-dependent decay controls the expression of the ubiquitin-conjugating E2 enzyme UBE2D3. In turn, UBE2D3 activates the NFκB pathway, resulting in chemokine production and myeloid infiltration in tumors. Our work identifies a novel IRE1/UBE2D3 proinflammatory axis that plays an instrumental role in GB immune regulation.","INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Department of Biochemistry and Biotechnology, Larissa, Greece.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Biosit H2P2, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Hospital of St Malo, France.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;CÚRAM, Ireland.;CÚRAM, Ireland.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;INSERM U1242, Rennes, France.;CNRS UMR6290, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.","NA",0,"1523-5866","Neuro Oncol","Neuro Oncol",2023,"2024","26","10.1093/neuonc/noad256","858-871","EU H2020 MSCA ITN-675448;MSCA RISE-734749","la Ligue Contre le Cancer;INSERM;INCR;INSERM;Institut National du Cancer;Région Bretagne;Rennes Métropole;Fondation pour la recherche Médicale;la Ligue Contre le Cancer Comités d'Ille-et-Vilaine;des Côtes d'Armor et du Morbihan;European Regional Development Fund","38153426","38153426","PUBMED","INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Department of Biochemistry and Biotechnology, Larissa, Greece.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Biosit H2P2, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Hospital of St Malo, France.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;CÚRAM, Ireland.;CÚRAM, Ireland.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;INSERM U1242, Rennes, France.;CNRS UMR6290, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France."
"Bizot A;Karimi M;Rassy E;Heudel PE;Levy C;Vanlemmens L;Uzan C;Deluche E;Genet D;Saghatchian M;Giacchetti S;Grenier J;Patsouris A;Dieras V;Pierga JY;Petit T;Ladoire S;Jacot W;Benderra MA;De Jesus A;Delaloge S;Lambertini M;Pistilli B","Bizot, Alexandra;Karimi, Maryam;Rassy, Elie;Heudel, Pierre Etienne;Levy, Christelle;Vanlemmens, Laurence;Uzan, Catherine;Deluche, Elise;Genet, Dominique;Saghatchian, Mahasti;Giacchetti, Sylvie;Grenier, Juline;Patsouris, Anne;Dieras, Véronique;Pierga, Jean-Yves;Petit, Thierry;Ladoire, Sylvain;Jacot, William;Benderra, Marc-Antoine;De Jesus, Anne;Delaloge, Suzette;Lambertini, Matteo;Pistilli, Barbara","Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.","British journal of cancer","England","eng","Journal Article","","Adult;Aged;Breast Neoplasms;COVID-19;Female;France;Humans;Italy;Medical Oncology;Middle Aged;Pandemics;Patient Satisfaction;Remote Consultation;Surveys and Questionnaires;Telemedicine","Adult;Aged;Breast Neoplasms;COVID-19;Female;France;Humans;Italy;Medical Oncology;Middle Aged;Pandemics;Patient Satisfaction;Remote Consultation;Surveys and Questionnaires;Telemedicine","During the COVID-19 pandemic, teleconsultation was implemented in clinical practice to limit patient exposure to COVID-19 while monitoring their treatment and follow-up. We sought to examine the satisfaction of patients with breast cancer (BC) who underwent teleconsultations during this period. Eighteen centres in France and Italy invited patients with BC who had at least one teleconsultation during the first wave of the COVID-19 pandemic to participate in a web-based survey that evaluated their satisfaction (EORTC OUT-PATSAT 35 and Telemedicine Satisfaction Questionnaire [TSQ] scores) with teleconsultation. Among the 1299 participants eligible for this analysis, 53% of participants were undergoing standard post-treatment follow-up while 22 and 17% were currently receiving active anticancer therapy for metastatic and localised cancers, respectively. The mean satisfaction scores were 77.4 and 73.3 for the EORTC OUT-PATSAT 35 and TSQ scores, respectively. In all, 52.6% of participants had low/no anxiety. Multivariable analysis showed that the EORTC OUT-PATSAT 35 score correlated to age, anxiety score and teleconsultation modality. The TSQ score correlated to disease status and anxiety score. Patients with BC were satisfied with oncology teleconsultations during the COVID-19 pandemic. Teleconsultation may be an acceptable alternative follow-up modality in specific circumstances.","Medical Oncology Department, Gustave Roussy, Villejui, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Institut Normand du Sein, Centre Francois Baclesse, Caen, France.;Centre Oscar Lambret, Lille, France.;Breast and Gynecologic Surgery, Assistance Publique - Hopitaux De Paris, Paris, France.;Medical Oncology Department, CHU Limoges - Hopital Dupuytren, Limoges, France.;Medical Oncology Department, Clinique Chenieux, Limoges, France.;Breast Cancer Unit, American Hospital of Paris, Neuilly-Sur-Seine, France.;Breast Cancer Unit, AP university Hospital St Louis, Paris, France.;Medical Oncology Department, Institut Ste Catherine, Avignon, France.;Medical Oncology Department, ICO - Institut de Cancérologie de l'Ouest Nantes-Angers, Angers, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Medical Oncology Department, Institut Curie & St Cloud, Université de Paris, Paris, France.;Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology Department, Centre Georges-François Leclerc (Dijon), Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM, U1194, Montpellier, France.;Medical Oncology Department, Hopital Tenon, Paris, France.;Patient Relationship Coordination, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.;Medical Oncology Department, Gustave Roussy, Villejui","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2021,"2021","125","10.1038/s41416-021-01555-y","1486-1493","","","34588616","34588616","PUBMED","Medical Oncology Department, Gustave Roussy, Villejui, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Institut Normand du Sein, Centre Francois Baclesse, Caen, France.;Centre Oscar Lambret, Lille, France.;Breast and Gynecologic Surgery, Assistance Publique - Hopitaux De Paris, Paris, France.;Medical Oncology Department, CHU Limoges - Hopital Dupuytren, Limoges, France.;Medical Oncology Department, Clinique Chenieux, Limoges, France.;Breast Cancer Unit, American Hospital of Paris, Neuilly-Sur-Seine, France.;Breast Cancer Unit, AP university Hospital St Louis, Paris, France.;Medical Oncology Department, Institut Ste Catherine, Avignon, France.;Medical Oncology Department, ICO - Institut de Cancérologie de l'Ouest Nantes-Angers, Angers, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Medical Oncology Department, Institut Curie & St Cloud, Université de Paris, Paris, France.;Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology Department, Centre Georges-François Leclerc (Dijon), Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM, U1194, Montpellier, France.;Medical Oncology Department, Hopital Tenon, Paris, France.;Patient Relationship Coordination, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.;Medical Oncology Department, Gustave Roussy, Villejui"
"Rogers JH;Asch F;Sorajja P;Mahoney P;Price MJ;Maisano F;Denti P;Morse MA;Rinaldi M;Bedogni F;De Marco F;Rollefson W;Chehab B;Williams MR;Leurent G;Morikawa T;Asgar AW;Rodriguez E;von Bardeleben RS;Kar S","Rogers, Jason H;Asch, Federico;Sorajja, Paul;Mahoney, Paul;Price, Matthew J;Maisano, Francesco;Denti, Paolo;Morse, Michael A;Rinaldi, Michael;Bedogni, Francesco;De Marco, Federico;Rollefson, William;Chehab, Bassem;Williams, Mathew R;Leurent, Guillaume;Morikawa, Takao;Asgar, Anita W;Rodriguez, Evelio;von Bardeleben, Ralph Stephan;Kar, Saibal","Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study.","JACC. Cardiovascular interventions","United States","eng","Multicenter Study","MitraClip system;TEER;mitral regurgitation;mitral valve repair;transcatheter edge-to-edge repair","Humans;Prospective Studies;Quality of Life;Reactive Oxygen Species;Treatment Outcome;Constriction, Pathologic;Mitral Valve Insufficiency;Cardiomyopathies","Humans;Prospective Studies;Quality of Life;Reactive Oxygen Species;Treatment Outcome;Constriction, Pathologic;Mitral Valve Insufficiency;Cardiomyopathies","Anatomical and clinical criteria to define mitral transcatheter edge-to-edge repair (TEER) ""unsuitability"" have been proposed on the basis of a Heart Valve Collaboratory consensus opinion from physician experience with early-generation TEER devices but lacked an evidence-based approach. The aim of this study was to explore the spectrum of TEER suitability using echocardiographic and clinical outcomes from the EXPAND G4 real-world postapproval study. EXPAND G4 is a global, prospective, multicenter, single-arm study that enrolled 1,164 subjects with mitral regurgitation (MR) treated with the MitraClip G4 System. Three groups were defined using the Heart Valve Collaboratory TEER unsuitability criteria: 1) risk of stenosis (RoS); 2) risk of inadequate MR reduction (RoIR); and 3) subjects with baseline moderate or less MR (MMR). A TEER-suitable (TS) group was defined by the absence of these characteristics. Endpoints included independent core laboratory-assessed echocardiographic characteristics, procedural outcomes, MR reduction, NYHA functional class, Kansas City Cardiomyopathy Questionnaire score, and major adverse events through 30 days. Subjects in the RoS (n = 56), RoIR (n = 54), MMR (n = 326), and TS (n = 303) groups had high 30-day MR reduction rates (≤1+: RoS 97%, MMR 93%, and TS 91%; ≤2+: RoIR 94%). Thirty-day improvements in functional capacity (NYHA functional class I or II at 30 days vs baseline: RoS 94% vs 29%, RoIR 88% vs 30%, MMR 79% vs 26%, and TS 83% vs 33%) and quality of life (change in Kansas City Cardiomyopathy Questionnaire score: RoS +27 ± 26, RoIR +16 ± 26, MMR +19 ± 26, and TS +19 ± 24) were safely achieved in all groups, with low major adverse events (<3%) and all-cause mortality (RoS 1.8%, RoIR 0%, MMR 1.5%, and TS 1.3%). Patients previously deemed TEER unsuitable can be safely and effectively treated with the mitral TEER fourth-generation device.","University of California Davis Medical Center, Sacramento, California;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Sentara Heart and Valve and Structural Disease Center, Norfolk, Virginia, USA.;Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;Carolinas Medical Center, Charlotte, North Carolina, USA.;IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi Hospital, University of Kansas, Wichita, Kansas, USA.;NYU Langone Medical Center, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;The Sakakibara Heart Institute of Okayama, Okayama, Japan.;Institut de Cardiologie de Montréal, Montreal, Quebec, Canada.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;University Medical Center of Mainz, Mainz, Germany.;Los Robles Regional Medical Center, Thousand Oaks, California, USA.","NA",0,"1876-7605","JACC Cardiovasc Interv","JACC Cardiovasc Interv",2023,"2023","16","10.1016/j.jcin.2023.05.014","1474-1485","","","37380229","37380229","PUBMED","University of California Davis Medical Center, Sacramento, California;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Sentara Heart and Valve and Structural Disease Center, Norfolk, Virginia, USA.;Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;Carolinas Medical Center, Charlotte, North Carolina, USA.;IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi Hospital, University of Kansas, Wichita, Kansas, USA.;NYU Langone Medical Center, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;The Sakakibara Heart Institute of Okayama, Okayama, Japan.;Institut de Cardiologie de Montréal, Montreal, Quebec, Canada.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;University Medical Center of Mainz, Mainz, Germany.;Los Robles Regional Medical Center, Thousand Oaks, California, USA."
"Carril-Ajuria L;Lavaud P;Dalban C;Negrier S;Gravis G;Motzer RJ;Chevreau C;Tannir NM;Oudard S;McDermott DF;Laguerre B;Hammers HJ;Barthelemy P;Plimack ER;Borchiellini D;Gross-Goupil M;Jiang R;Lee CW;de Silva H;Rini BI;Escudier B;Albigès L","Carril-Ajuria, Lucia;Lavaud, Pernelle;Dalban, Cecile;Negrier, Sylvie;Gravis, Gwénaëlle;Motzer, Robert J;Chevreau, Christine;Tannir, Nizar M;Oudard, Stéphane;McDermott, David F;Laguerre, Brigitte;Hammers, Hans J;Barthelemy, Philippe;Plimack, Elizabeth R;Borchiellini, Delphine;Gross-Goupil, Marine;Jiang, Ruiyun;Lee, Chung-Wei;de Silva, Heshani;Rini, Brian I;Escudier, Bernard;Albigès, Laurence","Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Antiangiogenics;Biomarkers;LIPI;Prognosis;Renal cell carcinoma;immune checkpoint inhibitors","Humans;Carcinoma, Renal Cell;Kidney Neoplasms;Male;Female;Middle Aged;Aged;Prognosis;Lung Neoplasms;Prospective Studies;Biomarkers, Tumor;Sunitinib;Immune Checkpoint Inhibitors;Nivolumab;Progression-Free Survival;Adult","Humans;Carcinoma, Renal Cell;Kidney Neoplasms;Male;Female;Middle Aged;Aged;Prognosis;Lung Neoplasms;Prospective Studies;Biomarkers, Tumor;Sunitinib;Immune Checkpoint Inhibitors;Nivolumab;Progression-Free Survival;Adult","The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS). In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis. Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.","Gustave Roussy, Villejuif;Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Leon Bernard, Lyon, France.;Université de Lyon, Centre Leon Bernard, Lyon, France.;Institut Paoli-Calmettes, Aix-Marseille, France.;Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Européen Georges Pompidou, Oncology department, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.;Dana-Farber/Harvard Cancer Center, Boston, MA, USA.;Centre Eugene Marquis, Rennes, France.;UT Southwestern Kidney Cancer Program, Dallas, TX, USA.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Fox Chase Cancer Center, Philadelphia, PA, USA.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Vanderbilt-Ingram Cancer Center, Nashville, USA.;Gustave Roussy, Villejuif, France.;Gustave Roussy, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2024,"2024","204","10.1016/j.ejca.2024.114048","114048","","","38653033","38653033","PUBMED","Gustave Roussy, Villejuif;Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Leon Bernard, Lyon, France.;Université de Lyon, Centre Leon Bernard, Lyon, France.;Institut Paoli-Calmettes, Aix-Marseille, France.;Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Européen Georges Pompidou, Oncology department, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.;Dana-Farber/Harvard Cancer Center, Boston, MA, USA.;Centre Eugene Marquis, Rennes, France.;UT Southwestern Kidney Cancer Program, Dallas, TX, USA.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Fox Chase Cancer Center, Philadelphia, PA, USA.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Vanderbilt-Ingram Cancer Center, Nashville, USA.;Gustave Roussy, Villejuif, France.;Gustave Roussy, Villejuif"
"Pujol P;De La Motte Rouge T;Penault-Llorca F","Pujol, Pascal;De La Motte Rouge, Thibault;Penault-Llorca, Frédérique","From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","cancer predisposing genes;secondary findings;somatic analysis","","","The expanding use of tumor genome analysis by next generation sequencing to drive target therapies has led to increased germline findings in genes predisposing to hereditary cancer. These putative germline findings obtained from theranostic analyses, such as   gene testing, large panels, whole-exome, or whole-genome sequencing, need to be managed carefully and in an anticipated way with the patient. Before the genetic analysis of a tumor, specific information should be given to patients, who should be aware that the results may have extra-therapeutic medical issues for themselves and relatives. We previously published a list of 36 actionable genes predisposing to cancer for which informing the patient is recommended prior to pangenomic germline analysis because of available screening or preventive strategies. Here, we report clinical practice considerations and schemes for managing germline findings in tumor analyses, including written informed consent and a multidisciplinary approach involving an oncologist, molecular biologist/pathologist, and geneticist in case of germline findings. A somatic result showing a deleterious mutation in a known predisposing gene in a patient who has consented to this purpose should result in referral to a geneticist who is part of the multidisciplinary team. At any time of the somatic analysis process, the patient may have access to a geneticist consultation if additional information is required. This framework will optimally manage both personalized theranostic issues and specific preventive strategies for individuals and relatives; it will also simplify and accelerate the process of genetic testing.","Department of Cancer Genetics, University Hospital of Montpellier, 34000 Montpellier;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of pathology, Centre Jean Perrin, 63000 Clermont-Ferrand, France.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2019,"2019","9","10.3390/diagnostics9030083",NA,"","","31357515","31357515","PUBMED","Department of Cancer Genetics, University Hospital of Montpellier, 34000 Montpellier;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of pathology, Centre Jean Perrin, 63000 Clermont-Ferrand, France."
"Bourgon N;Garde A;Bruel AL;Lefebvre M;Mau-Them FT;Moutton S;Sorlin A;Nambot S;Delanne J;Chevarin M;Pöe C;Thevenon J;Lehalle D;Jean-Marçais N;Kuentz P;Lambert L;El Chehadeh S;Schaefer E;Willems M;Laffargue F;Francannet C;Fradin M;Gaillard D;Blesson S;Goldenberg A;Capri Y;Sagot P;Rousseau T;Simon E;Binquet C;Ascencio ML;Duffourd Y;Philippe C;Faivre L;Vitobello A;Thauvin-Robinet C","Bourgon, Nicolas;Garde, Aurore;Bruel, Ange-Line;Lefebvre, Mathilde;Mau-Them, Frederic Tran;Moutton, Sebastien;Sorlin, Arthur;Nambot, Sophie;Delanne, Julian;Chevarin, Martin;Pöe, Charlotte;Thevenon, Julien;Lehalle, Daphné;Jean-Marçais, Nolween;Kuentz, Paul;Lambert, Laetitia;El Chehadeh, Salima;Schaefer, Elise;Willems, Marjolaine;Laffargue, Fanny;Francannet, Christine;Fradin, Mélanie;Gaillard, Dominique;Blesson, Sophie;Goldenberg, Alice;Capri, Yline;Sagot, Paul;Rousseau, Thierry;Simon, Emmanuel;Binquet, Christine;Ascencio, Marie-Laure;Duffourd, Yannis;Philippe, Christophe;Faivre, Laurence;Vitobello, Antonio;Thauvin-Robinet, Christel","Same performance of exome sequencing before and after fetal autopsy for congenital abnormalities: toward a paradigm shift in prenatal diagnosis?","European journal of human genetics : EJHG","England","eng","Journal Article","","Abnormalities, Multiple;Autopsy;Congenital Abnormalities;Exome;Female;Fetus;Humans;Pregnancy;Prenatal Diagnosis;Ultrasonography, Prenatal;Exome Sequencing","Abnormalities, Multiple;Autopsy;Congenital Abnormalities;Exome;Female;Fetus;Humans;Pregnancy;Prenatal Diagnosis;Ultrasonography, Prenatal;Exome Sequencing","Prenatal exome sequencing could be complex because of limited phenotypical data compared to postnatal/portmortem phenotype in fetuses affected by multiple congenital abnormalities (MCA). Here, we investigated limits of prenatal phenotype for ES interpretation thanks to a blindly reanalysis of postmortem ES data using prenatal data only in fetuses affected by MCA and harboring a (likely)pathogenic variant or a variant of unknown significance (VUS). Prenatal ES identified all causative variant previously reported by postmortem ES (22/24 (92%) and 2/24 (8%) using solo-ES and trio-ES respectively). Prenatal ES identified 5 VUS (in four fetuses). Two of them have been previously reported by postmortem ES. Prenatal ES were negative for four fetuses for which a VUS were diagnosed after autopsy. Our study suggests that prenatal phenotype is not a limitation for implementing pES in the prenatal assessment of unsolved MCA to personalize fetal medicine and could influence indication of postmortem examination.","INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Département Génétique Médicale, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de génétique, Unité de Génétique Clinique, Centre Hospitalier Régional Universitaire de Rouen, Rouen, France.;Département de génétique, Hôpital Robert Debré, APHP, Paris, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon","NA",0,"1476-5438","Eur J Hum Genet","Eur J Hum Genet",2021,"2022","30","10.1038/s41431-022-01117-7","967-975","","","35577939","35577939","PUBMED","INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Département Génétique Médicale, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de génétique, Unité de Génétique Clinique, Centre Hospitalier Régional Universitaire de Rouen, Rouen, France.;Département de génétique, Hôpital Robert Debré, APHP, Paris, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon"
"de Hoog S;Walsh TJ;Ahmed SA;Alastruey-Izquierdo A;Arendrup MC;Borman A;Chen S;Chowdhary A;Colgrove RC;Cornely OA;Denning DW;Dufresne PJ;Filkins L;Gangneux J-P;Gené J;Groll AH;Guillot J;Haase G;Halliday C;Hawksworth DL;Hay R;Hoenigl M;Hubka V;Jagielski T;Kandemir H;Kidd SE;Kus JV;Kwon-Chung J;Lockhart SR;Meis JF;Mendoza L;Meyer W;Nguyen MH;Song Y;Sorrell TC;Stielow JB;Vilela R;Vitale RG;Wengenack NL;White PL;Ostrosky-Zeichner L;Zhang SX","de Hoog, Sybren;Walsh, Thomas J;Ahmed, Sarah A;Alastruey-Izquierdo, Ana;Arendrup, Maiken Cavling;Borman, Andrew;Chen, Sharon;Chowdhary, Anuradha;Colgrove, Robert C;Cornely, Oliver A;Denning, David W;Dufresne, Philippe J;Filkins, Laura;Gangneux, Jean-Pierre;Gené, Josepa;Groll, Andreas H;Guillot, Jaques;Haase, Gerhard;Halliday, Catriona;Hawksworth, David L;Hay, Roderick;Hoenigl, Martin;Hubka, Vit;Jagielski, Tomasz;Kandemir, Hazal;Kidd, Sarah E;Kus, Julianne V;Kwon-Chung, June;Lockhart, Shawn R;Meis, Jacques F;Mendoza, Leonel;Meyer, Wieland;Nguyen, M Hong;Song, Yinggai;Sorrell, Tania C;Stielow, J Benjamin;Vilela, Rachel;Vitale, Roxana G;Wengenack, Nancy L;White, P Lewis;Ostrosky-Zeichner, Luis;Zhang, Sean X","Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology.","Journal of clinical microbiology","United States","eng","Journal Article","fungal disease;nomenclature;proposal","Humans;Animals;Terminology as Topic;Fungi;Mycoses;Opportunistic Infections","Humans;Animals;Terminology as Topic;Fungi;Mycoses;Opportunistic Infections","Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host's immune and metabolic status. Diseases caused by primary pathogens and common opportunists, causing the top approximately 80% of fungal diseases [D. W. Denning, Lancet Infect Dis, 24:e428-e438, 2024, https://doi.org/10.1016/S1473-3099(23)00692-8], tend to follow a predictive pattern, while those by occasional opportunists are more variable. For this reason, it is recommended that diseases caused by primary pathogens and the common opportunists are named after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not be done for occasional opportunists that should be named as [causative fungus] [clinical syndrome], for example,   cutaneous infection. The addition of a descriptor that identifies the location or clinical type of infection is required, as the general name alone may cover widely different clinical syndromes, for example, ""rhinocerebral mucormycosis."" A list of major recommended human and animal disease entities (nomenclature) is provided in alignment with their causative agents. Fungal disease names may encompass several genera of etiologic agents, consequently being less susceptible to taxonomic changes of the causative species, for example, mucormycosis covers numerous mucormycetous molds.","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Division of Infectious Diseases, Mount Auburn Hospital, and Harvard Medical School, Cambridge, Massachusetts, USA.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Manchester Fungal Infection Group, Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.;Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada.;Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de Référence Aspergilloses chroniques, ECMM Excellence Center in Mycology, Rennes, France.;Unitat de Micologia i Microbiologia Ambiental, Facultat de Medicina i Ciènces de la Salut, Universitat Rovira i Virgili, Reus, Spain.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.;Oniris, VetAgroBio Nantes, IRF, SFR ICAT, Université d'Angers, Angers, France.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Royal Botanic Gardens, Kew, Richmond, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;St. John's Institute of Dermatology, King's College London, London, United Kingdom.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, Medical University of Graz, Graz, Austria.;Department of Botany, Charles University, Prague, Czechia.;Department of Medical Microbiology, University of Warsaw, Warsaw, Poland.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;National Mycology Reference Centre, SA Pathology, Adelaide, Australia.;School of Biological Sciences, Faculty of Sciences Engineering and Technology, University of Adelaide, Adelaide, Australia.;Public Health Ontario Toronto, Toronto, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China.;Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.;Bioinformatics, Helmholtz Institute for One Health, Greifswald, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Hospital JM Ramos Mejía, Buenos Aires, Argentina.;Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;McGovern Medical School, Division of Infectious Diseases, University of Texas Health Science Center, Houston, Texas, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2024,"2024","62","10.1128/jcm.00937-24","e0093724","","","39526838","39526838","PUBMED","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Division of Infectious Diseases, Mount Auburn Hospital, and Harvard Medical School, Cambridge, Massachusetts, USA.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Manchester Fungal Infection Group, Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.;Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada.;Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de Référence Aspergilloses chroniques, ECMM Excellence Center in Mycology, Rennes, France.;Unitat de Micologia i Microbiologia Ambiental, Facultat de Medicina i Ciènces de la Salut, Universitat Rovira i Virgili, Reus, Spain.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.;Oniris, VetAgroBio Nantes, IRF, SFR ICAT, Université d'Angers, Angers, France.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Royal Botanic Gardens, Kew, Richmond, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;St. John's Institute of Dermatology, King's College London, London, United Kingdom.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, Medical University of Graz, Graz, Austria.;Department of Botany, Charles University, Prague, Czechia.;Department of Medical Microbiology, University of Warsaw, Warsaw, Poland.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;National Mycology Reference Centre, SA Pathology, Adelaide, Australia.;School of Biological Sciences, Faculty of Sciences Engineering and Technology, University of Adelaide, Adelaide, Australia.;Public Health Ontario Toronto, Toronto, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China.;Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.;Bioinformatics, Helmholtz Institute for One Health, Greifswald, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Hospital JM Ramos Mejía, Buenos Aires, Argentina.;Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;McGovern Medical School, Division of Infectious Diseases, University of Texas Health Science Center, Houston, Texas, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA."
"Corniola MV;Roche PH;Bruneau M;Cavallo LM;Daniel RT;Messerer M;Froelich S;Gardner PA;Gentili F;Kawase T;Paraskevopoulos D;Régis J;Schroeder HWS;Schwartz TH;Sindou M;Cornelius JF;Tatagiba M;Meling TR","Corniola, Marco V;Roche, Pierre-Hugues;Bruneau, Michaël;Cavallo, Luigi M;Daniel, Roy T;Messerer, Mahmoud;Froelich, Sebastien;Gardner, Paul A;Gentili, Fred;Kawase, Takeshi;Paraskevopoulos, Dimitrios;Régis, Jean;Schroeder, Henry W S;Schwartz, Theodore H;Sindou, Marc;Cornelius, Jan F;Tatagiba, Marcos;Meling, Torstein R","Management of cavernous sinus meningiomas: Consensus statement on behalf of the EANS skull base section.","Brain & spine","Netherlands","eng","Journal Article","Cavernous sinus;Consensus statement;Cranial nerves;Gammaknife;Gross total resection;Intracranial meningiomas;Meningioma;Microsurgery;Neurosurgery;Pituitary;Radiosurgery;Radiotherapy","","","The evolution of cavernous sinus meningiomas (CSMs) might be unpredictable and the efficacy of their treatments is challenging due to their indolent evolution, variations and fluctuations of symptoms, heterogeneity of classifications and lack of randomized controlled trials. Here, a dedicated task force provides a consensus statement on the overall management of CSMs. To determine the best overall management of CSMs, depending on their clinical presentation, size, and evolution as well as patient characteristics. Using the PRISMA 2020 guidelines, we included literature from January 2000 to December 2020. A total of 400 abstracts and 77 titles were kept for full-paper screening. The task force formulated 8 recommendations (Level C evidence). CSMs should be managed by a highly specialized multidisciplinary team. The initial evaluation of patients includes clinical, ophthalmological, endocrinological and radiological assessment. Treatment of CSM should involve experienced skull-base neurosurgeons or neuro-radiosurgeons, radiation oncologists, radiologists, ophthalmologists, and endocrinologists. Radiosurgery is preferred as first-line treatment in small, enclosed, pauci-symptomatic lesions/in elderly patients, while large CSMs not amenable to resection or WHO grade II-III are candidates for radiotherapy. Microsurgery is an option in aggressive/rapidly progressing lesions in young patients presenting with oculomotor/visual/endocrinological impairment. Whenever surgery is offered, open cranial approaches are the current standard. There is limited experience reported about endoscopic endonasal approach for CSMs and the main indication is decompression of the cavernous sinus to improve symptoms. Whenever surgery is indicated, the current trend is to offer decompression followed by radiosurgery.","Department of Neurosurgery, Centre Hospitalier Universitaire de Rennes/Pontchaillou, Rennes, France.;Faculty of Medicine, University of Rennes, Rennes, France.;MediCIS Research Group, INSERM UR1, UMR 1099 LTSI, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Service de Neurochirurgie, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France.;Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium.;Department of Neurological Sciences, Division of Neurosurgery, Università Degli Studi di Napoli Federico II, Naples, Italy.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service de Neurochirurgie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, APHP Nord, Paris, France.;Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.;Department of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.;Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan.;Department of Neurosurgery, Barts Health NHS Trust, St. Bartholomew's and the Royal London Hospital, London, United Kingdom.;Department of Functional and Stereotactic Neurosurgery and Radiosurgery, Timone University Hospital, Marseille, France.;Department of Neurosurgery, Ernst Moritz Arndt University, Greifswald, Germany.;Department of Neurosurgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, USA.;University of Lyon, France.;IRR Flavigny, UGECAM Nord-Est, Nancy, France.;Pediatric Neurosurgery Department, Centre Hospitalier Régional de Nancy, Nancy, France.;Department of Neurosurgery, Heinrich Heine Universität, Düsseldorf, Germany.;Department of Neurosurgery, Uniklinik Tübingen, Tübingen, Germany.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland.","NA",0,"2772-5294","Brain Spine","Brain Spine",2021,"2022","2","10.1016/j.bas.2022.100864","100864","","","36248124","36248124","PUBMED","Department of Neurosurgery, Centre Hospitalier Universitaire de Rennes/Pontchaillou, Rennes, France.;Faculty of Medicine, University of Rennes, Rennes, France.;MediCIS Research Group, INSERM UR1, UMR 1099 LTSI, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Service de Neurochirurgie, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France.;Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium.;Department of Neurological Sciences, Division of Neurosurgery, Università Degli Studi di Napoli Federico II, Naples, Italy.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service de Neurochirurgie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, APHP Nord, Paris, France.;Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.;Department of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.;Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan.;Department of Neurosurgery, Barts Health NHS Trust, St. Bartholomew's and the Royal London Hospital, London, United Kingdom.;Department of Functional and Stereotactic Neurosurgery and Radiosurgery, Timone University Hospital, Marseille, France.;Department of Neurosurgery, Ernst Moritz Arndt University, Greifswald, Germany.;Department of Neurosurgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, USA.;University of Lyon, France.;IRR Flavigny, UGECAM Nord-Est, Nancy, France.;Pediatric Neurosurgery Department, Centre Hospitalier Régional de Nancy, Nancy, France.;Department of Neurosurgery, Heinrich Heine Universität, Düsseldorf, Germany.;Department of Neurosurgery, Uniklinik Tübingen, Tübingen, Germany.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland."
"Frenel JS;Mathiot L;Cropet C;Borcoman E;Hervieu A;Coquan E;De La Motte Rouge T;Saada-Bouzid E;Sabatier R;Lavaud P;Jimenez M;Legrand F;Le Saux O;Charafe E;Gonçalves A","Frenel, Jean-Sébastien;Mathiot, Laurent;Cropet, Claire;Borcoman, Edith;Hervieu, Alice;Coquan, Elodie;De La Motte Rouge, Thibault;Saada-Bouzid, Esma;Sabatier, Renaud;Lavaud, Pernelle;Jimenez, Marta;Legrand, François;Le Saux, Olivia;Charafe, Emmanuelle;Gonçalves, Anthony","Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.","Journal for immunotherapy of cancer","England","eng","Journal Article","Cervical Cancer;Chemotherapy;Immune Checkpoint Inhibitor","Humans;Female;Uterine Cervical Neoplasms;Antineoplastic Combined Chemotherapy Protocols;Vinorelbine;Middle Aged;Antibodies, Monoclonal, Humanized;Adult;Aged;Antibodies, Monoclonal;Neoplasm Recurrence, Local;Administration, Metronomic;Administration, Oral","Humans;Female;Uterine Cervical Neoplasms;Antineoplastic Combined Chemotherapy Protocols;Vinorelbine;Middle Aged;Antibodies, Monoclonal, Humanized;Adult;Aged;Antibodies, Monoclonal;Neoplasm Recurrence, Local;Administration, Metronomic;Administration, Oral","The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort. Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression. The primary efficacy endpoint was the clinical benefit rate (CBR) based on the Response Evaluation Criteria in Solid Tumors V.1.1, which was analyzed using a Bayesian approach RESULTS: A total of 31 patients were enrolled and treated in the cervical cancer cohort. The median number of previous lines of chemotherapy for advanced disease was 2 (0-6), with all (100%) and 12 (38.7%) patients pretreated with cisplatin and bevacizumab, respectively. At the data cut-off, the median follow-up duration was 12.8 (Q1-Q3, 6.1-34.6) months. The CBR was 53.1% (95% CI, 36.0% to 69.8%), using a non-informative prior distribution (beta(1, 1)). The overall response rate was 41.9%, five patients achieved a complete response (16.1%), and eight patients (25.8%) had a partial response irrespective of histological subtype or programmed death-ligand 1 (PD-L1) expression. Of the 31 patients, 28 (90.3%) experienced treatment-related adverse events (TRAEs), 13 (41.9%) reported grade ≥3 immune-related adverse events (AEs), and 13 (41.9%) reported grade ≥3 chemotherapy-related AEs. The definitive discontinuation rate due to TRAEs was 16.1%. Dual checkpoint blockade of PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 combined with metronomic oral vinorelbine demonstrated meaningful and durable clinical activity in patients with previously treated advanced cervical cancer. Toxicity was significant but manageable.","Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain;Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.","NA",0,"2051-1426","J Immunother Cancer","J Immunother Cancer",2024,"2025","13","10.1136/jitc-2024-010708",NA,"","","39773562","39773562","PUBMED","Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain;Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France."
"Sletten OJ;Aalen JM;Izci H;Duchenne J;Remme EW;Larsen CK;Hopp E;Galli E;Sirnes PA;Kongsgard E;Donal E;Voigt JU;Smiseth OA;Skulstad H","Sletten, Ole J;Aalen, John M;Izci, Hava;Duchenne, Jürgen;Remme, Espen W;Larsen, Camilla K;Hopp, Einar;Galli, Elena;Sirnes, Per A;Kongsgard, Erik;Donal, Erwan;Voigt, Jens U;Smiseth, Otto A;Skulstad, Helge","Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block.","JACC. Cardiovascular imaging","United States","eng","Journal Article","cardiac resynchronization therapy;heart failure;left bundle branch block;myocardial work;septal rebound stretch;strain","Bundle-Branch Block;Cardiac Resynchronization Therapy;Heart Failure;Humans;Predictive Value of Tests;Stroke Volume;Treatment Outcome;Ventricular Function, Left","Bundle-Branch Block;Cardiac Resynchronization Therapy;Heart Failure;Humans;Predictive Value of Tests;Stroke Volume;Treatment Outcome;Ventricular Function, Left","This study sought to investigate if contractile asymmetry between septum and left ventricular (LV) lateral wall drives heart failure development in patients with left bundle branch block (LBBB) and whether the presence of lateral wall dysfunction affects potential for recovery of LV function with cardiac resynchronization therapy (CRT). LBBB may induce or aggravate heart failure. Understanding the underlying mechanisms is important to optimize timing of CRT. In 76 nonischemic patients with LBBB and 11 controls, we measured strain using speckle-tracking echocardiography and regional work using pressure-strain analysis. Patients with LBBB were stratified according to LV ejection fraction (EF) ≥50% (EF ), 36% to 49% (EF ), and ≤35% (EF ). Sixty-four patients underwent CRT and were re-examined after 6 months. Septal work was successively reduced from controls, through EF , EF , and EF  (all p < 0.005), and showed a strong correlation to left ventricular ejection fraction (LVEF; r = 0.84; p < 0.005). In contrast, LV lateral wall work was numerically increased in EF  and EF  versus controls, and did not significantly correlate with LVEF in these groups. In EF  however, LV lateral wall work was substantially reduced (p < 0.005). There was a moderate overall correlation between LV lateral wall work and LVEF (r = 0.58; p < 0.005). In CRT recipients, LVEF was normalized (≥50%) in 54% of patients with preserved LV lateral wall work, but only in 13% of patients with reduced LV lateral wall work (p < 0.005). In early stages, LBBB-induced heart failure is associated with impaired septal function but preserved lateral wall function. The advent of LV lateral wall dysfunction may be an optimal time-point for CRT.","Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; The Intervention Center, Oslo University Hospital, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Ostlandske hjertesenter, Moss, Norway.;Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo","NA",0,"1876-7591","JACC Cardiovasc Imaging","JACC Cardiovasc Imaging",2021,"2021","14","10.1016/j.jcmg.2021.04.017","2059-2069","","","34147454","34147454","PUBMED","Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; The Intervention Center, Oslo University Hospital, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Ostlandske hjertesenter, Moss, Norway.;Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo"
"Kenji SF;Kurma K;Collet B;Oblet C;Debure L;Di Primo C;Minder L;Vérité F;Danger Y;Jean M;Penna A;Levoin N;Legembre P","Kenji, Shoji F;Kurma, Keerthi;Collet, Brigitte;Oblet, Christelle;Debure, Laure;Di Primo, Carmelo;Minder, Laëtitia;Vérité, Franck;Danger, Yannic;Jean, Mickael;Penna, Aubin;Levoin, Nicolas;Legembre, Patrick","MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways.","Cell death & disease","England","eng","Journal Article","","fas Receptor;Matrix Metalloproteinase 7;Apoptosis;Leucine;Phosphatidylinositol 3-Kinases;Protein Sorting Signals;Arginine","fas Receptor;Matrix Metalloproteinase 7;Apoptosis;Leucine;Phosphatidylinositol 3-Kinases;Protein Sorting Signals;Arginine","CD95 is a death receptor that can promote oncogenesis through molecular mechanisms that are not fully elucidated. Although the mature CD95 membrane receptor is considered to start with the arginine at position 17 after elimination of the signal peptide, this receptor can also be cleaved by MMP7 upstream of its leucine at position 37. This post-translational modification occurs in cancer cells but also in normal cells such as peripheral blood leukocytes. The non-cleaved CD95 amino-terminal region consists in a disordered domain and its in silico reconstitution suggests that it might contribute to receptor aggregation and thereby, regulate the downstream death signaling pathways. In agreement with this molecular modeling analysis, the comparison of CD95-deficient cells reconstituted with full-length or N-terminally truncated CD95 reveals that the loss of the amino-terminal region of CD95 impairs the initial steps of the apoptotic signal while favoring the induction of pro-survival signals, including the PI3K and MAPK pathways.","IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;Université de Rennes-1, INSERM U1242, rue bataille Flandres Dunkerque, 35042, Rennes, France.;University Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, F-33000, Bordeaux, France.;University Bordeaux, CNRS, INSERM, UAR 3033, US001, IECB, F-33000, Bordeaux, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;Université de Rennes 1, Institut des Sciences Chimiques de Rennes - UMR CNRS 6226 Equipe COrInt, F-35000, Rennes, France.;IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;4CS, CNRS UMR6041, Université de Poitiers, 86073, Poitiers, France.;Bioprojet Biotech, rue du Chesnay Beauregard, 35760, Saint-Grégoire, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges","NA",0,"2041-4889","Cell Death Dis","Cell Death Dis",2022,"2022","13","10.1038/s41419-022-05352-0","895","","","36274061","36274061","PUBMED","IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;Université de Rennes-1, INSERM U1242, rue bataille Flandres Dunkerque, 35042, Rennes, France.;University Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, F-33000, Bordeaux, France.;University Bordeaux, CNRS, INSERM, UAR 3033, US001, IECB, F-33000, Bordeaux, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;Université de Rennes 1, Institut des Sciences Chimiques de Rennes - UMR CNRS 6226 Equipe COrInt, F-35000, Rennes, France.;IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;4CS, CNRS UMR6041, Université de Poitiers, 86073, Poitiers, France.;Bioprojet Biotech, rue du Chesnay Beauregard, 35760, Saint-Grégoire, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges"
"Garret C;Douillard M;David A;Péré M;Quenehervé L;Legros L;Archambeaud I;Douane F;Lerhun M;Regenet N;Gournay J;Coron E;Frampas E;Reignier J","Garret, Charlotte;Douillard, Marion;David, Arthur;Péré, Morgane;Quenehervé, Lucille;Legros, Ludivine;Archambeaud, Isabelle;Douane, Frédéric;Lerhun, Marc;Regenet, Nicolas;Gournay, Jerome;Coron, Emmanuel;Frampas, Eric;Reignier, Jean","Infected pancreatic necrosis complicating severe acute pancreatitis in critically ill patients: predicting catheter drainage failure and need for necrosectomy.","Annals of intensive care","Germany","eng","Journal Article","Acute pancreatitis;Catheter drainage;Infected necrosis;Intensive care;Necrosectomy;Organ failure","","","Recent guidelines advocate a step-up approach for managing suspected infected pancreatic necrosis (IPN) during acute pancreatitis. Nearly half the patients require secondary necrosectomy after catheter drainage. Our primary objective was to assess the external validity of a previously reported nomogram for catheter drainage, based on four predictors of failure. Our secondary objectives were to identify other potential predictors of catheter-drainage failure. We retrospectively studied consecutive patients admitted to the intensive care units (ICUs) of three university hospitals in France between 2012 and 2016, for severe acute pancreatitis with suspected IPN requiring catheter drainage. We assessed drainage success and failure rates in 72 patients, with success defined as survival without subsequent necrosectomy and failure as death and/or subsequent necrosectomy required by inadequate improvement. We plotted the receiver operating characteristics (ROC) curve for the nomogram and computed the area under the curve (AUROC). Catheter drainage alone was successful in 32 (44.4%) patients. The nomogram predicted catheter-drainage failure with an AUROC of 0.71. By multivariate analysis, catheter-drainage failure was independently associated with a higher body mass index [odds ratio (OR), 1.12; 95% confidence interval (95% CI), 1.00-1.24; P = 0.048], heterogeneous collection (OR, 16.7; 95% CI, 1.83-152.46; P = 0.01), and respiratory failure onset within 24 h before catheter drainage (OR, 18.34; 95% CI, 2.18-154.3; P = 0.007). Over half the patients required necrosectomy after failed catheter drainage. Newly identified predictors of catheter-drainage failure were heterogeneous collection and respiratory failure. Adding these predictors to the nomogram might help to identify patients at high risk of catheter-drainage failure. gov number: NCT03234166.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Plateforme de Méthodologie et Biostatistique, Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Brest, 29200, Brest, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Rennes, 35203, Rennes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2021,"2022","12","10.1186/s13613-022-01039-z","71","","","35916981","35916981","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Plateforme de Méthodologie et Biostatistique, Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Brest, 29200, Brest, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Rennes, 35203, Rennes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France."
"Cancel M;Fromont G;Blonz C;Chevreau C;Rioux-Leclercq N;Laguerre B;Oudard S;Gross-Goupil M;Gravis G;Goldwasser F;Rolland F;Delva R;Moise L;Emambux S;Vassal C;Zanetta S;Penel N;Fléchon A;Barthélémy P;Saldana C;Lefort F;Escudier B;Linassier C;Albiges L","Cancel, Mathilde;Fromont, Gaelle;Blonz, Cyriac;Chevreau, Christine;Rioux-Leclercq, Nathalie;Laguerre, Brigitte;Oudard, Stéphane;Gross-Goupil, Marine;Gravis, Gwenaelle;Goldwasser, François;Rolland, Frédéric;Delva, Rémy;Moise, Laura;Emambux, Sheik;Vassal, Cécile;Zanetta, Sylvie;Penel, Nicolas;Fléchon, Aude;Barthélémy, Philippe;Saldana, Carolina;Lefort, Félix;Escudier, Bernard;Linassier, Claude;Albiges, Laurence","Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Everolimus;First-line treatment;IMDC risk groups;Metastatic;Papillary renal cell carcinoma;Prognostic factors;Real world;Sunitinib","","","Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib or a mammalian target of rapamycin (mTOR) inhibitor in first- and second-line treatment, the optimal strategy remained unknown. In 23 centres of the Groupe d'Etude des Tumeurs Urogénitales group, after centralised pathological review, we analysed retrospectively progression-free survival (PFS) of patients with mpRCC treated in first-line treatment (PFS-1) with sunitinib or everolimus (primary end-point), PFS in second-line treatment (PFS-2), overall survival (OS), objective response rate, disease control rate (DCR), overall sequence and prognostic factors for OS (secondary end-points). One hundred thirty-eight patients (119 men and 19 women), median age 62.5 years, with mpRCC type 1 (n = 24) or non-type 1 (n = 114), received first-line sunitinib (n = 107) or everolimus (n = 31). With a median follow-up of 92 months, we found no significant difference between the treatment groups in terms of PFS-1 (5.5 versus 6.2 months) and DCR (69% versus 83%). Ninety-eight patients received a second-line treatment, 69% with mTOR inhibitors after sunitinib and 100% with tyrosine kinase inhibitors after everolimus, with similar DCR (64% versus 58%), median PFS-2 (3.4 versus 4.8 months) and OS (16.0 versus 20.3 months). No factor was prognostic for PFS-1, whereas leukocytosis, anaemia and the time from diagnosis to first systemic therapy < 1 year were prognostic for OS. We found no prognostic difference between both pRCC subtypes. The International Metastatic Renal Cell Database Consortium risk factors were prognostic for OS. Sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC.","Department of Medical Oncology, CHU Bretonneau Tours, France.;Department of Pathology, CHU Bretonneau, Tours, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, IUCT Oncopole - CLCC Institut Claudius Regaud, Toulouse, France.;Department of Pathology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, CHU Hôpital Européen Georges Pompidou, Paris, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, CHU Hôpital Cochin, Paris.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, CHU La Milétrie, Poitiers, France.;Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, CHU Mondor, Créteil, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Bretonneau Tours;Department of Medical Oncology, Gustave Roussy, Villejuif, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","158","10.1016/j.ejca.2021.08.046","1-11","","","34619467","34619467","PUBMED","Department of Medical Oncology, CHU Bretonneau Tours, France.;Department of Pathology, CHU Bretonneau, Tours, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, IUCT Oncopole - CLCC Institut Claudius Regaud, Toulouse, France.;Department of Pathology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, CHU Hôpital Européen Georges Pompidou, Paris, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, CHU Hôpital Cochin, Paris.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, CHU La Milétrie, Poitiers, France.;Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, CHU Mondor, Créteil, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Bretonneau Tours;Department of Medical Oncology, Gustave Roussy, Villejuif, France."
"Kabirian R;Franzoi MA;Havas J;Coutant C;Tredan O;Levy C;Cottu P;Dhaini Mérimèche A;Guillermet S;Ferrero JM;Giacchetti S;Petit T;Dalenc F;Rouanet P;Everhard S;Martin AL;Pistilli B;Lambertini M;Vaz-Luis I;Di Meglio A","Kabirian, Rayan;Franzoi, Maria Alice;Havas, Julie;Coutant, Charles;Tredan, Olivier;Levy, Christelle;Cottu, Paul;Dhaini Mérimèche, Asma;Guillermet, Sophie;Ferrero, Jean-Marc;Giacchetti, Sylvie;Petit, Thierry;Dalenc, Florence;Rouanet, Philippe;Everhard, Sibille;Martin, Anne-Laure;Pistilli, Barbara;Lambertini, Matteo;Vaz-Luis, Ines;Di Meglio, Antonio","Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.","JAMA network open","United States","eng","Multicenter Study","","Female;Humans;Breast Neoplasms;Quality of Life;Amenorrhea;Cohort Studies;Prospective Studies","Female;Humans;Breast Neoplasms;Quality of Life;Amenorrhea;Cohort Studies;Prospective Studies","Younger survivors of breast cancer frequently report more treatment-related symptoms, mostly related to the menopausal transition. To assess factors associated with chemotherapy-related amenorrhea (CRA) and to evaluate its association with long-term quality of life (QOL). The prospective, longitudinal Cancer Toxicities Study, a multicenter French cohort study, includes women with a diagnosis of stage I to III breast cancer and collects data approximately yearly after diagnosis. The current study reports outcomes up to 4 years after diagnosis for participants enrolled from 2012 to 2017. Participants included premenopausal women younger than 50 years treated with chemotherapy and not receiving adjuvant ovarian function suppression. Data analysis was performed from September 2021 to June 2023. Clinical, socioeconomic, tumor, and treatment characteristics assessed at diagnosis (for the analysis of factors associated with CRA) and persistent CRA (for the QOL analysis). The main outcome of interest was CRA at year 1 (Y1), year 2 (Y2), and year 4 (Y4) after diagnosis. Generalized estimating equations assessed associations of exposure variables with CRA. In the QOL analysis, QOL at Y4 (assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and BR23) was the outcome of interest. Multivariable random-effect mixed models assessed the association of persistent CRA (ie, never recovering menses after treatment) with QOL. Among 1636 women, the mean (SD) age at diagnosis was 42.2 (5.6) years. Overall, 1242 of 1497 women (83.0%) reported CRA at Y1, 959 of 1323 women (72.5%) reported it at Y2, and 599 of 906 women (66.1%) reported it at Y4. Older age vs 18 to 34 years (adjusted odds ratio [OR] for 35 to 39 years, 1.84 [95% CI, 1.32 to 2.56]; adjusted OR for 40 to 44 years, 5.90 [95% CI, 4.23 to 8.24]; and adjusted OR for ≥45 years, 21.29 [95% CI, 14.34 to 31.61]) and receipt of adjuvant tamoxifen (adjusted OR, 1.97 [95% CI, 1.53 to 2.53]) were associated with higher likelihood of CRA. In the QOL analysis, 416 of 729 women (57.1%) had persistent CRA. However, late menses recovery among women aged 18 to 34 years with no menses at Y2 were reported by 11 of 21 women (52.4%) between Y2 and Y4. Persistent CRA was associated with worse insomnia (mean difference vs recovery at any time, 9.9 points [95% CI, 3.2 to 16.5 points]; P = .004), systemic therapy-related adverse effects (mean difference, 3.0 points [95% CI, 0.2 to 5.8 points]; P = .04), and sexual functioning (mean difference, -9.2 points [95% CI, -14.3 to -4.1 points]; P < .001) at Y4. In this cohort study of premenopausal women with breast cancer, persistent CRA was common, although some women recovered menses late, and was associated with worse long-term QOL. This study can help inform risk communication, personalized counseling, and early supportive care referrals for such patients.","Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Sorbonne Université, Paris, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Centre Georges François Leclerc, Dijon, France.;Centre Léon Bérard, Lyon, France.;Centre François Baclesse, Caen, France.;Institut Curie, Paris, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France.;Now with Centre Hospitalier de Lunéville-Ghemm, Pôle Mère-Enfant, Lunéville, France.;Centre Eugene-Marquis, Rennes, France.;Centre Antoine Lacassagne, Nice, France.;Hopital Saint Louis, Paris, France.;Centre Paul Strauss Centre de Lutte Contre le Cancer, Strasbourg, France.;Institut Claudius-Regaud, IUCT-Oncopole, Toulouse, France.;CRLC Val d'Aurelle, Montpellier, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Internal Medicine and Medical Specialties, School of Medicine University of Genova, Genova, Italy.;Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2023,"2023","6","10.1001/jamanetworkopen.2023.43910","e2343910","","","37971739","37971739","PUBMED","Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Sorbonne Université, Paris, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Centre Georges François Leclerc, Dijon, France.;Centre Léon Bérard, Lyon, France.;Centre François Baclesse, Caen, France.;Institut Curie, Paris, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France.;Now with Centre Hospitalier de Lunéville-Ghemm, Pôle Mère-Enfant, Lunéville, France.;Centre Eugene-Marquis, Rennes, France.;Centre Antoine Lacassagne, Nice, France.;Hopital Saint Louis, Paris, France.;Centre Paul Strauss Centre de Lutte Contre le Cancer, Strasbourg, France.;Institut Claudius-Regaud, IUCT-Oncopole, Toulouse, France.;CRLC Val d'Aurelle, Montpellier, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Internal Medicine and Medical Specialties, School of Medicine University of Genova, Genova, Italy.;Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France."
"Michaud K;de Tayrac M;D'Astous M;Paquet C;Gould PV;Saikali S","Michaud, Karine;de Tayrac, Marie;D'Astous, Myreille;Paquet, Claudie;Gould, Peter Vincent;Saikali, Stéphan","Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.","PloS one","United States","eng","Journal Article","","Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Oligodendroglioma;Proto-Oncogene Proteins c-myc;Survival Rate","Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Oligodendroglioma;Proto-Oncogene Proteins c-myc;Survival Rate","To study the presence of 9p deletion and p16, cyclin D1 and Myc expression and their respective diagnostic and prognostic interest in oligodendrogliomas. We analyzed a retrospective series of 40 consecutive anaplastic oligodendrogliomas (OIII) from a single institution and compared them to a control series of 10 low grade oligodendrogliomas (OII). Automated FISH analysis of chromosome 9p status and immunohistochemistry for p16, cyclin D1 and Myc was performed for all cases and correlated with clinical and histological data, event free survival (EFS) and overall survival (OS). Chromosome 9p deletion was observed in 55% of OIII (22/40) but not in OII. Deletion was highly correlated to EFS (median = 29 versus 53 months, p<0.0001) and OS (median = 48 versus 83 months, p<0.0001) in both the total cohort and the OIII population. In 9p non-deleted oligodendrogliomas, p16 hyperexpression correlated with a shorter OS (p = 0.02 in OII and p = 0.0001 in OIII) whereas lack of p16 expression was correlated to a shorter EFS and OS in 9p deleted OIII (p = 0.001 and p = 0.0002 respectively). Expression of Cyclin D1 was significantly higher in OIII (median expression 45% versus 14% for OII, p = 0.0006) and was correlated with MIB-1 expression (p<0.0001), vascular proliferation (p = 0.002), tumor necrosis (p = 0.04) and a shorter EFS in the total cohort (p = 0.05). Hyperexpression of Myc was correlated to grade (median expression 27% in OII versus 35% in OIII, p = 0.03), and to a shorter EFS in 9p non-deleted OIII (p = 0.01). Chromosome 9p deletion identifies a subset of OIII with significantly worse prognosis. The combination of 9p status and p16 expression level identifies two distinct OIII populations with divergent prognosis. Hyperexpression of Bcl1 and Myc appears highly linked to anaplasia but the prognostic value is unclear and should be investigated further.","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.","NA",0,"1932-6203","PLoS One","PLoS One",2017,"2018","13","10.1371/journal.pone.0193213","e0193213","","","29489901","29489901","PUBMED","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada."
"Frenel JS;Zeghondy J;Guérin-Charbonnel C;Mailliez A;Volant E;Poumeaud F;Patsouris A;Arnedos M;Bailleux C;Cabal J;Galland L;de Nonneville A;Guiu S;Dalenc F;Pistilli B;Bachelot T;Pierga JY;Le Du F;Bocquet F;Larrouquere L;Loirat D","Frenel, Jean-Sebastien;Zeghondy, Jean;Guérin-Charbonnel, Catherine;Mailliez, Audrey;Volant, Elsa;Poumeaud, François;Patsouris, Anne;Arnedos, Monica;Bailleux, Caroline;Cabal, Julie;Galland, Loick;de Nonneville, Alexandre;Guiu, Séverine;Dalenc, Florence;Pistilli, Barbara;Bachelot, Thomas;Pierga, Jean-Yves;Le Du, Fanny;Bocquet, François;Larrouquere, Louis;Loirat, Delphine","Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.","JAMA network open","United States","eng","Journal Article","","Humans;Middle Aged;Female;Breast Neoplasms;Capecitabine;Cohort Studies;Prospective Studies;Trastuzumab;Brain Neoplasms;Disease Progression;Receptor, ErbB-2;Oxazoles;Pyridines;Quinazolines","Humans;Middle Aged;Female;Breast Neoplasms;Capecitabine;Cohort Studies;Prospective Studies;Trastuzumab;Brain Neoplasms;Disease Progression;Receptor, ErbB-2;Oxazoles;Pyridines;Quinazolines","Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). To investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan. This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022. Tucatinib combined with trastuzumab and capecitabine administered at the recommended dose. Clinical end points included progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and overall response rate (ORR). A total of 101 patients with MBC were included (median age, 56 [range, 31-85] years). The median number of prior treatment lines for metastatic disease at TTC treatment initiation was 4 (range, 2-15), including 82 patients (81.2%) with previous trastuzumab and/or pertuzumab and 94 (93.1%) with previous ado-trastuzumab-emtansine) exposure. The median duration of trastuzumab-deruxtecan treatment was 8.9 (range, 1.4-25.8) months, and 82 patients (81.2%) had disease progression during trastuzumab-deruxtecan treatment, whereas 18 (17.8%) had stopped trastuzumab-deruxtecan for toxic effects and 1 (1.0%) for other reasons. Tucatinib combined with trastuzumab and capecitabine was provided as a third- or fourth-line treatment in 37 patients (36.6%) and was the immediate treatment after trastuzumab-deruxtecan in 86 (85.1%). With a median follow-up of 11.6 (95% CI, 10.5-13.4) months, 76 of 101 patients (75.2%) stopped TTC treatment due to disease progression. The median PFS was 4.7 (95% CI, 3.9-5.6) months; median TTNT, 5.2 (95% CI, 4.5-7.0) months; and median OS, 13.4 (95% CI, 11.1 to not reached [NR]) months. Patients who received TTC immediately after trastuzumab-deruxtecan had a median PFS of 5.0 (95% CI, 4.2-6.0) months; median TTNT of 5.5 (95% CI, 4.8-7.2) months, and median OS of 13.4 (95% CI, 11.9-NR) months. Those who received TTC due to trastuzumab-deruxtecan toxicity-related discontinuation had a median PFS of 7.3 (95% CI, 3.0-NR) months. Best ORR was 29 of 89 patients (32.6%). Sixteen patients with active brain metastasis had a median PFS of 4.7 (95% CI, 3.0-7.3) months, median TTNT of 5.6 (95% CI, 4.4 to NR), and median OS of 12.4 (95% CI, 8.3-NR) months. In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2-positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.","Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Data Factory, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2024,"2024","7","10.1001/jamanetworkopen.2024.4435","e244435","","","38568692","38568692","PUBMED","Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Data Factory, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France."
"Gangneux JP;Padoin C;Michallet M;Saillio E;Kumichel A;Peffault de La Tour R;Ceballos P;Gastinne T;Pigneux A","Gangneux, Jean-Pierre;Padoin, Christophe;Michallet, Mauricette;Saillio, Emeline;Kumichel, Alexandra;Peffault de La Tour, Régis;Ceballos, Patrice;Gastinne, Thomas;Pigneux, Arnaud","Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study.","Journal of fungi (Basel, Switzerland)","Switzerland","eng","Journal Article","antifungal prophylaxis;haematological malignancies;invasive fungal disease;neutropenia","","","Antifungal prophylaxis (AFP) is recommended by international guidelines for patients with acute myeloid leukaemia (AML) undergoing induction chemotherapy and allogeneic hematopoietic cell transplantation. Nonetheless, treatment of breakthrough fungal infections remains challenging. This observational, prospective, multicentre, non-comparative study of patients undergoing myelosuppressive and intensive chemotherapy for AML who are at high-risk of invasive fungal diseases (IFDs), describes AFP management and outcomes for 404 patients (65.6% newly diagnosed and 73.3% chemotherapy naïve). Ongoing chemotherapy started 1.0 ± 4.5 days before inclusion and represented induction therapy for 79% of participants. In 92.3% of patients, posaconazole was initially prescribed, and 8.2% of all patients underwent at least one treatment change after 17 ± 24 days, mainly due to medical conditions influencing AFP absorption (65%). The mean AFP period was 24 ± 32 days, 66.8% stopped their prophylaxis after the high-risk period and 31.2% switched to a non-prophylactic treatment (2/3 empirical, 1/3 pre-emptive/curative). Overall, 9/404 patients (2.2%) were diagnosed with probable or proven IFDs. During the follow-up, 94.3% showed no signs of infection. Altogether, 20 patients (5%) died, and three deaths (0.7%) were IFD-related. In conclusion, AFP was frequently prescribed and well tolerated by these AML patients, breakthrough infections incidence and IFD mortality were low and very few treatment changes were required.","Mycology Department, Centre Hospitalier Universitaire de Rennes, University Rennes, INSERM, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR S_1085, 35000 Rennes, France.;Pharmacy Department, CHU Martinique Site P. Zobda Quitman, 97261 Fort de France, Martinique, France.;Clinical Haematology Department, Centre Léon Bérard (Anticancer Center), 28 Rue Laennec, 69373 Lyon, France.;Department of Medical Affairs, MSD France, 10-12 cours Michelet, 92800 Puteaux, France.;Scientific Department, ClinSearch, 110 Avenue Pierre Brossolette, 92240 Malakoff, France.;Haematology-Bone Marrow Transplant Department, Saint-Louis Hospital APHP, 1 Avenue Claude-Vellefaux, 75010 Paris, France.;Clinical Haematology Department, CHRU Lapeyronie, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.;Clinical Haematology Department, CHU Nantes, 1 Place Alexis-Ricordeau, 44093 Nantes, France.;Blood Diseases Department, Hospital Group Haut Leveque, Avenue de Magellan, 33604 Pessac, France.","NA",0,"2309-608X","J Fungi (Basel)","J Fungi (Basel)",2020,"2020","6","10.3390/jof6040281",NA,"The SAPHIR study","MSD France","33198192","33198192","PUBMED","Mycology Department, Centre Hospitalier Universitaire de Rennes, University Rennes, INSERM, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR S_1085, 35000 Rennes, France.;Pharmacy Department, CHU Martinique Site P. Zobda Quitman, 97261 Fort de France, Martinique, France.;Clinical Haematology Department, Centre Léon Bérard (Anticancer Center), 28 Rue Laennec, 69373 Lyon, France.;Department of Medical Affairs, MSD France, 10-12 cours Michelet, 92800 Puteaux, France.;Scientific Department, ClinSearch, 110 Avenue Pierre Brossolette, 92240 Malakoff, France.;Haematology-Bone Marrow Transplant Department, Saint-Louis Hospital APHP, 1 Avenue Claude-Vellefaux, 75010 Paris, France.;Clinical Haematology Department, CHRU Lapeyronie, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.;Clinical Haematology Department, CHU Nantes, 1 Place Alexis-Ricordeau, 44093 Nantes, France.;Blood Diseases Department, Hospital Group Haut Leveque, Avenue de Magellan, 33604 Pessac, France."
"Carril-Ajuria L;Colomba E;Cerbone L;Romero-Ferreiro C;Crouzet L;Laguerre B;Thibault C;Vicier C;de Velasco G;Fléchon A;Saldana C;Benusiglio PR;Bressac-de Paillerets B;Guillaud-Bataille M;Gaignard P;Scoazec JY;Richard S;Caron O;Escudier B;Albiges L","Carril-Ajuria, Lucia;Colomba, Emeline;Cerbone, Luigi;Romero-Ferreiro, Carmen;Crouzet, Laurence;Laguerre, Brigitte;Thibault, Constance;Vicier, Cécile;de Velasco, Guillermo;Fléchon, Aude;Saldana, Carolina;Benusiglio, Patrick R;Bressac-de Paillerets, Brigitte;Guillaud-Bataille, Marine;Gaignard, Pauline;Scoazec, Jean-Yves;Richard, Stéphane;Caron, Olivier;Escudier, Bernard;Albiges, Laurence","Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.","European journal of cancer (Oxford, England : 1990)","England","eng","Comparative Study","Antiangiogenics;FH-deficient RCC;Hereditary leiomyomatosis;Immunotherapy;Non–clear cell RCC","Adult;Angiogenesis Inhibitors;Biomarkers, Tumor;Disease Progression;Female;France;Fumarate Hydratase;Genetic Predisposition to Disease;Humans;Immune Checkpoint Inhibitors;Kidney Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Phenotype;Protein Kinase Inhibitors;Retrospective Studies;Spain;TOR Serine-Threonine Kinases;Time Factors;Treatment Failure;Young Adult","Adult;Angiogenesis Inhibitors;Biomarkers, Tumor;Disease Progression;Female;France;Fumarate Hydratase;Genetic Predisposition to Disease;Humans;Immune Checkpoint Inhibitors;Kidney Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Phenotype;Protein Kinase Inhibitors;Retrospective Studies;Spain;TOR Serine-Threonine Kinases;Time Factors;Treatment Failure;Young Adult","Fumarate hydratase-deficient (FHdef) renal cell carcinoma (RCC) is a rare entity associated with the hereditary leiomyomatosis and RCC syndrome with no standard therapy approved. The aim of this retrospective study was to evaluate the efficacy of different systemic treatments in this population. We performed a multicentre retrospective analysis of Fhdef RCC patients to determine the response to systemic treatments. The endpoints were objective response rate (ORR), time-to-treatment failure (TTF), and overall survival (OS). The two latter were estimated using the Kaplan-Meier method. Twenty-four Fhdef RCC patients were identified, and 21 under systemic therapy were included in the analysis: ten received cabozantinib, 14 received sunitinib, nine received ""other antiangiogenics"" (sorafenib, pazopanib, and axitinib), three received erlotinib-bevacizumab (E-B), three received mTOR inhibitors, and 11 received immune checkpoint blockers (ICBs). ORR for treatments were 50% for cabozantinib, 43% for sunitinib, 63% for ""other antiangiogenics,"" and 30% for E-B, whereas ORR was 0% for mTOR inhibitors and 18% for ICBs. The median TTF (mTTF) was significantly higher with antiangiogenics (11.6 months) than with mTOR inhibitors (4.4 months) or ICBs (2.7 months). In the first-line setting, antiangiogenics presented a higher ORR compared with nivolumab-ipilimumab (64% versus 25%) and a significantly superior mTTF (11.0 months vs 2.5 months; p = 0.0027). The median OS from the start of the first systemic treatment was 44.0 months (95% confidence interval: 13.0-95.0). We report the first European retrospective study of Fhdef RCC patients treated with systemic therapy with a remarkably long median OS of 44.0 months. Our results suggest that antiangiogenics may be superior to ICB/mTOR inhibitors in this population.","Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;CIBERESP, Instituto i+12, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France.;Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France; Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;Biochemistry Department, Hôpital Bicêtre, APHP Université Paris-Saclay, Le Kremlin Bicêtre F-94275, France.;Department of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.;Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France; Génétique Oncologique EPHE, PSL Research University, Paris, France; UMR9019 CNRS Genome Integrity and Cancers, Institute Gustave Roussy, Villejuif, France.;Laboratory Integrative Tumor Immunology and Genetic Oncology, Institute Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","151","10.1016/j.ejca.2021.04.009","106-114","","","33975058","33975058","PUBMED","Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;CIBERESP, Instituto i+12, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France.;Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France; Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;Biochemistry Department, Hôpital Bicêtre, APHP Université Paris-Saclay, Le Kremlin Bicêtre F-94275, France.;Department of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.;Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France; Génétique Oncologique EPHE, PSL Research University, Paris, France; UMR9019 CNRS Genome Integrity and Cancers, Institute Gustave Roussy, Villejuif, France.;Laboratory Integrative Tumor Immunology and Genetic Oncology, Institute Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre"
"Thille AW;Coudroy R;Gacouin A;Ehrmann S;Contou D;Dangers L;Romen A;Guitton C;Lacave G;Quenot JP;Lacombe B;Pradel G;Terzi N;Prat G;Labro G;Reignier J;Beduneau G;Dellamonica J;Nay MA;Rouze A;Delbove A;Sedillot N;Mira JP;Bourenne J;Lautrette A;Argaud L;Levrat Q;Devaquet J;Vivier E;Azais MA;Leroy C;Dres M;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Coudroy, Rémi;Gacouin, Arnaud;Ehrmann, Stephan;Contou, Damien;Dangers, Laurence;Romen, Antoine;Guitton, Christophe;Lacave, Guillaume;Quenot, Jean-Pierre;Lacombe, Béatrice;Pradel, Gael;Terzi, Nicolas;Prat, Gwenael;Labro, Guylaine;Reignier, Jean;Beduneau, Gaetan;Dellamonica, Jean;Nay, Mai-Anh;Rouze, Anahita;Delbove, Agathe;Sedillot, Nicholas;Mira, Jean-Paul;Bourenne, Jeremy;Lautrette, Alexandre;Argaud, Laurent;Levrat, Quentin;Devaquet, Jérôme;Vivier, Emmanuel;Azais, Marie-Ange;Leroy, Christophe;Dres, Martin;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","T-piece versus pressure-support ventilation for spontaneous breathing trials before extubation in patients at high risk of reintubation: protocol for a multicentre, randomised controlled trial (TIP-EX).","BMJ open","England","eng","Journal Article","adult intensive & critical care;respiratory medicine (see thoracic medicine);respiratory physiology","Airway Extubation;France;Humans;Positive-Pressure Respiration;Respiration, Artificial;Ventilator Weaning","Airway Extubation;France;Humans;Positive-Pressure Respiration;Respiration, Artificial;Ventilator Weaning","In intensive care unit (ICU), the decision of extubation is a critical time because mortality is particularly high in case of reintubation. To reduce that risk, guidelines recommend to systematically perform a spontaneous breathing trial (SBT) before extubation in order to mimic the postextubation physiological conditions. SBT is usually performed with a T-piece disconnecting the patient from the ventilator or with low levels of pressure-support ventilation (PSV). However, work of breathing is lower during PSV than during T-piece. Consequently, while PSV trial may hasten extubation, it may also increase the risk of reintubation. We hypothesise that, compared with T-piece, SBT performed using PSV may hasten extubation without increasing the risk of reintubation. This study is an investigator-initiated, multicentre randomised controlled trial comparing T-piece vs PSV for SBTs in patients at high risk of reintubation in ICUs. Nine hundred patients will be randomised with a 1:1 ratio in two groups according to the type of SBT. The primary outcome is the number of ventilator-free days at day 28, defined as the number of days alive and without invasive mechanical ventilation between the initial SBT (day 1) and day 28. Secondary outcomes include the number of days between the initial SBT and the first extubation attempt, weaning difficulty, the number of patients extubated after the initial SBT and not reintubated within the following 72 hours, the number of patients extubated within the 7 days following the initial SBT, the number of patients reintubated within the 7 days following extubation, in-ICU length of stay and mortality in ICU, at day 28 and at day 90. The study has been approved by the central ethics committee 'Ile de France V' (2019-A02151-56) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. NCT04227639.","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy d'Argenteuil, Argenteuil, Île-de-France, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint-Denis, La Réunion, Réunion.;Service de Réanimation, Centre Hospitalier de Pau, Pau, Aquitaine-Limousin-Poitou, France.;Médecine intensive réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Réanimation Polyvalente, Centre Hospitalier de Bretagne Sud, Lorient, Bretagne, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, Rhône-Alpes, France.;INSERM, U1042, HP2, Université Grenoble Alpes, Saint-Martin-d'Heres, Rhône-Alpes, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Service de Réanimation Médicale, Site Emile Muller, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, Grand Est, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Département de Réanimation Médicale, Hôpital Charles Nicolle, Normandie Université, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Réanimation Médicale Archet 1, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Cote d'Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Centre de Réanimation, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, Hauts-de-France, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, Rhône-Alpes, France.;Groupe Hospitalier Paris Centre - Cochin University Hospital - Medical Intensive Care Unit, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU La Timone 2, Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Service de Réanimation, Unicancer, Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.;Service de Réanimation, Centre hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation Polyvalente, Hopital Foch, Suresnes, Île-de-France, France.;Reanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, Auvergne, France.;Service de Pneumologie, Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2020,"2020","10","10.1136/bmjopen-2020-042619","e042619","","","33234658","33234658","PUBMED","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy d'Argenteuil, Argenteuil, Île-de-France, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint-Denis, La Réunion, Réunion.;Service de Réanimation, Centre Hospitalier de Pau, Pau, Aquitaine-Limousin-Poitou, France.;Médecine intensive réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Réanimation Polyvalente, Centre Hospitalier de Bretagne Sud, Lorient, Bretagne, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, Rhône-Alpes, France.;INSERM, U1042, HP2, Université Grenoble Alpes, Saint-Martin-d'Heres, Rhône-Alpes, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Service de Réanimation Médicale, Site Emile Muller, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, Grand Est, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Département de Réanimation Médicale, Hôpital Charles Nicolle, Normandie Université, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Réanimation Médicale Archet 1, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Cote d'Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Centre de Réanimation, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, Hauts-de-France, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, Rhône-Alpes, France.;Groupe Hospitalier Paris Centre - Cochin University Hospital - Medical Intensive Care Unit, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU La Timone 2, Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Service de Réanimation, Unicancer, Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.;Service de Réanimation, Centre hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation Polyvalente, Hopital Foch, Suresnes, Île-de-France, France.;Reanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, Auvergne, France.;Service de Pneumologie, Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France."
"Curtit E;Pivot X;Henriques J;Paget-Bailly S;Fumoleau P;Rios M;Bonnefoi H;Bachelot T;Soulié P;Jouannaud C;Bourgeois H;Petit T;Tennevet I;Assouline D;Mathieu MC;Jacquin JP;Lavau-Denes S;Darut-Jouve A;Ferrero JM;Tarpin C;Lévy C;Delecroix V;Trillet-Lenoir V;Cojocarasu O;Meunier J;Pierga JY;Kerbrat P;Faure-Mercier C;Blanché H;Sahbatou M;Boland A;Bacq D;Besse C;Thomas G;Deleuze JF;Pauporté I;Romieu G;Cox DG","Curtit, Elsa;Pivot, Xavier;Henriques, Julie;Paget-Bailly, Sophie;Fumoleau, Pierre;Rios, Maria;Bonnefoi, Hervé;Bachelot, Thomas;Soulié, Patrick;Jouannaud, Christelle;Bourgeois, Hugues;Petit, Thierry;Tennevet, Isabelle;Assouline, David;Mathieu, Marie-Christine;Jacquin, Jean-Philippe;Lavau-Denes, Sandrine;Darut-Jouve, Ariane;Ferrero, Jean-Marc;Tarpin, Carole;Lévy, Christelle;Delecroix, Valérie;Trillet-Lenoir, Véronique;Cojocarasu, Oana;Meunier, Jérôme;Pierga, Jean-Yves;Kerbrat, Pierre;Faure-Mercier, Céline;Blanché, Hélène;Sahbatou, Mourad;Boland, Anne;Bacq, Delphine;Besse, Céline;Thomas, Gilles;Deleuze, Jean-François;Pauporté, Iris;Romieu, Gilles;Cox, David G","Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.","Breast cancer research : BCR","England","eng","Journal Article","Breast cancer;Genetic variant;Prognosis;Risk score;Single nucleotide polymorphism","Adult;Aged;Aged, 80 and over;Alleles;Biomarkers, Tumor;Breast Neoplasms;Clinical Trials, Phase III as Topic;Cohort Studies;Female;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Staging;Polymorphism, Single Nucleotide;Prognosis;Randomized Controlled Trials as Topic;Survival Analysis;Tumor Burden;Young Adult","Adult;Aged;Aged, 80 and over;Alleles;Biomarkers, Tumor;Breast Neoplasms;Clinical Trials, Phase III as Topic;Cohort Studies;Female;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Staging;Polymorphism, Single Nucleotide;Prognosis;Randomized Controlled Trials as Topic;Survival Analysis;Tumor Burden;Young Adult","Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer. A 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS. The median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1-97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival. In a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients' outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis. PHARE cohort: NCT00381901 , Sept. 26, 2006 - SIGNAL cohort: INCa RECF1098, Jan. 28, 2009.","Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon;Department of Medical Oncology, University Hospital Jean Minjoz, 3, boulevard Alexandre Fleming, 25030, Besancon Cedex;Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Georges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France.;Institut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France.;Institut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Centre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France.;Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France.;Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France.;Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France.;Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.;Centre Henri Becquerel, rue d'Amiens, 76038, Rouen, France.;Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France.;Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.;Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France.;Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France.;Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France.;Centre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France.;Institut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Centre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France.;Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France.;Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France.;Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France.;Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France.;Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France.;Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Oncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France.;Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France.","NA",0,"1465-542X","Breast Cancer Res","Breast Cancer Res",2016,"2017","19","10.1186/s13058-017-0888-4","98","","","28830573","28830573","PUBMED","Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon;Department of Medical Oncology, University Hospital Jean Minjoz, 3, boulevard Alexandre Fleming, 25030, Besancon Cedex;Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Georges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France.;Institut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France.;Institut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Centre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France.;Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France.;Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France.;Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France.;Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.;Centre Henri Becquerel, rue d'Amiens, 76038, Rouen, France.;Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France.;Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.;Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France.;Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France.;Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France.;Centre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France.;Institut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Centre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France.;Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France.;Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France.;Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France.;Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France.;Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France.;Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Oncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France.;Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France."
"Ducray F;Ramirez C;Robert M;Fontanilles M;Bronnimann C;Chinot O;Estrade F;Durando X;Cartalat S;Bastid J;Bienayme H;Lemarchand C","Ducray, François;Ramirez, Carole;Robert, Marie;Fontanilles, Maxime;Bronnimann, Charlotte;Chinot, Olivier;Estrade, Florian;Durando, Xavier;Cartalat, Stéphanie;Bastid, Jeremy;Bienayme, Hugues;Lemarchand, Caroline","A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.","Pharmaceutics","Switzerland","eng","Journal Article","bioequivalence;oral suspension;pediatric formulation;temozolomide","","","Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO ) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed the safety and the bioequivalence of this novel pediatric formulation with existing TMZ oral capsules. In vitro dissolution profiles and the bioequivalence were evaluated following the European Medicines Agency ""Guidelines on the investigation of Bioequivalence"". The phase I, multicenter, randomized, open-label, crossover, single-dose bioequivalence study enrolled 36 adult patients with glioblastoma multiforme or lower-grade glioma. Each patient received 200 mg/m  Ped-TMZ suspension and TMZ capsules (Temodal ) on 2 consecutive days, with the order being randomly assigned. Fourteen blood samples were collected up to 10 h post-dosing. Bioequivalence was assessed by comparing the 90% confidence interval for the ratio of the geometric means of maximum TMZ plasma concentration (C ) and the area under the curve (AUCt). Other endpoints included further pharmacokinetic parameters and safety. Both formulations exhibited a fast in vitro dissolution profile with more than 85% of TMZ dissolved within 15 min. For the bioequivalence study, thirty patients completed the trial as per the protocol. The ratio of Ped-TMZ/TMZ capsule geometric means (90% CI) for AUCt and C  were 97.18% (95.05-99.35%) and 107.62% (98.07-118.09%), respectively, i.e., within the 80-125% bioequivalence limits. No buccal toxicity was associated with Ped-TMZ liquid formulation. This study showed that Ped-TMZ oral suspension and TMZ oral capsule treatment are immediate release and bioequivalent medicines. There were also no unexpected safety signals or local toxicity (funded by ORPHELIA Pharma; ClinicalTrials.gov number, NCT04467346).","Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Services de Neurologie et D'oncologie Médicale, CHU et ICHUSE de Saint-Etienne, 42055 Saint-Etienne, France.;Institut de Cancérologie de l'Ouest, Medical Oncology, 44800 Saint Herblain, France.;INSERM U1245 Unit, Cancer Centre Henri Becquerel, Université Rouen Normandie, 76038 Rouen, France.;Le Havre Hospital Group, 76083 Le Havre, France.;CHU de Bordeaux, Service D'oncologie Médicale, Hôpital Saint André, 33075 Bordeaux, France.;Aix-Marseille Université, Neuro-Oncology Department, APHM, CNRS, Institut de Neurophysiopathologie, CHU Timone, Service de Neuro-Oncologie, 13385 Marseille, France.;Centre Eugène Marquis, 35042 Rennes, France.;INSERM U1240 IMoST, University of Clermont Auvergne, 63001 Clermont-Ferrand, France.;UMR 501, Clinical Investigation Centre, 63011 Clermont-Ferrand, France.;Clinical Research and Innovation Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Oncology Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.","NA",0,"1999-4923","Pharmaceutics","Pharmaceutics",2023,"2023","15","10.3390/pharmaceutics15122664",NA,"N/A","Orphelia Pharma (France)","38140005","38140005","PUBMED","Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Services de Neurologie et D'oncologie Médicale, CHU et ICHUSE de Saint-Etienne, 42055 Saint-Etienne, France.;Institut de Cancérologie de l'Ouest, Medical Oncology, 44800 Saint Herblain, France.;INSERM U1245 Unit, Cancer Centre Henri Becquerel, Université Rouen Normandie, 76038 Rouen, France.;Le Havre Hospital Group, 76083 Le Havre, France.;CHU de Bordeaux, Service D'oncologie Médicale, Hôpital Saint André, 33075 Bordeaux, France.;Aix-Marseille Université, Neuro-Oncology Department, APHM, CNRS, Institut de Neurophysiopathologie, CHU Timone, Service de Neuro-Oncologie, 13385 Marseille, France.;Centre Eugène Marquis, 35042 Rennes, France.;INSERM U1240 IMoST, University of Clermont Auvergne, 63001 Clermont-Ferrand, France.;UMR 501, Clinical Investigation Centre, 63011 Clermont-Ferrand, France.;Clinical Research and Innovation Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Oncology Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France."
"Bettuzzi T;Jourdes A;Robineau O;Alcaraz I;Manda V;Molina JM;Mehlen M;Cazanave C;Tattevin P;Mensi S;Terrier B;Régent A;Ghosn J;Charlier C;Martin-Blondel G;Dupin N","Bettuzzi, Thomas;Jourdes, Aurélie;Robineau, Olivier;Alcaraz, Isabelle;Manda, Victoria;Molina, Jean Michel;Mehlen, Maxime;Cazanave, Charles;Tattevin, Pierre;Mensi, Sami;Terrier, Benjamin;Régent, Alexis;Ghosn, Jade;Charlier, Caroline;Martin-Blondel, Guillaume;Dupin, Nicolas","Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study.","The Lancet. Infectious diseases","United States","eng","Journal Article","","Adult;Anti-Bacterial Agents;Ceftriaxone;Female;France;Humans;Male;Middle Aged;Neurosyphilis;Penicillin G;Retrospective Studies;Treatment Outcome","Adult;Anti-Bacterial Agents;Ceftriaxone;Female;France;Humans;Male;Middle Aged;Neurosyphilis;Penicillin G;Retrospective Studies;Treatment Outcome","Intravenous benzylpenicillin is the gold-standard treatment for neurosyphilis, but it requires prolonged hospitalisation. Ceftriaxone is a possible alternative treatment, the effectiveness of which remains unclear. We aimed to assess the effectiveness of ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis. We did a retrospective multicentre study including patients with neurosyphilis who were treated at one of eight tertiary care centres in France, from Jan 1, 1997, to Dec 31, 2017. We defined neurosyphilis as positive treponemal and non-treponemal tests and at least one of otic syphilis, ocular syphilis, either neurological symptom with a positive result on cerebrospinal fluid (CSF)-VDRL or CSF-PCR tests, or more than five leukocytes in a CSF cell count. Patients with neurosyphilis were identified from the medical information department database of each centre and assigned to one of two groups on the basis of the initial treatment received (ie, benzylpenicillin group or ceftriaxone group). The primary outcome was the overall clinical response (ie, proportion of patients with a complete or partial response) 1 month after treatment initiation. The secondary endpoints were proportions of patients with a complete response at 1 month and serological response at 6 months, and length of hospital stay. Of 365 patients with a coded diagnosis of neurosyphilis in one of the eight care centres during 1997-2017, 208 were included in this study (42 in the ceftriaxone group and 166 in the benzylpenicillin group). The mean age of patients was 44·4 years (SD 13·4), and 193 (93%) were men. We observed 41 instances of overall clinical response (98%) in the ceftriaxone group versus 125 (76%) in the benzylpenicillin group (crude odds ratio [OR] 13·02 [95% CI 1·73-97·66], p=0·017). After propensity score weighting, overall clinical response rates remained different between the groups (OR 1·22 [95% CI 1·12-1·33], p<0·0001). 22 (52%) patients in the ceftriaxone group and 55 (33%) in the benzylpenicillin group had a complete response (crude OR 2·26 [95% CI 1·12-4·41], p=0·031), with no significant difference after propensity score weighting (OR 1·08 [95% CI 0·94-1·24], p=0·269). Serological response at 6 months did not differ between the groups (21 [88%] of 24 in the ceftriaxone group vs 76 [82%] of 93 in the benzylpenicillin group; crude OR 1·56 [95% CI 0·42-5·86], p=0·50), whereas hospital stay was shorter for patients in the ceftriaxone group than for those in the benzylpenicillin group (mean 13·8 days [95% CI 12·8-14·8] vs 8·9 days [5·7-12·0], p<0·0001). No major adverse effects were reported in either group. Our results suggest that ceftriaxone is similarly effective to benzylpenicillin for the treatment of neurosyphilis, potentially decreasing the length of hospital stay. Randomised, controlled trials should be done to confirm these results. None.","Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; EpiDermE, University Paris Est Créteil, Créteil, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Maladies Infectieuses, Hôpital Bichat, AP-HP, Paris, France.;Université de Paris, Paris, France; Service de Maladies Infectieuses, Hôpital Necker, AP-HP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; INSERM UMR 1291 - CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases, Université Toulouse III, Toulouse, France.;Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Centre National de Référence de la Syphilis, Institut Cochin, Unité Inserm U1016, Université de Paris, Paris","NA",0,"1474-4457","Lancet Infect Dis","Lancet Infect Dis",2020,"2021","21","10.1016/S1473-3099(20)30857-4","1441-1447","","","34051142","34051142","PUBMED","Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; EpiDermE, University Paris Est Créteil, Créteil, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Maladies Infectieuses, Hôpital Bichat, AP-HP, Paris, France.;Université de Paris, Paris, France; Service de Maladies Infectieuses, Hôpital Necker, AP-HP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; INSERM UMR 1291 - CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases, Université Toulouse III, Toulouse, France.;Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Centre National de Référence de la Syphilis, Institut Cochin, Unité Inserm U1016, Université de Paris, Paris"
"Sanchis-Borja M;Ricordel C;Chiappa AM;Hureaux J;Odier L;Jeannin G;Descourt R;Gervais R;Monnet I;Auliac JB;Chouaïd C","Sanchis-Borja, Mateo;Ricordel, Charles;Chiappa, Anne Marie;Hureaux, José;Odier, Luc;Jeannin, Gaelle;Descourt, Renaud;Gervais, Radj;Monnet, Isabelle;Auliac, Jean-Bernard;Chouaïd, Christos","Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.","Lung cancer (Amsterdam, Netherlands)","Ireland","eng","Journal Article","Encephalitis;Immunotherapy;Lung cancer;Management","Aged;Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Encephalitis;Female;Follow-Up Studies;Humans;Immunotherapy;Lung Neoplasms;Male;Middle Aged;Prognosis;Retrospective Studies","Aged;Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Encephalitis;Female;Follow-Up Studies;Humans;Immunotherapy;Lung Neoplasms;Male;Middle Aged;Prognosis;Retrospective Studies","Using immune-checkpoint inhibitors (ICIs) to manage cancer is associated with various immune-related adverse events. Central and/or peripheral neurological disorders are rare and potentially serious. We analyzed the characteristics of non-small-cell lung cancer (NSCLC) patients who developed immune-related encephalitis under anti-programmed-death protein-1 or its ligand (PD-1/PD-L1). Clinical, biological and radiological characteristics of ICI-treated NSCLC patients with immune-related encephalitis, from 6 centers, were evaluated retrospectively. The 6 centers included 9 patients: all men, all smokers, median (range) age 67 (48-77) years, 78% adenocarcinomas, first- or second-line ICI for 5 and 4 patients, respectively. Two patients had non-active cerebral metastases at ICI onset. A median of 5 (1-22) ICI infusions preceded neurological symptoms, the most frequent being confusion (78%), fever (45%) and cerebellar ataxia (33%). CSF analyses revealed a median white blood cell count of 22/mm  (1-210/mm ), with hyperlymphocytosis in 8 patients and high protein levels in all. All bacteriological and virological analyses were negative. Cerebral MRI was considered normal for 5 patients; 4 patients had FLAIR hypersignals consistent with brain parenchyma inflammation. Three patients required intensive care. All patients received corticosteroids (different doses), a median of 8.5 (6-18) days post-onset. Corticosteroids achieved rapid symptom regression without sequelae in 8 patients. The last patient, with the longest time until corticosteroid introduction, died. ICIs were never restarted in any patient. Immune encephalitis, a rare but serious complication of anti-PD-1/PD-L1 therapy, carries a good prognosis when managed with early corticosteroids.","Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Centre Hospitalier de Cornouailles, Quimper, France.;Service de Pneumologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Pneumologie, Centre Hospitalier de Villefranche-sur-Soane, Villefranche-sur-Soane, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Oncologie, Centre Anti-Cancéreux François-Baclesse, Caen, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.","NA",0,"1872-8332","Lung Cancer","Lung Cancer",2019,"2020","143","10.1016/j.lungcan.2020.03.006","36-39","","","32200139","32200139","PUBMED","Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Centre Hospitalier de Cornouailles, Quimper, France.;Service de Pneumologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Pneumologie, Centre Hospitalier de Villefranche-sur-Soane, Villefranche-sur-Soane, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Oncologie, Centre Anti-Cancéreux François-Baclesse, Caen, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France."
"Edeline J;Hirano S;Bertaut A;Konishi M;Benabdelghani M;Uesaka K;Watelet J;Ohtsuka M;Hammel P;Kaneoka Y;Joly JP;Yamamoto M;Monard L;Ambo Y;Louvet C;Ando M;Malka D;Nagino M;Phelip JM;Ebata T","Edeline, Julien;Hirano, Satoshi;Bertaut, Aurélie;Konishi, Masaru;Benabdelghani, Meher;Uesaka, Katsuhiko;Watelet, Jérôme;Ohtsuka, Masayuki;Hammel, Pascal;Kaneoka, Yuji;Joly, Jean-Paul;Yamamoto, Masakazu;Monard, Laure;Ambo, Yoshiyasu;Louvet, Christophe;Ando, Masahiko;Malka, David;Nagino, Masato;Phelip, Jean-Marc;Ebata, Tomoki","Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Adjuvant treatment;Biliary tract cancer;Chemotherapy;Cholangiocarcinoma;Gemcitabine","Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Deoxycytidine;Humans;Neoplasm Recurrence, Local;Randomized Controlled Trials as Topic;Gemcitabine","Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Deoxycytidine;Humans;Neoplasm Recurrence, Local;Randomized Controlled Trials as Topic;Gemcitabine","Although gemcitabine-based chemotherapy is the standard of care for advanced biliary tract cancers (BTCs), adjuvant phase III studies (BCAT in Japan, PRODIGE 12 in France) failed to show benefit, possibly owing to fewer patients (n = 225 and n = 194) compared with the adjuvant capecitabine BILCAP trial (n = 447). We performed a combined analysis of both gemcitabine-based chemotherapy adjuvant studies. We performed individual patient data meta-analysis of all patients included in BCAT and PRODIGE 12. BCAT study randomised patients with extrahepatic cholangiocarcinoma to single-agent gemcitabine or observation. PRODIGE 12 randomised patients with all BTC subtypes to gemcitabine-oxaliplatin combination or observation. Combined analysis was performed using Kaplan-Meier curves and a Cox regression model stratified on the trial. Two hundred and twelve versus 207 patients were randomised in the gemcitabine-based chemotherapy versus observation arms. Baseline characteristics were balanced between arms. The median follow-up was 5.5 years. After 258 relapse-free survival (RFS) events, there was no difference in RFS (log-rank p = 0.45; hazard ratio [HR] = 0.91 [95% confidence interval [CI] 0.71-1.16]; p = 0.46). RFS rates at five years were 40.8% (95%CI: 33.9%-47.5%) for gemcitabine-based chemotherapy versus 36.6% (95%CI: 29.8%-43.4%) for observation. After 201 deaths, there was no difference in overall survival (OS) (log-rank p = 0.83; HR = 1.03 [95%CI: 0.78-1.35]; p = 0.85). OS rates at five years were 50.5% (95%CI: 43.1%-57.4%) for gemcitabine-based chemotherapy versus 49.3% (95%CI: 41.6%-56.5%) for observation. With 419 patients included, this analysis did not show significant improvement in RFS and no trend in improvement in OS. Gemcitabine-based chemotherapy should not be used as an adjuvant treatment for BTC.","Medical Oncology, Centre Eugène Marquis, av de la bataille Flandres-Dunkerque, 35042 Rennes;Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo;Methodology and Biostatistics Unit, Centre Georges-François Leclerc, Dijon;Department of Hepatobiliary-Pancreatic Surgery, National Cancer Centre Hospital East, Kashiwa;Centre Paul Strauss, Strasbourg;Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, Shizuoka;CHU Brabois, Vondoeuvre les Nancy;Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba;AP-HP hôpital Beaujon, Clichy;Department of Surgery, Ogaki Municipal Hospital, Ogaki;CHU Nord, Amiens;Department of Surgery, Institute of Gastroenterology, TokyoWomen's Medical University, Tokyo;Unicancer, Paris;Department of Surgery, Teine-Keijinkai Hospital, Sapporo;Institut Mutualiste Montsouris, Paris;Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya;Gustave Roussy, Villejuif;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine;CHU St Etienne, St Etienne;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","164","10.1016/j.ejca.2022.01.009","80-87","","","35182925","35182925","PUBMED","Medical Oncology, Centre Eugène Marquis, av de la bataille Flandres-Dunkerque, 35042 Rennes;Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo;Methodology and Biostatistics Unit, Centre Georges-François Leclerc, Dijon;Department of Hepatobiliary-Pancreatic Surgery, National Cancer Centre Hospital East, Kashiwa;Centre Paul Strauss, Strasbourg;Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, Shizuoka;CHU Brabois, Vondoeuvre les Nancy;Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba;AP-HP hôpital Beaujon, Clichy;Department of Surgery, Ogaki Municipal Hospital, Ogaki;CHU Nord, Amiens;Department of Surgery, Institute of Gastroenterology, TokyoWomen's Medical University, Tokyo;Unicancer, Paris;Department of Surgery, Teine-Keijinkai Hospital, Sapporo;Institut Mutualiste Montsouris, Paris;Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya;Gustave Roussy, Villejuif;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine;CHU St Etienne, St Etienne;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine"
"Faron M;Cheugoua-Zanetsie M;Tierney J;Thirion P;Nankivell M;Winter K;Yang H;Shapiro J;Vernerey D;Smithers BM;Walsh T;Piessen G;Nilsson M;Boonstra J;Ychou M;Law S;Cunningham D;de Vathaire F;Stahl M;Urba S;Valmasoni M;Williaume D;Thomas J;Lordick F;Tepper J;Roth J;Gebski V;Burmeister B;Paoletti X;van Sandick J;Fu J;Pignon JP;Ducreux M;Michiels S","Faron, Matthieu;Cheugoua-Zanetsie, Maurice;Tierney, Jayne;Thirion, Pierre;Nankivell, Matthew;Winter, Kathryn;Yang, Hong;Shapiro, Joel;Vernerey, Dewi;Smithers, B Mark;Walsh, Thomas;Piessen, Guillaume;Nilsson, Magnus;Boonstra, Jurjen;Ychou, Marc;Law, Simon;Cunningham, David;de Vathaire, Florent;Stahl, Michael;Urba, Susan;Valmasoni, Michele;Williaume, Danièle;Thomas, Janine;Lordick, Florian;Tepper, Joel;Roth, Jack;Gebski, Val;Burmeister, Bryan;Paoletti, Xavier;van Sandick, Johanna;Fu, Jianhua;Pignon, Jean-Pierre;Ducreux, Michel;Michiels, Stefan","Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Meta-Analysis","","Female;Humans;Carcinoma;Chemoradiotherapy;Chemotherapy, Adjuvant;Esophageal Neoplasms;Esophagogastric Junction;Neoadjuvant Therapy;Randomized Controlled Trials as Topic;Male","Female;Humans;Carcinoma;Chemoradiotherapy;Chemotherapy, Adjuvant;Esophageal Neoplasms;Esophagogastric Junction;Neoadjuvant Therapy;Randomized Controlled Trials as Topic;Male","The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158). IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99),   = .03 and HR = 0.77 (0.68 to 0.87),   < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09),   = .27 (consistency   = .26, heterogeneity   = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (  = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (  = .003, .012, respectively). Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.","Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;St Luke Hospital, Dublin, Ireland.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Erasmus University Medical Center, Rotterdam, the Netherlands.;CHRU Jean Minjoz, Besançon, France.;University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.;Connolly Hospital Blanchardstown, Dublin, Ireland.;CHU de Lille, Lille, France.;Division of Surgery, Department of Clinical Science, Intervention and Technoglogy, Karolinska Institutet, Stockholm, Sweden.;Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.;Leiden University Medical Center, Leiden, the Netherlands.;Val d'Aurelles, Montpellier, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, United Kingdom.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Evang. Kliniken Essen-Mitte, Essen, Germany.;University of Michigan, Ann Arbor, MI.;Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Center for Esophageal Diseases, Padova, Italy.;Centre Eugène Marquis, Rennes, France.;Princess Alexandra Hospital, Woolloongabba, Australia.;University of Leipzig, Leipzig, Germany.;University of North Carolina School of Medicine, Chapel Hill, NC.;MD Anderson, Houston, TX.;NHMRC, Sydney, Australia.;Princess Alexandra Hospital, Woolloongabba, Australia.;Institut Curie, Paris, France.;The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Departement d'Oncologie Médicale, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2023,"2023","41","10.1200/JCO.22.02279","4535-4547","MC_UU_00004/06;MC_UU_12023/20","Medical Research Council;Medical Research Council","37467395","37467395","PUBMED","Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;St Luke Hospital, Dublin, Ireland.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Erasmus University Medical Center, Rotterdam, the Netherlands.;CHRU Jean Minjoz, Besançon, France.;University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.;Connolly Hospital Blanchardstown, Dublin, Ireland.;CHU de Lille, Lille, France.;Division of Surgery, Department of Clinical Science, Intervention and Technoglogy, Karolinska Institutet, Stockholm, Sweden.;Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.;Leiden University Medical Center, Leiden, the Netherlands.;Val d'Aurelles, Montpellier, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, United Kingdom.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Evang. Kliniken Essen-Mitte, Essen, Germany.;University of Michigan, Ann Arbor, MI.;Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Center for Esophageal Diseases, Padova, Italy.;Centre Eugène Marquis, Rennes, France.;Princess Alexandra Hospital, Woolloongabba, Australia.;University of Leipzig, Leipzig, Germany.;University of North Carolina School of Medicine, Chapel Hill, NC.;MD Anderson, Houston, TX.;NHMRC, Sydney, Australia.;Princess Alexandra Hospital, Woolloongabba, Australia.;Institut Curie, Paris, France.;The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Departement d'Oncologie Médicale, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France."
"Blay JY;Devin Q;Duffaud F;Toulmonde M;Firmin N;Collard O;Bompas E;Verret B;Ray-Coquard I;Salas S;Henon C;Honoré C;Brahmi M;Dufresne A;Pracht M;Hervieu A;Penel N;Bertucci F;Rios M;Saada-Bouzid E;Soibinet P;Perol D;Chabaud S;Italiano A;Cesne AL","Blay, Jean-Yves;Devin, Quentin;Duffaud, Florence;Toulmonde, Maud;Firmin, Nelly;Collard, Olivier;Bompas, Emmanuelle;Verret, Benjamin;Ray-Coquard, Isabelle;Salas, Sebastien;Henon, Clemence;Honoré, Charles;Brahmi, Mehdi;Dufresne, Armelle;Pracht, Marc;Hervieu, Alice;Penel, Nicolas;Bertucci, Francois;Rios, Maria;Saada-Bouzid, Esma;Soibinet, Pauline;Perol, David;Chabaud, Sylvie;Italiano, Antoine;Cesne, Axel Le","Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.","The Lancet. Oncology","England","eng","Journal Article","","Humans;Gastrointestinal Stromal Tumors;Imatinib Mesylate;Male;Female;Middle Aged;Aged;Follow-Up Studies;Protein Kinase Inhibitors;Antineoplastic Agents;France;Gastrointestinal Neoplasms;Progression-Free Survival;Adult;Time Factors;Drug Resistance, Neoplasm;Withholding Treatment;Drug Administration Schedule","Humans;Gastrointestinal Stromal Tumors;Imatinib Mesylate;Male;Female;Middle Aged;Aged;Follow-Up Studies;Protein Kinase Inhibitors;Antineoplastic Agents;France;Gastrointestinal Neoplasms;Progression-Free Survival;Adult;Time Factors;Drug Resistance, Neoplasm;Withholding Treatment;Drug Administration Schedule","The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial. BFR14, an open-label, randomised, phase 3 trial, was done in 17 comprehensive cancer centres or hospitals across France. Patients with advanced GIST aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-3, no previous treatment with imatinib, and no previous malignancy were eligible. Patients were treated with oral imatinib 400 mg daily. Patients with a complete or partial response, or stable disease, according to Response Evaluation Criteria in Solid Tumours (1.0) at 1 year, 3 years, and 5 years from the start of treatment were randomly assigned (1:1) to treatment discontinuation until progression (interruption group) or treatment continuation until progression (continuation group). Randomisation was done centrally with computer-generated permuted blocks of two and six patients stratified by participating centre and presence or absence of residual disease on CT scan. The primary endpoint was progression-free survival. Secondary endpoints included time to imatinib resistance and overall survival. Analyses were conducted on an intention-to-treat basis in all randomly assigned patients who were not lost to follow-up. This trial is registered with ClinicalTrial.gov, NCT00367861. Between May 12, 2003, and March 16, 2004, after 1 year of imatinib, 32 patients were randomly assigned to the interruption group and 26 to the continuation group. Between June 13, 2005, and May 30, 2007, after 3 years of imatinib, 25 patients were randomly assigned to the interruption group and 25 to the continuation group. Between Nov 9, 2007, and July 12, 2010, after 5 years of imatinib, 14 patients were randomly assigned to the interruption group and 13 to the continuation group. Median follow-up was 235·2 months (IQR 128·8-236·6) after the 1-year randomisation, 200·9 months (190·2-208·4) after the 3-year randomisation, and 164·5 months (134·4-176·4) after the 5-year randomisation. Median progression-free survival in the interruption group versus the continuation group after 1 year of imatinib was 6·1 months (95% CI 2·5-10·1) versus 27·8 months (19·5-37·9; hazard ratio [HR] 0·36 [95% CI 0·20-0·64], log-rank p=0·0003), after 3 years of imatinib was 7·0 months (3·5-11·7) versus 67·0 months (48·8-85·6; 0·15 [0·07-0·32], log-rank p<0·0001), and after 5 years of imatinib was 12·0 months (9·0-16·6) versus not reached (NR; NR-NR; 0·13 [0·03-0·58], log-rank p=0·0016). The median time to imatinib resistance after 1 year of imatinib was 28·7 months (95% CI 18·1-39·1) versus 90·6 months (25·3-156·1; HR 0·93 [95% CI 0·51-1·71], log-rank p=0·82), after 3 years was 66·2 months (43·0-89·6) versus 127·3 months (15·0-239·7; 0·35 [0·17-0·72, log-rank p=0·0028), and after 5 years was 58·6 months (0·0-167·4) versus NR (NR-NR; 0·24 [0·05-1·12], log-rank p=0·049). Median overall survival after 1 year of imatinib was 56·0 months (95% CI 30·3-82·9) versus 105·0 months (20·6-189·6; HR 0·84 [95% CI 0·46-1·54], log-rank p=0·57), after 3 years was 104·0 months (90·7-118·7) versus 134·0 months (89·7-178·3; 0·40 [0·20-0·82], log-rank p=0·0096), and after 5 years was NR (NR-NR) versus 110·4 months (82·7-154·1; 1·28 [0·41-3·99]; log-rank p=0·67), INTERPRETATION: Imatinib interruption in patients with GIST without progressive disease is not recommended. Imatinib interruption in non-progressing patients with GIST was associated with rapid progression, faster resistance to imatinib, and shorter overall survival in the long-term follow-up when compared with imatinib continuation in patients after 3 years and 5 years of imatinib. Centre Léon Bérard, INCa, CONTICANET, Ligue Contre le Cancer, and Novartis.","Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologi Val d'Aurelle, Montpellier, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Hopitaux Privés de la Loire, St Etienne, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Hopitaux Privés de la Loire, St Etienne, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Eugene Marquis, Rennes, France.;Centre George-François Leclerc, Dijon, France.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Gustave Roussy, Villejuif, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2024","25","10.1016/S1470-2045(24)00318-8","1163-1175","","","39127063","39127063","PUBMED","Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologi Val d'Aurelle, Montpellier, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Hopitaux Privés de la Loire, St Etienne, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Hopitaux Privés de la Loire, St Etienne, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Eugene Marquis, Rennes, France.;Centre George-François Leclerc, Dijon, France.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Gustave Roussy, Villejuif, France."
"Demoor-Goldschmidt C;Veillon P;Esvan M;Leonard M;Chauvet S;Bertrand A;Carausu L;Delehaye F;Lejeune J;Rouger J;Schneider P;Thomas C;Millot F;Claude L;Leseur J;Missohou F;Supiot S;Bihannic N;Debroise I;Jeanneaud C;Lebreton E;Roumy M;Aguerris L;Chrétien JM;Gandemer V;Pellier I","Demoor-Goldschmidt, Charlotte;Veillon, Pascal;Esvan, Maxime;Leonard, Mathilde;Chauvet, Sophie;Bertrand, Amandine;Carausu, Liana;Delehaye, Fanny;Lejeune, Julien;Rouger, Jérémie;Schneider, Pascale;Thomas, Caroline;Millot, Frédéric;Claude, Line;Leseur, Julie;Missohou, Fernand;Supiot, Stéphane;Bihannic, Nathalie;Debroise, Isabelle;Jeanneaud, Carole;Lebreton, Esther;Roumy, Marianne;Aguerris, Les;Chrétien, Jean-Marie;Gandemer, Virginie;Pellier, Isabelle","A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility.","BMC cancer","England","eng","Journal Article","Adolescent cancer;Chemotherapy;Childhood cancer;Database;Medical tool;Personalized survivorship care plan;Radiotherapy;Survivorship","Child;Humans;Adolescent;Aftercare;Feasibility Studies;Quality of Life;Retrospective Studies;Neoplasms;Software","Child;Humans;Adolescent;Aftercare;Feasibility Studies;Quality of Life;Retrospective Studies;Neoplasms;Software","Treatment summaries and a personalized survivorship care plans based on internationally approved, organ-specific follow-up care recommendations are essential in preserving the health and quality of life for cancer survivors. Cohorts made up of survivors of childhood cancer have made significant contributions to the understanding of early mortality, somatic late complications, and psychosocial outcomes among former patients. New treatment protocols are needed to enhance survival and reduce the potential risk and severity of late effects, and working with treatment databases is crucial in doing so. In the GOCE (Grand Ouest Cancer de l'Enfant [Western Region Childhood Cancer]) network, in a participative approach, we developed the LOG-after medical tool, on which health data are registered and can be extracted for analysis. Its name emphasizes the tool's goal, referring to 'logiciel' (the French word for software) that focuses on the period ""after"" the acute phase. This tool is hosted on a certified health data server. Several interfaces have been developed that can be used depending on the user's profile. Here we present this innovative co-constructed tool that takes national aspects into account, including the results of the feasibility/satisfaction study and its perspective. The database contains data relating to 2558 patients, with samples from 1702 of these (66.54%) being held in a tumor bank. The average year in which treatment started was 2015 (ranging from December 1967 to November 2022: 118 patients were treated before 2012 and registered retrospectively when seen in long-term follow-up consultations or for another cancer since November 2021). A short questionnaire was distributed to healthcare professionals using the tool (physicians and research associates or technicians, n = 14), of whom 11 answered and were all satisfied. Access to the patient interface is currently open to 124 former patients. This was initially offered to 30 former patients who were over 15 years old, affected by the disease within the last 5 years, and had agreed to test it. Their opinions were collected by their doctor by e-mail, telephone, or during a consultation in an open-ended question and a non-directive interview. All patients were satisfied with the tool, with interest in testing it in the long term. Some former patients found that the tool provided them with some ease of mind; one, for instance, commented: ""I feel lighter. I allow myself to forget. I know I will get a notification when the time comes."" Freely available to all users, LOG-after: (1) provides help with determining personalized survivorship care plans for follow-up; (2) builds links with general practitioners; (3) empowers the patient; and (4) enables health data to be exported for analysis. Database URL for presentation: https://youtu.be/2Ga64iausJE.","Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen;Department of Supportive Care, Centre François Baclesse, University of Caen, Caen;Inserm U 1018, Epidemiology of Radiation, Gustave Roussy, Villejuif;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, IHope, Lyon, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Rouen, Rouen, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Poitiers, Poitiers, France.;Department of Radiotherapy, Centre Leon Berard, Lyon, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen, France.;Department of Radiotherapy, Institut de Cancérologie de L'Ouest, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Association Les Aguerris, Paris, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Association Les Aguerris, Paris, France.;Data Science Department, Clinical and Innovation Direction, CHU Angers, Angers, France.;Department of Oncohematopediatrics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2023,"2024","24","10.1186/s12885-024-11857-y","130","","","38267891","38267891","PUBMED","Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen;Department of Supportive Care, Centre François Baclesse, University of Caen, Caen;Inserm U 1018, Epidemiology of Radiation, Gustave Roussy, Villejuif;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, IHope, Lyon, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Rouen, Rouen, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Poitiers, Poitiers, France.;Department of Radiotherapy, Centre Leon Berard, Lyon, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen, France.;Department of Radiotherapy, Institut de Cancérologie de L'Ouest, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Association Les Aguerris, Paris, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Association Les Aguerris, Paris, France.;Data Science Department, Clinical and Innovation Direction, CHU Angers, Angers, France.;Department of Oncohematopediatrics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France."
"Charpentier P;Mouriaux F","Charpentier, Pierre;Mouriaux, Frederic","Total recovery of optic nerve sheath meningioma.","BMJ case reports","England","eng","Case Reports","","Adult;Diagnosis, Differential;Dose Fractionation, Radiation;Female;Humans;Magnetic Resonance Imaging;Meningioma;Optic Nerve Neoplasms;Radiotherapy, Intensity-Modulated;Recovery of Function;Visual Acuity;Visual Fields","Adult;Diagnosis, Differential;Dose Fractionation, Radiation;Female;Humans;Magnetic Resonance Imaging;Meningioma;Optic Nerve Neoplasms;Radiotherapy, Intensity-Modulated;Recovery of Function;Visual Acuity;Visual Fields","We reported the case of a 43-year-old woman with a rapid progressive visual loss. The diagnosis of primary optic nerve sheath meningioma was made thanks to atypia evolution, clinical and radiological findings. The patient was treated with an intensity-modulated radiotherapy of 50.4 Gy in 28 fractions 2 months after the diagnosis. Visual acuity and visual field were completely recovered after 2 years of follow-up. No late side effects of irradiation were recorded.","Centre Hospitalier Universitaire de Rennes, ille et Vilaine, Rennes, Catalunya, Girona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2016,"2016","2016","10.1136/bcr-2016-215532",NA,"","","27769976","27769976","PUBMED","Centre Hospitalier Universitaire de Rennes, ille et Vilaine, Rennes, Catalunya, Girona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France."
"Beaumont J;Acosta O;Devillers A;Palard-Novello X;Chajon E;de Crevoisier R;Castelli J","Beaumont, J;Acosta, O;Devillers, A;Palard-Novello, X;Chajon, E;de Crevoisier, R;Castelli, J","Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers.","EJNMMI research","Germany","eng","Journal Article","Locally advanced head and neck cancers;Radiomics;Radiotherapy;Recurrence prediction;Voxel-based analysis","","","Overall, 40% of patients with a locally advanced head and neck cancer (LAHNC) treated by chemoradiotherapy (CRT) present local recurrence within 2 years after the treatment. The aims of this study were to characterize voxel-wise the sub-regions where tumor recurrence appear and to predict their location from pre-treatment  F-fluorodeoxyglucose (FDG) positron emission tomography (PET) images. Twenty-six patients with local failure after treatment were included in this study. Local recurrence volume was identified by co-registering pre-treatment and recurrent PET/CT images using a customized rigid registration algorithm. A large set of voxel-wise features were extracted from pre-treatment PET to train a random forest model allowing to predict local recurrence at the voxel level. Out of 26 expert-assessed registrations, 15 provided enough accuracy to identify recurrence volumes and were included for further analysis. Recurrence volume represented on average 23% of the initial tumor volume. The MTV with a threshold of 50% of SUVmax plus a 3D margin of 10 mm covered on average 89.8% of the recurrence and 96.9% of the initial tumor. SUV and MTV alone were not sufficient to identify the area of recurrence. Using a random forest model, 15 parameters, combining radiomics and spatial location, were identified, allowing to predict the recurrence sub-regions with a median area under the receiver operating curve of 0.71 (range 0.14-0.91). As opposed to regional comparisons which do not bring enough evidence for accurate prediction of recurrence volume, a voxel-wise analysis of FDG-uptake features suggested a potential to predict recurrence with enough accuracy to consider tailoring CRT by dose escalation within likely radioresistant regions.","Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes","NA",0,"2191-219X","EJNMMI Res","EJNMMI Res",2019,"2019","9","10.1186/s13550-019-0556-z","90","","","31535233","31535233","PUBMED","Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes"
"de Hoog S;Walsh TJ;Ahmed SA;Alastruey-Izquierdo A;Alexander BD;Arendrup MC;Babady E;Bai F-Y;Balada-Llasat J-M;Borman A;Chowdhary A;Clark A;Colgrove RC;Cornely OA;Dingle TC;Dufresne PJ;Fuller J;Gangneux J-P;Gibas C;Glasgow H;Graser Y;Guillot J;Groll AH;Haase G;Hanson K;Harrington A;Hawksworth DL;Hayden RT;Hoenigl M;Hubka V;Johnson K;Kus JV;Li R;Meis JF;Lackner M;Lanternier F;Leal SM;Lee F;Lockhart SR;Luethy P;Martin I;Kwon-Chung KJ;Meyer W;Nguyen MH;Ostrosky-Zeichner L;Palavecino E;Pancholi P;Pappas PG;Procop GW;Redhead SA;Rhoads DD;Riedel S;Stevens B;Sullivan KO;Vergidis P;Roilides E;Seyedmousavi A;Tao L;Vicente VA;Vitale RG;Wang Q-M;Wengenack NL;Westblade L;Wiederhold N;White L;Wojewoda CM;Zhang SX","de Hoog, Sybren;Walsh, Thomas J;Ahmed, Sarah A;Alastruey-Izquierdo, Ana;Alexander, Barbara D;Arendrup, Maiken Cavling;Babady, Esther;Bai, Feng-Yan;Balada-Llasat, Joan-Miquel;Borman, Andrew;Chowdhary, Anuradha;Clark, Andrew;Colgrove, Robert C;Cornely, Oliver A;Dingle, Tanis C;Dufresne, Philippe J;Fuller, Jeff;Gangneux, Jean-Pierre;Gibas, Connie;Glasgow, Heather;Graser, Yvonne;Guillot, Jacques;Groll, Andreas H;Haase, Gerhard;Hanson, Kimberly;Harrington, Amanda;Hawksworth, David L;Hayden, Randall T;Hoenigl, Martin;Hubka, Vit;Johnson, Kristie;Kus, Julianne V;Li, Ruoyu;Meis, Jacques F;Lackner, Michaela;Lanternier, Fanny;Leal, Sixto M;Lee, Francesca;Lockhart, Shawn R;Luethy, Paul;Martin, Isabella;Kwon-Chung, Kyung J;Meyer, Wieland;Nguyen, M Hong;Ostrosky-Zeichner, Luis;Palavecino, Elizabeth;Pancholi, Preeti;Pappas, Peter G;Procop, Gary W;Redhead, Scott A;Rhoads, Daniel D;Riedel, Stefan;Stevens, Bryan;Sullivan, Kaede Ota;Vergidis, Paschalis;Roilides, Emmanuel;Seyedmousavi, Amir;Tao, Lili;Vicente, Vania A;Vitale, Roxana G;Wang, Qi-Ming;Wengenack, Nancy L;Westblade, Lars;Wiederhold, Nathan;White, Lewis;Wojewoda, Christina M;Zhang, Sean X","Reply to Kidd et al., ""Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion"".","Journal of clinical microbiology","United States","eng","Letter","","","","NA","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Research Center for Medical Mycology, Peking University, Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Medical Mycological Society of the Americas (MMSA).;Departments of Medicine and Pathology, Duke University, Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.;Mycology Committee of Chinese Society for Microbiology, Beijing, China.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences, Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia PacificSociety for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital, Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA), Arlington, Virginia, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Mycology, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Texas Health Science Center, San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University, Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique, Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, Center for Bone Marrow Transplantation, University Children's Hospital, Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Utah School of Medicine, Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Loyola University Health System, Loyola University Chicago, Maywood, Illinois, USA.;Royal Botanic Gardens, Kew, Richmond, Surrey, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Department of Botany, Charles University, Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Public Health Ontario, Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto, Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Research Center for Medical Mycology, Peking University, Beijing, China.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Institut Pasteur, Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Dartmouth Health, Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Texas Health Science Center at Houston, Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;The American Board of Pathology, Tampa, Florida, USA.;American Board of Pathology (ABP), Chicago, Illinois, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada, Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Hippokration Hospital, Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Department of Laboratory Medicine, Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicasy Tecnológicas (CONICET), Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía, Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University, Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center, San Antonio, Texas, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2024,"2024","62","10.1128/jcm.01625-23","e0162523","","","38441056","38441056","PUBMED","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Research Center for Medical Mycology, Peking University, Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Medical Mycological Society of the Americas (MMSA).;Departments of Medicine and Pathology, Duke University, Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.;Mycology Committee of Chinese Society for Microbiology, Beijing, China.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences, Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia PacificSociety for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital, Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA), Arlington, Virginia, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Mycology, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Texas Health Science Center, San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University, Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique, Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, Center for Bone Marrow Transplantation, University Children's Hospital, Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Utah School of Medicine, Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Loyola University Health System, Loyola University Chicago, Maywood, Illinois, USA.;Royal Botanic Gardens, Kew, Richmond, Surrey, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Department of Botany, Charles University, Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Public Health Ontario, Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto, Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Research Center for Medical Mycology, Peking University, Beijing, China.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Institut Pasteur, Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Dartmouth Health, Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Texas Health Science Center at Houston, Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;The American Board of Pathology, Tampa, Florida, USA.;American Board of Pathology (ABP), Chicago, Illinois, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada, Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Hippokration Hospital, Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Department of Laboratory Medicine, Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicasy Tecnológicas (CONICET), Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía, Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University, Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center, San Antonio, Texas, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA."
"Mahfoudhi E;Ricordel C;Lecuyer G;Mouric C;Lena H;Pedeux R","Mahfoudhi, Emna;Ricordel, Charles;Lecuyer, Gwendoline;Mouric, Cécile;Lena, Hervé;Pedeux, Rémy","Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.","Frontiers in oncology","Switzerland","eng","Journal Article","3rd G EGFR-TKI;lung cancer;osimertinib;preclinical models;resistance mechanism","","","Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are currently recommended as first-line treatment for advanced non-small-cell lung cancer (NSCLC) with  -activating mutations. Third-generation (3rd G) EGFR-TKIs, including osimertinib, offer an effective treatment option for patients with NSCLC resistant 1st and 2nd EGFR-TKIs. However, the efficacy of 3rd G EGFR-TKIs is limited by acquired resistance that has become a growing clinical challenge. Several clinical and preclinical studies are being carried out to better understand the mechanisms of resistance to 3rd G EGFR-TKIs and have revealed various genetic aberrations associated with molecular heterogeneity of cancer cells. Studies focusing on epigenetic events are limited despite several indications of their involvement in the development of resistance. Preclinical models, established in most cases in a similar manner, have shown different prevalence of resistance mechanisms from clinical samples. Clinically identified mechanisms include EGFR mutations that were not identified in preclinical models. Thus, NRAS genetic alterations were not observed in patients but have been described in cell lines resistant to 3rd G EGFR-TKI. Mainly, resistance to 3rd G EGFR-TKI in preclinical models is related to the activation of alternative signaling pathways through tyrosine kinase receptor (TKR) activation or to histological and phenotypic transformations. Yet, preclinical models have provided some insight into the complex network between dominant drivers and associated events that lead to the emergence of resistance and consequently have identified new therapeutic targets. This review provides an overview of preclinical studies developed to investigate the mechanisms of acquired resistance to 3rd G EGFR-TKIs, including osimertinib and rociletinib, across all lines of therapy. In fact, some of the models described were first generated to be resistant to first- and second-generation EGFR-TKIs and often carried the T790M mutation, while others had never been exposed to TKIs. The review further describes the therapeutic opportunities to overcome resistance, based on preclinical studies.","Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2022,"2022","12","10.3389/fonc.2022.853501","853501","","","35463360","35463360","PUBMED","Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France."
"Féray C;Campion L;Mathurin P;Archambreaud I;Mirabel X;Bronowicki JP;Rio E;Perret C;Mineur L;Oberti F;Touchefeu Y;Gournay J;Regnault H;Edeline J;Rode A;Hillion P;Blanc JF;Khac EN;Azoulay D;Luciani A;Preglisasco AG;Faurel-Paul E;Auble H;Mornex F;Merle P","Féray, Cyrille;Campion, Loic;Mathurin, Philippe;Archambreaud, Isabelle;Mirabel, Xavier;Bronowicki, Jean Pierre;Rio, Emmanuel;Perret, Christophe;Mineur, Laurent;Oberti, Frédéric;Touchefeu, Yann;Gournay, Jérôme;Regnault, Hélène;Edeline, Julien;Rode, Agnès;Hillion, Patrick;Blanc, Jean Frédéric;Khac, Eric Nguyen;Azoulay, Daniel;Luciani, Alain;Preglisasco, Athena Galetto;Faurel-Paul, Elodie;Auble, Hélène;Mornex, Françoise;Merle, Philippe",NA,"JHEP reports : innovation in hepatology","Netherlands","eng","Journal Article","3-DCRT, three-dimensional conformal radiotherapy;AE, adverse event;ALBI, albumin–bilirubin;BCLC, Barcelona Clinic Liver Cancer;CRT, conformal radiotherapy;CT, computed tomography;CTV, clinical tumour volume;Conformal external radiotherapy;ECOG, Eastern Cooperative Oncology Group;HCC, hepatocellular carcinoma;HR, hazard ratio;Hepatocellular carcinoma;ITT, intention-to-treat;OS, overall survival;PFS, progression-free survival;PS, propensity score;RILD, radio-induced liver disease;SBRT, stereotaxic body radiation therapy;TACE, transcatheter arterial chemoembolisation;TTP, time to tumour progression;mRECIST, modified Response Evaluation Criteria in Solid Tumour","","","Transcatheter arterial chemoembolisation (TACE) is recommended for patients with hepatocellular carcinoma devoid of macrovascular invasion or extrahepatic spread but not eligible for curative therapies. We compared the efficacy and safety of the combination of a single TACE and external conformal radiotherapy (CRT)  . classical TACE. TACERTE was an open-labelled, randomised controlled trial with a 1:1 allocation rate to two or three TACE (arm A) or one TACE + CRT (arm B). Participants had a mean age of 70 years, and 86% were male. The aetiology was alcohol in 85%. The primary endpoint was liver progression-free survival (PFS) in the intention-to-treat population. The typical CRT schedule was 54 Gy in 18 sessions of 3 Gy. Of the 120 participants randomised, 64 were in arm A and 56 in arm B; 100 participants underwent the planned schedule and defined the 'per-protocol' group. In intention-to-treat participants, the liver PFS at 12 and 18 months were 59% and 19% in arm A and 61% and 36% in arm B (hazard ratio [HR] 0.69; 95% CI 0.40-1.18;   = 0.17), respectively. In the per-protocol population, treated liver PFS tended to be better in arm B (HR 0.61; 95% CI 0.34-1.06;   = 0.081) than in arm A. Liver-related grade III-IV adverse events were more frequent in arm B than in arm A. Median overall survival reached 30 months (95% CI 23-35) in arm A and 22 months (95% CI 15.7-26.2) in arm B. Although TACE + CRT tended to improve local control, this first Western randomised controlled trial showed that the combined strategy failed to increase PFS or overall survival and led more frequently to liver-related adverse effects. Hepatocellular carcinoma is frequently treated by arterial embolisation of the tumour and more recently by external radiotherapy. We tried to determine whether combination of the two treatments (irradiation after embolisation) might produce interesting results. Our results in this prospective randomised study were not able to demonstrate a beneficial effect of combining embolisation and irradiation in these patients. On the contrary, we observed more adverse effects with the combined treatment. NCT01300143.","Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Department of Biostatistics, Institut de Cancérologie de l'Ouest, Université Nantes, INSERM U307, Nantes, France.;Service des Maladies de l'Appareil Digestif, Hôpital Huriez, Université Lille, INSERM 1286, Lille, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Hepatology, CHU Nancy-Brabois, Nancy, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Radiology Department, Hôtel-Dieu, Nantes, France.;Digestive Oncology, Institut Sainte Catherine, Avignon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Angers, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Gastroenterology and Hepatology, Hôpital Henri Mondor, APHP, Université Paris Est, Creteil, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Radiology Department, Hôpital de la Croix-Rousse, Hospice Civil de Lyon; Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Dijon, France.;Department of Gastroenterology and Hepatology, Hôpital Sud Haut-Lévêque, Bordeaux, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Université Amiens, Amiens, France.;Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon, EMR 3738, Lyon, France.;Hepatology and Gastroenterology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard, INSERM U1052, Lyon, France.","NA",0,"2589-5559","JHEP Rep","JHEP Rep",2022,"2023","5","10.1016/j.jhepr.2023.100689","100689","","","36937990","36937990","PUBMED","Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Department of Biostatistics, Institut de Cancérologie de l'Ouest, Université Nantes, INSERM U307, Nantes, France.;Service des Maladies de l'Appareil Digestif, Hôpital Huriez, Université Lille, INSERM 1286, Lille, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Hepatology, CHU Nancy-Brabois, Nancy, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Radiology Department, Hôtel-Dieu, Nantes, France.;Digestive Oncology, Institut Sainte Catherine, Avignon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Angers, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Gastroenterology and Hepatology, Hôpital Henri Mondor, APHP, Université Paris Est, Creteil, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Radiology Department, Hôpital de la Croix-Rousse, Hospice Civil de Lyon; Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Dijon, France.;Department of Gastroenterology and Hepatology, Hôpital Sud Haut-Lévêque, Bordeaux, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Université Amiens, Amiens, France.;Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon, EMR 3738, Lyon, France.;Hepatology and Gastroenterology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard, INSERM U1052, Lyon, France."
"Dezellus A;Mirallie S;Leperlier F;Sauterey B;Bouet PE;Dessaint A;Duros S;Gremeau AS;Mouret-Reynier MA;Durand LM;Venat L;De Blay P;Robert M;Freour T;Campone M;Blanc-Lapierre A;Bordes V","Dezellus, A;Mirallie, S;Leperlier, F;Sauterey, B;Bouet, P-E;Dessaint, A;Duros, S;Gremeau, A S;Mouret-Reynier, M-A;Durand, L M;Venat, L;De Blay, P;Robert, M;Freour, T;Campone, M;Blanc-Lapierre, A;Bordes, V","Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Breast cancer;Fertility preservation;Neoadjuvant chemotherapy;Ovarian stimulation;Tamoxifen","Humans;Female;Fertility Preservation;Breast Neoplasms;Tamoxifen;Adult;Prospective Studies;Ovulation Induction;Follow-Up Studies;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Young Adult;Pregnancy;Neoadjuvant Therapy;Letrozole;Pregnancy Rate;Adolescent;Oocyte Retrieval;Cryopreservation","Humans;Female;Fertility Preservation;Breast Neoplasms;Tamoxifen;Adult;Prospective Studies;Ovulation Induction;Follow-Up Studies;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Young Adult;Pregnancy;Neoadjuvant Therapy;Letrozole;Pregnancy Rate;Adolescent;Oocyte Retrieval;Cryopreservation","Fertility issues are of great concern for young women undergoing treatment for breast cancer (BC). Fertility preservation (FP) protocols using controlled ovarian stimulation (COS) with letrozole have been widely used with overall good results. However, letrozole cannot be used in every country in this context. This study aimed to assess the efficacy of tamoxifen for COS in women with early BC undergoing FP. This multicentric prospective study included patients aged 18-40, diagnosed with stage I, II and III invasive BC, undergoing tamoxifen-COS before adjuvant or neoadjuvant chemotherapy (NAC). The primary endpoint was the efficacy of tamoxifen-COS protocol evaluated by the number of oocytes collected and vitrified. Secondary endpoints included the time interval before chemotherapy, breast cancer (BC) recurrence rates, and reproductive outcomes. Ninety-five patients were included between 2014 and 2017, aged 31.5 ± 4 years on average. 37.9 % received NAC and 62.1 % received adjuvant chemotherapy. FP procedure was successful in 89.5 % of the cycles. The mean number of collected and vitrified oocytes was 12.8 ± 7.9 and 9.8 ± 6.2, respectively. The mean duration of COS was 10.4 ± 1.9 days. Median time before chemotherapy initiation was 3.6 weeks (IQR 3.1; 4.1) for women receiving NAC. Five-year relapse-free and overall survival rates were in-line with those expected in this population. Twenty-one women had spontaneous full-term pregnancies, while 5 underwent IVF cycles with frozen-thawed oocytes, without pregnancy. Tamoxifen-COS protocols appear to be feasible before adjuvant or NAC treatment in young BC patients and efficient in terms of oocyte yield.","Institut de Cancérologie de l'Ouest, Saint Herblain et Angers;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU Angers, France.;Centre Eugène Marquis, Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Limoges, France.;Service d'oncologie, CHU de Limoges, France.;Service de Gynécologie-Obstétrique CH de Vendée, La Roche-sur-Yon, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France; Université Nantes/Angers, Inserm, CNRS, CRCI2NA, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.","NA",0,"1532-3080","Breast","Breast",2024,"2024","77","10.1016/j.breast.2024.103776","103776","","","39167853","39167853","PUBMED","Institut de Cancérologie de l'Ouest, Saint Herblain et Angers;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU Angers, France.;Centre Eugène Marquis, Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Limoges, France.;Service d'oncologie, CHU de Limoges, France.;Service de Gynécologie-Obstétrique CH de Vendée, La Roche-sur-Yon, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France; Université Nantes/Angers, Inserm, CNRS, CRCI2NA, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France."
"Le Daré B;Bacle A;Lhermitte R;Lesourd F;Lurton Y","Le Daré, Brendan;Bacle, Astrid;Lhermitte, Roxane;Lesourd, François;Lurton, Yves","Increasing vaccine supply with low dead-volume syringes and needles.","International journal of pharmaceutics","Netherlands","eng","Journal Article","COVID-19;Dead-volume;Medical device;Needle;Syringe;Vaccine","COVID-19;COVID-19 Vaccines;Humans;Needles;SARS-CoV-2;Syringes","COVID-19;COVID-19 Vaccines;Humans;Needles;SARS-CoV-2;Syringes","As global vaccine production capacity is limited, every optimization strategy must be explored to rapidly increase the number of people vaccinated. The objective of this study is to determine which medical devices allow the extraction of the maximum number of doses from different vaccine vials (Pfizer-BioNTech, AstraZeneca, Moderna and Johnson & Johnson vaccines) by analyzing all the factors involved in the preparation of the injected doses. By measuring the dead-volume of 32 syringe-needle combinations, we show that fixed-needle syringe with a dead-volume of less than 5 µL can extract up to 7 doses from Pfizer vials, 13 doses from AstraZeneca vials, 12 doses from Moderna vials and 6 doses from Johnson & Johnson vials. We found that the syringe accuracy is important, and can compromise the chances of extracting additional doses when withdrawing too large a volume. For Pfizer vaccine, particular attention must be paid to the choice of dilution syringe, which may compromise the extraction of the 7th dose. The withdrawal of extra doses from vaccine vials was not operator-dependent. In this unprecedented health context, the medical device considerations presented here could help to optimize every COVID-19 vaccine vial.","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.","NA",0,"1873-3476","Int J Pharm","Int J Pharm",2021,"2021","608","10.1016/j.ijpharm.2021.121053","121053","","","34461171","34461171","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France."
"Tiffney EA;Coombes JL;Legembre P;Flynn RJ","Tiffney, Ellen A;Coombes, Janine L;Legembre, Patrick;Flynn, Robin J","Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii.","Microbes and infection","France","eng","Journal Article","Arginase;CD95L;Cleaved CD95L;JAK/STAT;Macrophage;Toxoplasma gondii","Arginase;Fas Ligand Protein;Humans;Janus Kinases;Macrophages;Toxoplasma","Arginase;Fas Ligand Protein;Humans;Janus Kinases;Macrophages;Toxoplasma","Toxoplasma gondii infects approximately 1-2 billion people, and manipulation of the macrophage response is critical to host and parasite survival. A cleaved (cl)-CD95L form can promote cellular migration and we have previously shown that cl-CD95L aggravates inflammation and pathology in systemic lupus erythematosus (SLE). Findings have shown that CD95L is upregulated during human infection, therefore we examined the effect of cl-CD95L on the macrophage response to T. gondii. . We find that cl-CD95L promotes parasite replication in macrophages, associated with increased arginase-1 levels, mediated by signal transducer and activator of transcription (STAT)6. Inhibition of both arginase-1 and STAT6 reversed the effects of cl-CD95L. Phospho-kinase array showed that cl-CD95L alters Janus Kinases (JAK)/STAT, mammalian target of rapamycin (mTOR), and Src kinase signals. By triggering changes in JAK/STAT cl-CD95L may limit anti-parasite effectors.","Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Centre Eugène Marquis, Université Rennes-1, INSERM U1242, Rennes, France.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK; Graduate Studies Office, Department of Research, Innovation and Graduate Studies, Waterford Institute of Technology, X91 K0EK","NA",0,"1769-714X","Microbes Infect","Microbes Infect",2021,"2022","24","10.1016/j.micinf.2022.104952","104952","","Wellcome Trust","35240289","35240289","PUBMED","Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Centre Eugène Marquis, Université Rennes-1, INSERM U1242, Rennes, France.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK; Graduate Studies Office, Department of Research, Innovation and Graduate Studies, Waterford Institute of Technology, X91 K0EK"
"Rugo HS;Im SA;Joy AA;Shparyk Y;Walshe JM;Sleckman B;Loi S;Theall KP;Kim S;Huang X;Bananis E;Mahtani R;Finn RS;Diéras V","Rugo, Hope S;Im, Seock-Ah;Joy, Anil A;Shparyk, Yaroslav;Walshe, Janice M;Sleckman, Bethany;Loi, Sherene;Theall, Kathy Puyana;Kim, Sindy;Huang, Xin;Bananis, Eustratios;Mahtani, Reshma;Finn, Richard S;Diéras, Véronique","Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.","Breast (Edinburgh, Scotland)","Netherlands","eng","Randomized Controlled Trial","Advanced breast cancer;Chemotherapy;Palbociclib;Progression-free survival;Safety","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Fulvestrant;Receptor, ErbB-2","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Fulvestrant;Receptor, ErbB-2","Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative (HR+/HER2-) advanced breast cancer (ABC). Here, we evaluated TTC in relevant patient subgroups. These post hoc analyses evaluated TTC by subgroup using data from 2 randomized, phase 3 studies of women with HR+/HER2- ABC. In PALOMA-2, postmenopausal patients previously untreated for ABC were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus letrozole (LET; 2.5 mg/day; n = 444) or PBO plus LET (n = 222). In PALOMA-3, premenopausal or postmenopausal patients whose disease had progressed after prior ET were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus fulvestrant (FUL; 500 mg; n = 347) or PBO plus FUL (n = 174). First subsequent chemotherapy was received by 35.5% and 56.2% in PALOMA-2 and PALOMA-3 after progression on palbociclib plus ET or placebo plus ET. Across all subgroups analyzed, the median progression-free survival (PFS) was longer in the PAL plus ET arm than the PBO plus ET arm. TTC was longer with PAL plus ET versus PBO plus ET across the same patient subgroups in both studies. Across all subgroups, PAL plus ET versus PBO plus ET had longer median PFS and resulted in prolonged TTC in both the PALOMA-2 and PALOMA-3 studies. Pfizer Inc (NCT01740427, NCT01942135).","University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Department of Medicine (Hematology/Oncology), 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, 101 Daehak-ro, Jonro-gu, Seoul 03080;Cross Cancer Institute, University of Alberta, 11560 University Ave NW, Edmonton, AB T6G1Z2;Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv;Cancer Trials Ireland, St Vincent's University Hospital, Elm Park, Dublin 4;Mercy Hospital St. Louis, 607 S New Ballas Road, Suite 3300, St. Louis, MO, 63141;Peter MacCallum Cancer Centre, University of Melbourne;Pfizer Oncology, 300 Technology Square, Cambridge, MA 02139;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 235 E 42nd St, New York, NY, 10017;Miami Cancer Institute, Baptist Health South Florida, Member, Memorial Sloan Kettering Cancer Alliance, 1228 South Pine Island Road, Plantation, FL, 33324;David Geffen School of Medicine, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404;Unicancer Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex","NA",0,"1532-3080","Breast","Breast",2022,"2022","66","10.1016/j.breast.2022.11.005","324-331","","","36463643","36463643","PUBMED","University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Department of Medicine (Hematology/Oncology), 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, 101 Daehak-ro, Jonro-gu, Seoul 03080;Cross Cancer Institute, University of Alberta, 11560 University Ave NW, Edmonton, AB T6G1Z2;Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv;Cancer Trials Ireland, St Vincent's University Hospital, Elm Park, Dublin 4;Mercy Hospital St. Louis, 607 S New Ballas Road, Suite 3300, St. Louis, MO, 63141;Peter MacCallum Cancer Centre, University of Melbourne;Pfizer Oncology, 300 Technology Square, Cambridge, MA 02139;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 235 E 42nd St, New York, NY, 10017;Miami Cancer Institute, Baptist Health South Florida, Member, Memorial Sloan Kettering Cancer Alliance, 1228 South Pine Island Road, Plantation, FL, 33324;David Geffen School of Medicine, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404;Unicancer Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex"
"Jaïs X;Brenot P;Bouvaist H;Jevnikar M;Canuet M;Chabanne C;Chaouat A;Cottin V;De Groote P;Favrolt N;Horeau-Langlard D;Magro P;Savale L;Prévot G;Renard S;Sitbon O;Parent F;Trésorier R;Tromeur C;Piedvache C;Grimaldi L;Fadel E;Montani D;Humbert M;Simonneau G","Jaïs, Xavier;Brenot, Philippe;Bouvaist, Hélène;Jevnikar, Mitja;Canuet, Matthieu;Chabanne, Céline;Chaouat, Ari;Cottin, Vincent;De Groote, Pascal;Favrolt, Nicolas;Horeau-Langlard, Delphine;Magro, Pascal;Savale, Laurent;Prévot, Grégoire;Renard, Sébastien;Sitbon, Olivier;Parent, Florence;Trésorier, Romain;Tromeur, Cécile;Piedvache, Céline;Grimaldi, Lamiae;Fadel, Elie;Montani, David;Humbert, Marc;Simonneau, Gérald","Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.","The Lancet. Respiratory medicine","England","eng","Clinical Trial, Phase III","","Angioplasty;Angioplasty, Balloon;Chronic Disease;Follow-Up Studies;Humans;Hypertension, Pulmonary;Pulmonary Embolism;Pyrazoles;Pyrimidines;Randomized Controlled Trials as Topic;Treatment Outcome","Angioplasty;Angioplasty, Balloon;Chronic Disease;Follow-Up Studies;Humans;Hypertension, Pulmonary;Pulmonary Embolism;Pyrazoles;Pyrimidines;Randomized Controlled Trials as Topic;Treatment Outcome","Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised controlled trials comparing these treatments are lacking. We aimed to evaluate the efficacy and safety of BPA versus riociguat in patients with inoperable CTEPH. In this phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension, we enrolled treatment-naive patients aged 18-80 years with newly diagnosed, inoperable CTEPH and pulmonary vascular resistance of more than 320 dyn·s/cm . Patients were randomly assigned (1:1) to BPA or riociguat via a web-based randomisation system, with block randomisation (block sizes of two or four patients) without stratification. The primary endpoint was change in pulmonary vascular resistance at week 26, expressed as percentage of baseline pulmonary vascular resistance in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of riociguat or had at least one BPA session. Patients who completed the RACE trial continued into an ancillary 26-week follow-up during which symptomatic patients with pulmonary vascular resistance of more than 320 dyn·s/cm  benefited from add-on riociguat after BPA or add-on BPA after riociguat. This trial is registered at ClinicalTrials.gov, NCT02634203, and is completed. Between Jan 19, 2016, and Jan 18, 2019, 105 patients were randomly assigned to riociguat (n=53) or BPA (n=52). At week 26, the geometric mean pulmonary vascular resistance decreased to 39·9% (95% CI 36·2-44·0) of baseline pulmonary vascular resistance in the BPA group and 66·7% (60·5-73·5) of baseline pulmonary vascular resistance in the riociguat group (ratio of geometric means 0·60, 95% CI 0·52-0·69; p<0·0001). Treatment-related serious adverse events occurred in 22 (42%) of 52 patients in the BPA group and five (9%) of 53 patients in the riociguat group. The most frequent treatment-related serious adverse events were lung injury (18 [35%] of 52 patients) in the BPA group and severe hypotension with syncope (two [4%] of 53 patients) in the riociguat group. There were no treatment-related deaths. At week 52, a similar reduction in pulmonary vascular resistance was observed in patients treated with first-line riociguat or first-line BPA (ratio of geometric means 0·91, 95% CI 0·79-1·04). The incidence of BPA-related serious adverse events was lower in patients who were pretreated with riociguat (five [14%] of 36 patients vs 22 [42%] of 52 patients). At week 26, pulmonary vascular resistance reduction was more pronounced with BPA than with riociguat, but treatment-related serious adverse events were more common with BPA. The finding of fewer BPA-related serious adverse events among patients who were pretreated with riociguat in the follow-up study compared with those who received BPA as first-line treatment points to the potential benefits of a multimodality approach to treatment in patients with inoperable CTEPH. Further studies are needed to explore the effects of sequential treatment combining one or two medications and BPA in patients with inoperable CTEPH. Programme Hospitalier de Recherche Clinique of the French Ministry of Health and Bayer HealthCare. For the French translation of the abstract see Supplementary Materials section.","Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Radiologie, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Grenoble-Alpes, Service de Cardiologie, Grenoble, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Hôpitaux Universitaires de Strasbourg, Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, France.;Centre Hospitalier Régional Universitaire de Nancy-Brabois, Département de Pneumologie, Vandœuvre-lès-Nancy, France.;Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Pneumologie-Centre de Référence des Maladies Pulmonaires Rares, Lyon, France.;Centre Hospitalier Régional Universitaire de Lille, Service de Cardiologie, Lille, France.;Centre Hospitalier Universitaire de Dijon, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France.;Centre Hospitalier Universitaire de Nantes, Service de Pneumologie, Hôpital Laënnec, Nantes, France.;Centre Hospitalier Régional Universitaire de Tours, Service de Pneumologie, Hôpital Bretonneau, Tours, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Toulouse, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;Assistance Publique-Hôpitaux de Marseille (APHM), Service de Cardiologie, Hôpital de la Timone, Marseille, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Régional Universitaire de Brest, Département de Médecine Interne et Pneumologie, Hôpital de la Cavale Blanche, Brest, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Faculté de Médecine Simone Veil, Université Versailles Saint Quentin-Université Paris-Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.","NA",0,"2213-2619","Lancet Respir Med","Lancet Respir Med",2022,"2022","10","10.1016/S2213-2600(22)00214-4","961-971","","","35926542","35926542","PUBMED","Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Radiologie, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Grenoble-Alpes, Service de Cardiologie, Grenoble, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Hôpitaux Universitaires de Strasbourg, Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, France.;Centre Hospitalier Régional Universitaire de Nancy-Brabois, Département de Pneumologie, Vandœuvre-lès-Nancy, France.;Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Pneumologie-Centre de Référence des Maladies Pulmonaires Rares, Lyon, France.;Centre Hospitalier Régional Universitaire de Lille, Service de Cardiologie, Lille, France.;Centre Hospitalier Universitaire de Dijon, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France.;Centre Hospitalier Universitaire de Nantes, Service de Pneumologie, Hôpital Laënnec, Nantes, France.;Centre Hospitalier Régional Universitaire de Tours, Service de Pneumologie, Hôpital Bretonneau, Tours, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Toulouse, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;Assistance Publique-Hôpitaux de Marseille (APHM), Service de Cardiologie, Hôpital de la Timone, Marseille, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Régional Universitaire de Brest, Département de Médecine Interne et Pneumologie, Hôpital de la Cavale Blanche, Brest, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Faculté de Médecine Simone Veil, Université Versailles Saint Quentin-Université Paris-Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France."
"Shahim A;Donal E;Hage C;Oger E;Savarese G;Persson H;Haugen-Löfman I;Ennezat PV;Sportouch-Dukhan C;Drouet E;Daubert JC;Linde C;Lund LH","Shahim, Angiza;Donal, Erwan;Hage, Camilla;Oger, Emmanuel;Savarese, Gianluigi;Persson, Hans;Haugen-Löfman, Ida;Ennezat, Pierre-Vladimir;Sportouch-Dukhan, Catherine;Drouet, Elodie;Daubert, Jean-Claude;Linde, Cecilia;Lund, Lars H","Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fraction.","ESC heart failure","England","eng","Journal Article","Cardiovascular;Heart failure with preserved ejection fraction;Hospitalization;Trial design","Humans;Heart Failure;Female;Male;Stroke Volume;Aged;Prospective Studies;Aged, 80 and over;Hospitalization;Cause of Death;Prognosis;Follow-Up Studies;Survival Rate;Sweden;Natriuretic Peptide, Brain;Risk Factors;Ventricular Function, Left;Peptide Fragments","Humans;Heart Failure;Female;Male;Stroke Volume;Aged;Prospective Studies;Aged, 80 and over;Hospitalization;Cause of Death;Prognosis;Follow-Up Studies;Survival Rate;Sweden;Natriuretic Peptide, Brain;Risk Factors;Ventricular Function, Left;Peptide Fragments","The detailed sub-categories of death and hospitalization, and the impact of comorbidities on cause-specific outcomes, remain poorly understood in heart failure (HF) with preserved ejection fraction (HFpEF). We sought to evaluate rates and predictors of cardiovascular (CV) and non-CV outcomes in HFpEF. The Karolinska-Rennes study was a bi-national prospective observational study designed to characterize HFpEF (ejection fraction ≥45%). Patients were followed for cause-specific death and hospitalization. Baseline characteristics were pre-selected based on clinical relevance and potential eligibility criteria for HFpEF trials. The associations between characteristics and cause-specific outcomes were assessed with univariable and multivariable Cox regressions. Five hundred thirty-nine patients [56% females; median (inter-quartile range) age 79 (72-84) years; NT-proBNP/BNP 2448 (1290-4790)/429 (229-805) ng/L] were included. Over 1196 patient-years follow-up [median (min, max) 744 days (13-1959)], there were 159 (29%) deaths (13 per 100 patient-years: CV 5.1 per 100, dominated by HF 3.9 per 100; and non-CV 5.8 per 100, dominated by cancer, 2.3 per 100). There were 723 hospitalizations in 338 patients (63%; 60 per 100 patient-years: CV 33 per 100, dominated by HF 17 per 100; and non-CV 27 per 100, dominated by lung disease 5 per 100). Higher age and natriuretic peptides, lower serum natraemia and NYHA class III-IV were independent predictors of CV death; lower serum natraemia, anaemia and stroke of non-CV death; and anaemia and lower serum natraemia of non-CV death or hospitalizations. There were no apparent predictors of CV death or hospitalization. In a clinical cohort hospitalized and diagnosed with HFpEF, death and hospitalization rates were roughly similar for CV and non-CV causes. CV deaths were predicted primarily by severity of HF; non-CV deaths primarily by anaemia and prior stroke. Lower serum sodium predicted both. Hospitalizations were difficult to predict.","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Pharmacoepidemiology and Health Services Research, REPERES, University of Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.;Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Service de Cardiologie, CHU, Lille, France.;Département de Cardiologie, CHU Montpellier, Montpellier, France.;Société Française de Cardiologie, Paris, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2023,"2024","11","10.1002/ehf2.14928","3572-3583","2013-23897-104604-23;20080409;20100419;20080498;20110406;00556-2009;20110120;20090376;20110610","Fédération Française de Cardiologie;Medtronic Bakken Research Center, Maastricht, the Netherlands;Fédération Française de Cardiologie/Société Française de Cardiologie;Medtronic Bakken Research Center;Swedish Research Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Stockholm County Council;Stockholm County Council;Stockholm County Council;Stockholm County Council","39075721","39075721","PUBMED","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Pharmacoepidemiology and Health Services Research, REPERES, University of Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.;Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Service de Cardiologie, CHU, Lille, France.;Département de Cardiologie, CHU Montpellier, Montpellier, France.;Société Française de Cardiologie, Paris, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden."
"van Leeuwaarde RS;González-Clavijo AM;Pracht M;Emelianova G;Cheung WY;Thirlwell C;Öberg K;Spada F","van Leeuwaarde, Rachel S;González-Clavijo, Angélica M;Pracht, Marc;Emelianova, Galina;Cheung, Winson Y;Thirlwell, Christina;Öberg, Kjell;Spada, Francesca","A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires.","Journal of clinical medicine","Switzerland","eng","Journal Article","EORTC QLQ-C30;EORTC QLQ-G.I.NET21;NETs;neuroendocrine tumors;quality of life","","","Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires have been validated in several languages. We aim to assess patients' perceptions of these questionnaires. A cross-sectional qualitative pilot study was conducted among 65 adults from four countries with well-differentiated advanced gastro-entero-pancreatic (GEP) or unknown primary NENs. Patients completed the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires and then a survey containing statements concerning the questionnaires. The majority of patients had a small intestine NET (52%). Most tumors were functioning (55%) and grade 2 NET (52%). Almost half of the patients identified limitations in the questionnaires, with nine (14%) patients scoring the questionnaires as poor and 16 (25%) patients as moderate. Overall, 37 (57%) patients were positive towards the questionnaires. Approximately a quarter of patients considered the questionnaires not suitable for all ages, missing some of their complaints, not representative of their overall HR-QoL regarding the treatment of their NET and too superficial. The current validated EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires may show some limitations in the design of questions and the patients' final satisfaction reporting of the questionnaire. Large-scale, high-quality prospective studies are required in HR-QoL assessment regarding NETs.","Department of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.;Department of Physiological Sciences, School of Medicine, Universidad Nacional de Colombia, Bogota 111321, Colombia.;Instituto Nacional de Cancerología, Bogota 111321, Colombia.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Oncology, National Medical Research Center N.N. Blokhin, 115191 Moscow, Russia.;Department of Medicine and Dentistry, A.I. Yevdokimov Moscow State University, 127473 Moscow, Russia.;Department of Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.;Cancer Institute, University College London, London WC1E 6DD, UK.;Department of Medicine and Health, University of Exeter School, Exeter EX4 4PY, UK.;Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden.;Department of Medical Sciences, Uppsala University, 75236 Uppsala, Sweden.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico, 20141 Milan, Italy.","NA",0,"2077-0383","J Clin Med","J Clin Med",2022,"2022","11","10.3390/jcm11051271",NA,"","","35268362","35268362","PUBMED","Department of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.;Department of Physiological Sciences, School of Medicine, Universidad Nacional de Colombia, Bogota 111321, Colombia.;Instituto Nacional de Cancerología, Bogota 111321, Colombia.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Oncology, National Medical Research Center N.N. Blokhin, 115191 Moscow, Russia.;Department of Medicine and Dentistry, A.I. Yevdokimov Moscow State University, 127473 Moscow, Russia.;Department of Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.;Cancer Institute, University College London, London WC1E 6DD, UK.;Department of Medicine and Health, University of Exeter School, Exeter EX4 4PY, UK.;Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden.;Department of Medical Sciences, Uppsala University, 75236 Uppsala, Sweden.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico, 20141 Milan, Italy."
"Noirclerc N;Huttin O;de Chillou C;Selton-Suty C;Fillipetti L;Sellal JM;Bozec E;Donal E;Lamiral Z;Kobayashi M;Ferreira JP;Rossignol P;Girerd N","Noirclerc, Nathalie;Huttin, Olivier;de Chillou, Christian;Selton-Suty, Christine;Fillipetti, Laura;Sellal, Jean Marc;Bozec, Erwan;Donal, Erwan;Lamiral, Zohra;Kobayashi, Masatake;Ferreira, João Pedro;Rossignol, Patrick;Girerd, Nicolas","Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation.","Journal of clinical medicine","Switzerland","eng","Journal Article","atrial fibrillation;diastolic dysfunction;echocardiography;heart failure;left atrial remodeling","","","Atrial fibrillation (AF) leads to the development of cardiac remodeling/diastolic dysfunction and vice versa. We intended to determine whether cardiac remodeling/diastolic dysfunction is present at early stages of AF. We studied 175 patients with paroxysmal AF, compared with 175 matched control subjects, who had available echocardiography data to investigate the association between echocardiographic variables and AF from the STANISLAS cohort. In this study (mean age 55 years; 70.3% male), patients with paroxysmal AF had greater left ventricular mass compared to matched controls (  < 0.05). Patients with paroxysmal AF were also likely to have larger left atrial volume and a higher peak tricuspid regurgitation velocity, leading to higher prevalence (though <10% in the AF group) of diastolic dysfunction (all-  < 0.05). Multivariable conditional logistic regression models showed that paroxysmal AF was significantly associated with increased left ventricular mass and left atrial enlargement (all-  < 0.001), but not with e' and deceleration time of E wave (all-  > 0.1). Left ventricular mass and left atrial enlargement rather than diastolic dysfunction (as evaluated by echocardiography) were associated with paroxysmal AF irrespective of body mass index, blood pressure and renal function. These findings suggest that cardiac remodeling may occur very early in the natural history of AF.","Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.","NA",0,"2077-0383","J Clin Med","J Clin Med",2021,"2021","10","10.3390/jcm10173894",NA,"","","34501342","34501342","PUBMED","Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France."
"Oluwole OO;Forcade E;Muñoz J;de Guibert S;Vose JM;Bartlett NL;Lin Y;Deol A;McSweeney P;Goy AH;Kersten MJ;Jacobson CA;Farooq U;Minnema MC;Thieblemont C;Timmerman JM;Stiff P;Avivi I;Tzachanis D;Zheng Y;Vardhanabhuti S;Nater J;Shen RR;Miao H;Kim JJ;van Meerten T","Oluwole, Olalekan O;Forcade, Edouard;Muñoz, Javier;de Guibert, Sophie;Vose, Julie M;Bartlett, Nancy L;Lin, Yi;Deol, Abhinav;McSweeney, Peter;Goy, Andre H;Kersten, Marie José;Jacobson, Caron A;Farooq, Umar;Minnema, Monique C;Thieblemont, Catherine;Timmerman, John M;Stiff, Patrick;Avivi, Irit;Tzachanis, Dimitrios;Zheng, Yan;Vardhanabhuti, Saran;Nater, Jenny;Shen, Rhine R;Miao, Harry;Kim, Jenny J;van Meerten, Tom","Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.","Bone marrow transplantation","England","eng","Journal Article","","Humans;Lymphoma, Large B-Cell, Diffuse;Adrenal Cortex Hormones;Biological Products;Cytokine Release Syndrome;Leukoencephalopathies;Immunotherapy, Adoptive;Antigens, CD19","Humans;Lymphoma, Large B-Cell, Diffuse;Adrenal Cortex Hormones;Biological Products;Cytokine Release Syndrome;Leukoencephalopathies;Immunotherapy, Adoptive;Antigens, CD19","ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs) following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Prior analyses of cohort 6 with limited follow-up demonstrated no Grade ≥3 CRS, a low rate of NEs, and high response rates, without negatively impacting axi-cel pharmacokinetics. Herein, long-term outcomes of cohort 6 (N = 40) are reported (median follow-up, 26.9 months). Since the 1-year analysis (Oluwole, et al. Blood. 2022;138[suppl 1]:2832), no new CRS was reported. Two new NEs occurred in two patients (Grade 2 dementia unrelated to axi-cel; Grade 5 axi-cel-related leukoencephalopathy). Six new infections and eight deaths (five progressive disease; one leukoencephalopathy; two COVID-19) occurred. Objective and complete response rates remained at 95% and 80%, respectively. Median duration of response and progression-free survival were reached at 25.9 and 26.8 months, respectively. Median overall survival has not yet been reached. Eighteen patients (45%) remained in ongoing response at data cutoff. With ≥2 years of follow-up, prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab continued to demonstrate CRS improvement without compromising efficacy outcomes, which remained high and durable.","Vanderbilt University Medical Cancer Center, Nashville, TN;Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France.;Banner MD Anderson Cancer Center, Gilbert, AZ, USA.;Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Nebraska Medical Center, Omaha, NE, USA.;Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA.;Mayo Clinic, Rochester, MN, USA.;Karmanos Cancer Center, Wayne State University, Detroit, MI, USA.;Colorado Blood Cancer Institute, Denver, CO, USA.;John Theurer Cancer Center, Hackensack, NJ, USA.;Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands.;Dana-Farber Cancer Institute, Boston, MA, USA.;University of Iowa, Iowa City, IA, USA.;University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands.;Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France.;University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.;Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.;Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;University of California San Diego, La Jolla, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands.","NA",0,"1476-5365","Bone Marrow Transplant","Bone Marrow Transplant",2023,"2024","59","10.1038/s41409-023-02169-z","366-372","","","38177222","38177222","PUBMED","Vanderbilt University Medical Cancer Center, Nashville, TN;Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France.;Banner MD Anderson Cancer Center, Gilbert, AZ, USA.;Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Nebraska Medical Center, Omaha, NE, USA.;Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA.;Mayo Clinic, Rochester, MN, USA.;Karmanos Cancer Center, Wayne State University, Detroit, MI, USA.;Colorado Blood Cancer Institute, Denver, CO, USA.;John Theurer Cancer Center, Hackensack, NJ, USA.;Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands.;Dana-Farber Cancer Institute, Boston, MA, USA.;University of Iowa, Iowa City, IA, USA.;University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands.;Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France.;University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.;Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.;Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;University of California San Diego, La Jolla, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands."
"Cuvilliers C;Palard-Novello X;Pontoizeau C;Meneret P;Devillers A;Le Jeune F;Girard A","Cuvilliers, Cécile;Palard-Novello, Xavier;Pontoizeau, Clémence;Meneret, Pierre;Devillers, Anne;Le Jeune, Florence;Girard, Antoine","The Added Value of Bloodpool SPECT/CT in Painful Non-Operated Foot and Ankle Undiagnosed With Standard Three-Phase Bone Scintigraphy.","Frontiers in medicine","Switzerland","eng","Journal Article","ankle;bloodpool SPECT;bone scintigraphy;early SPECT/CT;foot","",""," To evaluate the interest of adding a bloodpool SPECT/CT to standard three-phase bone scintigraphy (BS) for etiological diagnosis of subacute and chronic lower extremity pains.   We prospectively included patients addressed for pain of lower extremities lasting for at least 6 weeks, without previous surgery. They underwent a standard three-phase BS including late phase SPECT/CT, modified with an additional bloodpool SPECT/CT acquisition. Two independent physicians interpreted the images provided by both protocols. Diagnostic conclusion, diagnostic confidence, and interrater agreements were compared.   One hundred and eighteen lower extremities from 113 patients were analyzed (71 men, median age of 53 years). Adding bloodpool SPECT/CT to standard three-phase BS changed diagnostic conclusions in 24.6% (29/118) of lower extremities. The modified protocol revealed at least one diagnostic conclusion explaining the pain in 89% of extremities, rather than 83.1% with the standard protocol (  = 0.02). Tendinopathies were diagnosed in 12.7% of lower extremities, rather than 4.2% with standard BS (  = 0.002). Adding bloodpool SPECT/CT substantially increased overall confidence of each reader (  < 0.001). Inter-reader agreement was not significantly impacted.   Adding bloodpool SPECT/CT to standard three-phase BS impacted diagnostic conclusion in a quarter of the patients with painful lower extremities, notably by revealing significantly more tendonitis.","Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.","NA",0,"2296-858X","Front Med (Lausanne)","Front Med (Lausanne)",2020,"2021","8","10.3389/fmed.2021.634419","634419","","","33763434","33763434","PUBMED","Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France."
"Boyer PH;Baldinger L;Degeilh B;Wirth X;Kamdem CM;Hansmann Y;Zilliox L;Boulanger N;Jaulhac B","Boyer, Pierre H;Baldinger, Lisa;Degeilh, Brigitte;Wirth, Xavier;Kamdem, Chasy Mewa;Hansmann, Yves;Zilliox, Laurence;Boulanger, Nathalie;Jaulhac, Benoît",NA,"Emerging microbes & infections","United States","eng","Journal Article","Neoehrlichia mikurensis;Neoehrlichiosis;Tick-borne diseases;post-tick bite fever;vector epidemiology","Aged;Anaplasmataceae;Anaplasmataceae Infections;Animals;Cohort Studies;Disease Vectors;Female;France;Humans;Male;Middle Aged;Prevalence;Tick-Borne Diseases;Ticks","Aged;Anaplasmataceae;Anaplasmataceae Infections;Animals;Cohort Studies;Disease Vectors;Female;France;Humans;Male;Middle Aged;Prevalence;Tick-Borne Diseases;Ticks"," is an intracellular bacterium transmitted in Europe and Asia by ticks of the   complex. Interest in this bacterium has increased since it was demonstrated to be responsible for febrile syndromes in patients. To date, most clinical cases have been reported in northern Europe, but case series have also been described in central Europe and China. Notably, thrombotic events occurred during the course of the disease. We investigated the presence of   in 10,885   nymphs in two regions of France (Alsace and Brittany) collected between 2013 and 2020 and in 934 patients suspected of human granulocytic anaplasmosis in Alsace, an endemic area for Lyme borreliosis, using a specific PCR assay.   was detected in 5.42% of the ticks from Alsace, whereas only one (0.03%) tick was found to be positive in Brittany. Spatiotemporal disparities were also noticed within the Alsace region over the four collection sites investigated, and a significant increase in the prevalence of nymphs carrying   was also observed in the last three years of collection. Four out of 934 screened patients were found to be positive for  . Two had malignancies, and the other two were apparently immunocompetent. Superficial thrombosis was noticed in one patient, and long-lasting bacteremia was noted in another patient. These four patients are the first clinical cases of neoehrlichiosis described in France. We suggest including   in the differential diagnosis of post-tick bite febrile syndromes to treat patients and prevent the occurrence of thrombotic complications.","Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes Cedex 9, France.;Laboratoire de Parasitologie Médicale Faculté de Médecine, Université de Rennes1., Rennes cedex, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.","NA",0,"2222-1751","Emerg Microbes Infect","Emerg Microbes Infect",2021,"2021","10","10.1080/22221751.2021.1973347","1731-1738","","","34432610","34432610","PUBMED","Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes Cedex 9, France.;Laboratoire de Parasitologie Médicale Faculté de Médecine, Université de Rennes1., Rennes cedex, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France."
